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Abstract
HER2 is over-expressed in 20-25 % of breast cancers. Due to the increase
in proliferation and survival signalling resulting from HER2 over-expression,
this sub-type is associated with more aggressive tumour progression and poor
prognosis. HER2 targeted-therapy has significantly improved patient prognosis,
however, despite all progress only a subgroup derives optimal benefit, whereas
others have refractory disease or develop resistance. It is therefore necessary to
identify new targets to improve patient outcome. A group of non-coding RNAs,
miRNAs, are often aberrantly expressed in tumours and miRNA expression
profiles have been seen to evolve over the course of treatment implicating them
in therapeutic resistance.
Using the lapatinib sensitive, BT-474, and resistant, BT-474/L, HER2 ex-
pressing cells, 44 miRNAs were found to be upregulated. The region with the
highest number of differentially expressed miRNAs is the 14q32 region. RT-
qPCR confirmed upregulation of 14q32 miRNAs in the BT-474/L compared to
BT-474 as well as 2 other pairs (HCC1954, HCC1954/L, and SKBR-3, SKBR-
3/L) linking increased miRNA expression with acquired resistance to lapatinib.
As the 14q32 region is regulated by DNA imprinting, we explored epigenetic
changes between the sensitive and resistant lines. Global methylation reversal
cased upregulation of all three miRNAs in the sensitive cells. This suggests loss
of methylation is a key in controlling 14q32 miRNA expression.
Since miRNAs are not suitable therapeutic targets, differential gene expres-
sion analysis combined with in silico analysis was used to identify targets of
the miRNAs. Silencing of five target genes seemed to decrease sensitivity of
the cells to HER2-targeted treatment. Analysis of the NeoALTTO clinical trial
data suggests high expression of four of these genes, SOCS2, BASP1, NEDD4L,
and SH3BGRL could be linked to better prognosis.
These results suggest upregulation of 14q32 miRNAs caused by loss of epi-
genetic regulation leads to decreased expression of SOCS2, BASP1, NEDD4L,
and SH3BGRL. This loss could contribute to HER2-targeted therapy resistance.
Therefore expression levels of 14q32 miRNAs could be used as a prognostic bio-
marker to identify patients likely to relapse.
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Three Minute Thesis Presentation Slide: HER2+ Breast Cancer and Targeted Therapy.
In the case of HER2+ breast cancer, normal breast tissue becomes cancerous with
overexpression of the HER2 receptor. Overexpression of the receptor can then be used
for a targeted therapy approach as healthy cells do not display as many HER2 receptors.
However the cancer cells can adapt and accumulate mutations so that they are no longer
vulnerable to the treatment.
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1 Introduction
1.1 Breast Cancer
Breast cancer is the most commonly diagnosed female cancer (2). Overall
mortality rates for this tumour type have been decreasing since the end of the
XXth century, when mass screening was phased in, as this allowed earlier de-
tection and treatment of the disease (3). Age is still the biggest risk factor
associated with the disease (4). Women under 40 have less than 0.5 % chance
of developing breast cancer but this increases with age; so women over 70 have
a 1 in 8 chance of being diagnosed with breast cancer (5).
1.1.1 Breast Cancer Development
Normal breast tissue is made of an intricate network of ducts (Figure 1.1),
set in adipose tissue, that connect lobes of lactiferous glands to the nipple. The
lobes consist of multiple lobules each composed of acini; each lobule, along with
its associated ducts, form the terminal ductal lobular units (6, 7 ). These are the
secretory units of the mammary gland. Both ducts and lobules are formed by
a single layer of polarised luminal epithelial cells surrounding a central lumen.
This complex is encircled by a single layer of basal, or myoepithelial, cells (Figure
1.1). This structure is contained in a layer of collagen and laminin, called the
basement membrane, which prevents secretions from entering the surrounding
stromal tissue (8).
Generally breast cancers initiate as benign epithelial lesions which have atyp-
ical ductal or lobular structure. If this progresses, abnormal proliferation will
generate an extra layer of cells in the lumen, this stage is called atypical hyper-
plasia and is considered a precancerous lesion (10, 11). With further cell growth
this can then become an in situ carcinoma, either ductal (DCIS) or lobular
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Figure 1.1: Schematic Representation of Breast Structure and Cancer Development.
Breast tissue is formed of ducts connecting secretory units, called lobules,
to the nipple. Each is formed of a single layer of luminal epithelial cells
surrounded by a single layer of basal epithelial or myoepithelial cells. Most
breast cancer arise from the epithelial layer and are thought to follow a spe-
cific series of steps starting from a benign epithelial lesion, called ductal
hyperplasia. With atypical proliferation this evolves into atypical hyper-
plasia which is considered a precancerous entity. Ductal Carcinoma In Situ
(DCIS) and its lobular equivalent Lobular Carcinoma In Situ (LCIS) are
non invasive lesions as they do not infiltrate the surrounding tissue. Over
time the tumours can become invasive and lead to metastasis (9).
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(LCIS), depending on the origin of the tumour. These are typically confined to
the lumen and are non invasive as they do not infiltrate the surrounding tissue,
however, over time the cells can undergo epithelial to mesenchymal transition
(EMT) and become invasive (12, 13) which can lead to metastatic spread (Fig-
ure 1.1).
Over 90 % of breast cancers originate from luminal epithelial cells as cell
renewal and proliferation generally occur in this layer. Breast cancers can either
arise in the ducts or in the lobules (14). As the disease progresses, loss of the
basal epithelial cell layer can occur which leads to a loss of structure in the tissue
(6, 15).
Breast cancer is a heterogeneous disease which leads to very different responses
to therapy depending on tumour transcriptome, therefore, breast cancer cannot
be treated as a single malignancy (16).
1.1.2 In Situ Breast Cancer Classification
There are multiple classifications used to subdivide and classify breast cancers.
These are based on diverse histopathological and biological features expressed
by tumours. This stratification is used to assess prognosis and guide treatment
strategies as they will vary in clinical outcome and response to therapy (17 ).
Cancer can be attributed a stage to describe its size and spread from its site
of origin, in this classification in situ carcinomas will be stage 0 as, although
DCIS and LCIS have uncontrolled cell proliferation, they do not invade the
surrounding tissue.
These lesions are also graded using a histological classification based on the
level of differentiation of the cells. A lower grade is attributed to tumours with
highly differentiated cells that still resemble their cells of origin and a higher
grade is given to poorly differentiated tumours. The tumour stage will progress
as the cancer invades the surrounding tissue (18).
1.1.3 Invasive Breast Cancer Classification
Invasive breast cancers are very heterogeneous and can be characterised by
stage or grade. They can also be classified using expression profiles of several
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Figure 1.2: Schematic Representation of the Molecular Subtypes of Breast Cancer.
Breast cancers are separated into groups based on the presence or ab-
sence of several biomarkers. ER: Œstrogen Receptor, PR: Progesterone
Receptor, HER2: Human Epidermal Growth Factor Receptor 2. Figure
adapted from Chivukula (21).
molecular biomarkers. The three main subtypes are based on expression, or lack
thereof, of the Œstrogen Receptor (ER), the Progesterone Receptor (PR), and
the Human Epidermal Growth Factor Receptor 2 (HER2) (19). Accordingly,
breast cancers are classified into: hormone receptor positive, which is ER and/or
PR positive; HER2 driven, characterised by an amplification of the HER2 onco-
gene; and triple negative (20), which is neither hormone nor HER2 expressing
(Figure 1.2).
Extensive gene expression profiling of both cell lines and patient data has
enabled further break-down of the classification into 4 groups with prognostic
relevance (22–25): Luminal A and Luminal B, basal like, and HER2 enriched
(Figure 1.2). The luminal subtypes are ER and/or PR positive and, overall,
have better survival rates than the other groups. Luminal A represents about
40 % of breast cancers and has high ER signalling with low HER2 expression
(26); luminal B accounts for 20 % of breast cancers. This subtype generally has
lower ER regulation, decreased PR, along with more proliferation than luminal
A cancers. Luminal B tumours can be either HER2 positive (HER2+) or HER2
negative (HER2−). Cross-talk occurs between the HER2 and ER pathways
which can lead to resistance to hormonal therapies. The absence of HER2 in
luminal B tumours has been found to be predictive of better outcome (27 ).
Luminal B cancers have been correlated to aggressive clinical behaviour and a
higher probability of relapse in patients (28, 29). Basal-like cancers are 15 %
of breast tumours, this classification is similar to the triple negative subtype as
the tumours do not have any ER, PR, or HER2 expression (30, 31). The HER2
enriched group, has an overexpression of HER2 and underexpression of luminal
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associated genes (32).
Differences in response to therapy and clinical outcome still occur between
tumours that display similar clinical and pathological characteristics. Thus,
with the continual progress of sequencing technology, new breast cancer classi-
fications are emerging to attempt to address this issue. A new classification is
based on genomic amplifications and duplications found in tumours. This sub-
divides breast cancers into ten different groups, or integrative clusters, which
have been associated with distinct clinical outcomes (33). The different molecu-
lar subtypes are divided between the various clusters. HER2+ cancers correlate
more strongly with clusters 5 and 10 and luminal B with cluster.
Another classification looks at predicting outcome based on the similarities
in phenotype of the tumour to that of normal cells. This classification uses
the expression status of three hormone receptors (HR): ER, Androgen Receptor
(AR), and Vitamin D Receptor (VDR). Expression of these receptors leads to the
classification in groups HR0 to HR3 depending on how many of these receptors
are expressed (34). Thus, tumours expressing one of the receptors, irrespective
of which one, will be classified as HR1, tumours expressing all three, will be
HR3. Approximately 45 % of HER2+ breast cancers are HR2, 25 % are HR1,
another 25 % are HR3, and 5 % are in the HR0 group (35). This classification
highlights the heterogeneity observed within the different molecular subtypes as
they are distributed across the various HR groups.
These new classifications can be used in order to refine the more traditional
breast cancer subtypes and stratify patients more accurately. Here, we will be
using the wider HER2+ classification based on amplification of the oncogene
irrespective of the ER and PR status to study resistance to HER2 therapies
more broadly.
1.2 HER2 Positive Breast Cancer
1.2.1 HER2 Signalling
HER2, also called neu in mice or ERBB2, is part of the human epidermal
growth factor receptor family. This receptor tyrosine kinase family comprises
three other members, the epidermal growth factor receptor (EGFR, HER1),
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HER3, and HER4. These three other transmembrane receptors require ligand
binding for dimerisation whereas HER2 does not (36). Therefore, in HER2+
breast cancer, the increased number of HER2 receptors present on the plasma
membrane of tumour cells leads to ligand independent dimerisation of the recept-
ors. The HER receptors homo- or hetero- dimerise allowing for autophosphoryla-
tion of the intracellular domains (37 ) leading to the activation of downstream ef-
fectors and to signalling through the Rat Sarcoma Viral Oncoprotein (RAS), Rac
and the phosphoinositide-3-kinase (PI3K)-Akt serine/threonine kinase (AKT)
pathways (38) which results in increased cell growth and survival signals (Figure
1.3).
After dimerisation of the HER partners, tyrosine residues in the C-terminal
region of the receptors are phosphorylated (39). These phosphotyrosines act as
docking sites for many signalling molecules containing phosphotyrosine-binding
(PTB) domains and Src Homology 2 (SH2) domains, allowing the activation
of numerous downstream effectors. The Growth factor receptor-bound protein
2 (GRB2) contains an SH2 domain and docks onto the phosphotyrosine site
on the receptor where it will act as an adaptor protein (38). It can then re-
cruit the RAS-guanine exchange factor (GEF), Son of Sevenless Homologue 1
(Drosophila) (SOS1), which exchanges guanosine diphosphate (GDP) bound to
inactive RAS for guanosine triphosphate (GTP); this activates RAS which, in
turn, activates the MAP Kinase pathway (40).
The PI3K regulatory subunit, p85, also contains an SH2 domain and is there-
fore recruited to a phosphotyrosine on the receptor (41, 42). Once it is loc-
alised at the membrane, PI3K will phosphorylate Phosphatidylinositol (4,5)-
bisphosphate (PIP2) to Phosphatidylinositol (3,4,5)-trisphosphate (PIP3) (43).
3-Phosphoinositide Dependent Protein Kinase 1 (PDPK1) and AKT proteins
will both bind to PIP3 leading to the phosphorylation of AKT by active PDPK1
and Mechanistic Target Of Rapamycin Kinase (mTOR) (44), phosphorylated
AKT then dissociates from PIP3 and phosphorylates BCL2 Associated Agonist
of Cell Death (BAD).
Phosphorylated BAD can then separate from the inactive apoptosis inhibitory
protein it was previously bound to and is inactivated by binding the 14-3-3
protein. The apoptosis inhibitory protein, no longer bound to BAD, is thus
activated leading to inhibition of apoptosis (45–47 ). AKT also inhibits other
proteins, such as Cyclin Dependent Kinase Inhibitor 1B (CDKN1B or p27Kip1)
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Figure 1.3: Overview of the HER2 Signalling Pathway. After ligand independent di-
merisation of the receptors, auto-phosphorylation of C-terminal tyrosine
residues occurs. These will act as docking sites for proteins containing
phosphotyrosine-binding (PTB) domains and Src Homology 2 (SH2) do-
mains. This will lead to the activation of downstream effectors, resulting
in increased proliferation, survival, and cell cycle progression signalling.
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and Glycogen Synthase Kinase 3 (GSK3), lifting their inhibition of Cyclin D
(CCND) and allowing cell cycle progression.
Therefore, increased levels of HER2 in breast cancers lead to more aggressive
tumours as signalling through this pathway leads to proliferation, cell survival,
and anti-apoptotic signalling.
1.2.2 Identification in Patients
Identifying the HER2 status of a patient is essential to determine the poten-
tial responsiveness of their tumour to therapies targeting HER2. In the clinic,
different tests are used to identify HER2+ breast cancers in patients. Gen-
erally, HER2 overexpression is graded by immunohistochemistry (IHC) which
asses levels of HER2 protein (48, 49); it is graded on a scale where 0 to 1 is
considered HER2 negative and 3+ is HER2+. HER2 staining is considered 3+
when more than 30 % of the invasive cells display a uniform and intense mem-
brane staining (50). If the score is 2+, the tumour is considered borderline and
further testing is required.
If the IHC results are equivocal, amplification of HER2 can be identified by
fluorescence in situ hybridisation (FISH), this is used to check for an increase
in copy number of the gene. If there are more than six copies of the HER2
gene per cell nucleus, or the ratio of HER2 to the chromosome 17 control probe
is greater than 2, the tumour is considered HER2+ (50, 51). If there are less
than 4 HER2 gene copies per nucleus, or a FISH ratio lower than 2, the results
require further validation. If it has not been done previously, then IHC can be
performed. Otherwise the FISH results should be reassessed by an individual
blinded to the previous analysis. If this recount still doesn’t conclude that the
tumour is HER2+, then the diagnosis will be HER2− (49).
HER2 overexpression occurs in approximately 20-25 % of breast cancers, and
is more common in younger patients who develop the disease. Untreated, this
tumour subtype is characterised by a poor prognosis compared to the other
subtypes (Figure 1.4). The 5 year survival rate of patients with HER2+ disease
compared to HER2 negative tumours is, respectively, 19.70 % and 24.50 % (52).
The use of targeted therapy has significantly improved the prognosis of patients
with HER2+ breast cancer.
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Figure 1.4: Overall Survival by HER2 Status and Treatment, from Dawood et al. (52).
1.2.3 Treatment with HER2-Targeting Therapy
HER2-targeting therapies are used for the treatment of HER2+ breast can-
cers, they can be specific or target multiple members of the ERBB protein fam-
ily (Table 1.1). The HER2-targeting monoclonal antibody trastuzumab (Her-
ceptin) (53) is currently the first line therapy used to treat early stage HER2+
breast cancer, however, many trials have been looking at treating these tumours
with a combination of trastuzumab and lapatinib (with chemotherapy) and are
finding the combination to be more beneficial than the single agent treatment
(54–56). Additionally, about half of HER2+ tumours also have expression of
hormone receptors, ER or PR, and therefore, in certain cases, can benefit from
the combination of both a HER2-targeting agent and endocrine therapy (57 )
Lapatinib is a small molecule inhibitor that targets EGFR and HER2. It binds
the adenosine triphosphate (ATP) binding pocket of the receptor, thus prevent-
ing autophosphorylation of the intracellular domain of the receptors. Thus
inhibiting signalling through the Mitogen-Activated Protein Kinase (MAPK)
and PI3K/AKT pathways (72). This also leads to decreased phosphorylation
of downstream effector proteins, such as Extracellular Signal-Regulated Kinase
(ERK), RAF, and AKT. An increase in MAPK p38 (p38), a stress induced
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Therapy Target Mode of Action References
Human
Monoclonal
Antibody
Trastuzumab HER2
Targets the extracellular domain causing internalisation and degradation
of the receptors, leading to antibody-dependant cellular cytotoxicity.
(58)
(59)
Pertuzumab HER2
Dimerisation inhibitor, binds to the extracellular domain, at a different
epitope than trastuzumab, preventing dimerisation of the receptors.
(60)
(61)
Antibody-Drug
Conjugate
Trastuzumab
Emtasine
HER2
T-DM1 Trastuzumab directs drug to HER2 and helps
delivery of DM1 to cancer cells, only works if high HER2
(62)
(63)
Small Molecule
Tyrosine Kinase
Inhibitor
Lapatinib
EGFR
HER2
Reversible inhibitor that targets the ATP-binding pocket
and prevents auto-phosphorylation of the intracellular domains.
(64)
(65)
Neratinib Pan-HER
Irreversibly binds the ATP-binding pocket of the receptor
preventing auto-phosphorylation of the intracellular domain.
(66)
(67 )
Dacomitinib Pan-HER
Targets the catalytic domain of the receptors causing covalent
modifications to cysteine residues stopping auto-phosphorylation.
(68)
(69)
Gefitinib EGFR
Binds the ATP-binding pocket of the receptor and
blocks auto-phosphorylation of the intracellular domains.
(70)
(71)
Table 1.1: HER Targeting Agents and their Mode of Action
tumour suppressive protein (73), is also achieved. p38 can in turn cause an
increase in expression of the cell cycle inhibitors, Cyclin Dependent Kinase In-
hibitor 1A (CDKN1A or p21Cip1) and CDKN1B (74). These proteins cause cell
cycle inhibition and senescence eventually causing cell cycle arrest in the G1
phase and apoptosis (75).
For metastatic disease, the monoclonal antibodies pertuzumab and trastuzu-
mab emtasine (62, 63) are the current standards in the clinic (76). Lapatinib
was previously use to treat patients with cancers progressing on trastuzumab.
Yet, despite all progress in HER2-directed therapy only a subgroup of patients
derives the optimal benefit, whereas other patients have refractory disease or
develop resistance (50, 77 ). It is therefore necessary to identify new targets to
improve patient outcome.
1.2.4 Resistance to HER2-Targeting Therapies
Resistance to therapy is a widely occurring issue in cancer treatment and this
is very true for HER2 directed therapy. Many patients who present the disease
are intrinsically resistant to the HER2-targeted therapies, or develop resistance
over the course of treatment. A multitude of mechanisms have been reported
for acquired resistance to trastuzumab and lapatinib.
With most targeted therapies, the most common mechanisms of resistance
involve the mutation of the therapeutic target. Here, for both lapatinib and
trastuzumab, this results in mutations in the HER2 receptor preventing inhib-
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ition by the drug (78, 79). The cell can also downregulate expression of the
target, thus escaping inhibition (80, 81) and rely on other pro-survival path-
ways, such as PI3K/AKT signalling (82–84) or the activation of other RTKs
like HER3 (85, 86) or Insulin Like Growth Factor 1 Receptor (IGF1R) (87–89).
Trastuzumab resistance can also be caused by increased EGFR signalling (90,
91), which can be overcome by lapatinib as it targets both EGFR and HER2 (92,
93). Increased levels of Heregulin (HRG), a HER3 ligand, can lead to lapatinib
resistance by inducing the formation of HER3-EGFR dimers promoting down-
stream signalling through PI3K and bypassing HER2 (94). Additionally, whilst
trastuzumab can cause mutation or loss of Phosphatase And Tensin Homolog
(PTEN) (95) which leads to resistance, lapatinib functions in a a PTEN inde-
pendent manner (96) meaning it can help surmount trastuzumab resistance.
Autophagy has been linked to trastuzumab resistance in breast cancer (97 ).
Additionally, increased autophagosome formation has been observed in lapatinib
resistant cell lines, and treatment with autophagy inhibitors restoring sensitivity
to lapatinib (98). Hypoxia can promote lapatinib resistance through increased
Hypoxia Inducible Factor 1 Subunit Alpha (HIF1A) levels by reducing expres-
sion of Dual Specificity Phosphatase 2 (DUSP2) leading to activation of the
ERK signalling pathway (99).
1.3 miRNAs and their Role in Cancer
microRNAs (miRNAs) are small non-coding RNAs, 20 to 22 nucleotides long
(100). They are involved in the RNA interference (RNAi) machinery respons-
ible for post-transcriptional gene regulation through mRNA repression (101).
miRNAs have been increasingly identified as having important roles in develop-
ment and disease.
1.3.1 miRNA Processing
In the canonical maturation pathway, the miRNA is transcribed by RNA
polymerase II or III in the nucleus as a primary miRNA transcript (pri-miRNA)
that ranges from hundreds to thousand of nucleotides in length. It has a fold-
back RNA precursor structure with imperfect base pairing, a 5’ cap, and a 3’
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poly(A) tail (Figure 1.5). The pri-miRNA is then cleaved by the micropro-
cessor complex made of the ribonuclease III enzyme, Drosha, and the dsRNA
specific ribonuclease, DiGeorge Syndrome Critical Region 8 (DGCR8 or Pasha)
giving the precursor hairpin structure (pre-miRNA) which is 60 to 70 nucle-
otides long (101). The pre-miRNA is exported to the cytoplasm by Exportin 5
(XPO5)-Ran-GTP. There, it is further processed by the dsRNase type III, Dicer
complex (102) and the double-stranded RNA-binding protein, Transactivation-
responsive RNA-binding protein (TRBP). This generates the mature duplex
miRNA, which is composed of a guide and passenger strand (103).
To obtain the single stranded mature miRNA, the passenger strand will be un-
wound and degraded (104). The mature miRNA is incorporated into the RNA
induced silencer complex (RISC) which contains the Argonaute (Ago2) and
Dicer1 proteins (Figure 1.5). Non-canonical processing pathways for miRNAs
also exist without ribonuclease III enzymes, however, miRNAs from these path-
ways are of low abundance and are generally poorly conserved (105, 106).
The mature miRNA is used to guide the RISC complex to post-transcriptionally
regulate genes in a sequence specific manner (107 ) by partial sequence comple-
mentarity, usually to the 3’ untranslated region (3′UTR) of a target messenger
RNA (mRNA) (108, 109), however, certain miRNA also target the 5′UTR and
certain gene coding regions. The region involved in recognition of the 3′UTR
consists of nucleotides 2 to 7 from the 5’ end of the miRNA and is called the
miRNA seed site. Nucleotides that are downstream of this region are less relev-
ant to the pairing of the miRNA and the 3′UTR, however, the can also contribute
to the base pairing (110). The degree of complementarity between the miRNA
and the mRNA will determine whether the gene is silenced by deadenylation
or translational repression (111). As only partial complementarity is required,
miRNAs have many targets, and are estimated to be in the hundreds or thou-
sands for a single miRNA (112). Computational predications have found that
over 60 % of human protein coding genes have at least one conserved miRNA
seed site (113), suggesting that miRNAs are important regulators of gene ex-
pression.
miRNA expression patterns have been found to be highly tissue-specific. Since
miRNAs regulate many aspects of biological processes, aberrations in the expres-
sion of individual or subsets of miRNAs has been implicated in many diseases,
including cancers. Additionally their expression profiles continues to evolve over
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Figure 1.5: Canonical miRNA Processing. miRNAs are transcribed in the nucleus
as primary miRNA transcripts (pri-miRNA) and are then processed by
the Drosha-DGCR8 complex making the precursor miRNA (pre-miRNA).
Drosha is a ribonuclease III enzyme and DGCR8 is a dsRNA specific ribo-
nuclease. The pre-miRNA is exported to the cytoplasm by Exportin 5
(XPO5)-Ran-GTP where it is then processed by the DICER complex.
Next, the mature miRNA along with Argonaute 2 (Ago2) is loaded onto
the RNA induced silencer complex (RISC). The passenger strand will be
degraded and the miR-RISC will bind and target miRNAs for repression
and cleavage.
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the course of the disease (114).
1.3.2 miRNAs in Cancer
As miRNAs are expressed in a time- and tissue-specific manner they can be
spatially and temporally aberrantly expressed in cancer. For instance, in breast
cancer, miR205 expression was found to be decreased in tumour compared to
healthy cells, however, it was also found to be upregulated in cancer initiating
cells (115). Thus its role promoting or inibiting cancer progression is modulated
by the cell type where the miRNA is expressed or not. In tumours miRNAs are
often deregulated (116, 117 ) affecting tumour proliferation and survival. Indeed
the bulk of miRNA genes has been found to be in cancer associated genomic
break points (118). These are fragile sites that are prone to genomic ampli-
fications and deletions as well as chromosomal translocations. The resulting
miRNAs can in turn lead to more instability through promoting cell cycle de-
fects, mitosis, and DNA damage repair (119).
In many cancers, miRNA signatures have been found to be predictive of clin-
ical outcome (120) and can be used to discriminate between cancer subtypes
(121, 122). This is the case for breast cancers, where miRNA expression is
often deregulated in tumours compared to healthy tissue (123). miRNA pat-
terns can be correlated to certain clinicopathological features, such as ER or
PR expression, as well as the tumour stage (124). miRNAs have been sug-
gested to be used as biomarkers to identify these clinic-pathological features.
The histological grade of a tumour can be identified based on levels of miR21,
miR126, miR155, and miR199a (125). Poor survival can also be predicted from
expression levels of miR20b-5p, miR93-5p, miR126-5p, miR195-5p, miR454-
3p, miR1274b, miR1825 (126, 127 ). In HER2+ breast cancer, expression of
miR10b, miR107, miR126, miR154, miR195, let7f, and let7g has been identified
as specific to the subtype (128).
The miRNAs that are deregulated in cancers can be categorised as tumour
suppressors or oncogenes depending on their target genes and the context (129–
133). Both oncogenic (134) and tumour suppressive (135, 136) miRNAs are
present in breast cancers. miR21 and miR27a, for instance, have been identified
as oncogenes as they promote tumour growth by targeting tumour suppressor
genes such as Tropomyosin 1 (TPM1) (137 ) and G2-M checkpoint regulators
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Zinc Finger And BTB Domain Containing 10 (ZBTB10) and Myelin Transcrip-
tion Factor 1 (MYT1) (138). miR125a and miR125b have been labelled as tu-
mour suppressors and are downregulated in HER2+ disease. Indeed, the HER2
and HER3 3′UTR regions contain seed sites for the miRNAs (139). let-7 on the
other hand has been found to be a tumour suppressive miRNA as it is involved in
regulation of self-renewal and its expression is reduced in breast cancer stem cells
(140). miR200, an inhibitor of angiogenesis, also acts as a tumour suppressor as
it prevents C-X-C Motif Chemokine Ligand 8 (IL8, CXCL8) and C-X-C Motif
Chemokine Ligand 1 (CXCL1) signalling which leads to an overall decrease in
tumour size (141). miR143 and miR145 are also decreased in breast cancers
are this loss correlates with an increase in HER3, KRAS Proto-Oncogene, GT-
Pase (KRAS), Vimentin (VIM), C-X-C Motif Chemokine Receptor 4 (CXCR4),
Matrix Metallopeptidase 9 (MMP9), and Cadherin 1 (E-Cadherin, CDH1) ex-
pression which positively correlate to increased tumour size, high histological
grade, metastasis, and recurrence (142).
As miRNA function is context dependant, some miRNAs can have ambivalent
roles. miR221 and miR222 have been labelled as tumour suppressors in high
grade luminal carcinomas where their decreased expression correlates to high
expression of Integrin Subunit b4 (ITGB4), disintegrins, and Matrix Metal-
lopeptidase 14 (MMP14), essential to an invasive phenotype (143). Increased
expression of miR221 and miR222, however, has been reported to promote meta-
stasis and the EMT phenotype by causing the downregulation of CDH1 (144).
Thus the function of these two miRNAs will depend on the cell type as well as
time in the tumour’s progression where they are expressed.
miRNAs can also contribute to metastasis by promoting migration and in-
vasion of tumour cells (145, 146). It has even been suggested that circulat-
ing miRNAs could be used to monitor metastasis progression as the metastasis
secretes a different miRNA profile to the primary tumour (147 ). This highlights
the potential applications of miRNAs as biomarkers since their expression is very
varied between healthy tissue and different tumour stages (148). miR210, a hyp-
oxia responsive miRNA, has been proposed as a prognostic marker for breast
cancer. As it is upregulated in patients with poor prognosis (149). The pres-
ence of metastases can be determined from expression levels of miR10b, miR21,
miR34a, and miR373 (150). Other miRNAs, miR155, miR195, and let-7a, de-
tected in patients with distant metastases have been suggested as markers of
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invasiveness (151–153). miRNAs of the miR200 family are hypermethylated in
certain tumours, which leads to a decrease in expression of the miRNAs. This
is commonly seen in cancers where EMT has occurred suggesting methylation
levels along with miRNA expression could be used to asses EMT occurrence
(154).
Over time miRNA profiles have been seen to evolve, especially when tu-
mours are subjected to treatment. Importantly miRNAs have been implicated in
therapeutic resistance (155–158). Resistance to chemotherapy can be determ-
ined based on expression patterns of miR7, miR17, miR21, miR34, miR125b,
miR205, miR221, miR210, miR340, and let-7a (159–161). In HER2+ breast
cancer, trastuzumab resistance has been associated with expression of various
miRNAs, such as miR221 (162). Plasma levels of miR210 have been found to
correlate with sensitivity to this treatment (163). High expression of miR21 has
also been shown to lead to trastuzumab resistance (164). For lapatinib, loss of
miR630 has been found to lead to resistance (165). One of the most common
mechanisms altering miRNA expression in cancer is epigenetic regulation (166).
Due to the increasingly important role miRNAs are being attributed in can-
cer development and progression, miRNAs are being investigated as therapies.
These anticancer treatments function by antagonising upregulated oncogenic
miRNAs or by enhancing tumour suppressive miRNAs (167 ). Oligonucleotides
can be generated to be the antisense pair of an oncogenic miRNA preventing
the interaction of the miRNA with its target. miRNA mimics function as re-
placements for the downregulated tumour suppressor miRNA. Various delivery
systems are being developed for these miRNA based therapies using viral vec-
tors, liposomes, nanoparticles, and nanocells (168).
1.4 Epigenetics
Epigenetic modifications lead to changes in gene expression without altering
the DNA sequence itself. These can be caused by chemical modification on
the DNA, DNA methylation, or to DNA associated proteins, histone modifica-
tions (Figure 1.6). Non-coding RNAs have also been suggested to be epigenetic
regulators due to their role in regulating gene expression (169).
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Figure 1.6: Schematic Overview of Different Epigenetic Modifications. Epigenetic al-
terations affect gene expression without changing the primary nucleotide
structure. The DNA double helix is wrapped around the histone core
forming a nucleosome. This is formed of the H3-H4 tetramer and two
H2A-H2B dimers. Each of these histones has an N-terminal tail which can
be post-translationally modified by, for instance, phosphorylation, methyl-
ation, and acetylation. The latter plays a key role in regulating the strength
of the DNA-histone interaction and in activating gene transcription as
acetylation of the histone tails which leads to a decrease in the overall
positive charge of the protein and weakens its interaction with the negat-
ively charged DNA molecule, affecting the tightness of DNA packing into
chromosomes. Nucleosomes are held together by a histone H1 linker pro-
tein. These complexes come together to form chromatin, which coils to
form chromatin fibres that are packed into chromosomes. The DNA itself
can undergo epigenetic modification by the addition of methyl groups to
cytosine residues. This will affect gene expression as the CH3 will stick out
into the major groove of the DNA, preventing transcription factors docking
in the promoter region.
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1.4.1 DNA Methylation
DNA methylation is one system of epigenetic regulation of gene expression. In
eukaryotes, cytosine residues (C) in DNA can be methylated by DNA methyl-
transferases, this leads to the addition of a methyl group (CH3) at position 5
of the cytosine ring (Figure 1.6) generating 5-methylcytosine (m5C) (170, 171).
Methylation of cytosine occurs at cytosine-guanine (CG) dinucleotides found in
palindromic sequences (172, 173). However, in vertebrates, the CG dinucleotide
is only found at one fifth of its randomly expected frequency. Yet in some re-
gions upstream of genes, CG dinucleotides can be found at their expected rate
of occurrence (174); these regions are called 5′-cytosine-phosphate-guanine-3′
(CpG) islands. Methylation of C residues in these regions has been found to
repress expression of the downstream transcribed gene (173).
The methylation reaction is initiated by the nucleophilic attack of a Cys thi-
olate group to the C6 position of the aromatic ring of the pyrimidine. This leads
to the activation of the C5 atom acting as a resonance-stabilised carbanion. This
leads to the C5 nucleophilic attack on the methyl group of S-adenosylmethionine
(SAM), acting as methyl donor in this reaction (175). This covalent intermedi-
ate is then decomposed to give 5-methylcytosine (m5C) (Figure 1.6). For this
reaction to occur the base is flipped out of the double helix structure allowing
DNA methyltransferases (DNA MTase) to start the nucleophilic attack, which,
due to the aromatic configuration of the base, is only possible from above or be-
low the carbon ring. The methyl group added projects into the major groove of
the DNA double helix allowing DNA binding proteins, which contain a conserved
methyl-CpG binding domain (MBD), to interact with it, without disturbing the
double helical structure of the DNA (176). These MBD containing proteins
inhibit transcription of the promoter methylated genes they are bound to by
recruiting protein complexes that alter the structure of the chromatin and pre-
vent transcription of genes in the region (177 ). Thus DNA methylation in the
promoter region will lead to silencing of the downstream transcribed gene, there-
fore the promoter region of housekeeping genes will generally be unmethylated
(178).
As mentioned previously, methylated C residues in CG dinucleotides are usu-
ally found in palindromic sequences. During cell division and DNA synthesis,
this allows the methylation pattern on the parental strand to guide methylation
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on the daughter strand so that methylation is conserved. This is called main-
tenance methylation, there is therefore inheritance of methylation patterns in
daughter cells allowing them to have the same differentiated phenotype as the
parental cell (179). This type of methylation is mediated by DNA (cytosine-
5)-methyltransferase 1 (DNMT1), indeed, this protein preferentially methylates
hemimethylated substrate DNA (180). This maintenance methylation is essen-
tial for cell differentiation and survival as shown by the death at early embryonic
stage of DNMT1 knock-out in mice (181).
Mature gametes, however, lose their DNA methylation after fertilisation due
to epigenetic reprogramming (182). By the time the blastocyst is formed, almost
all methylation marks are lost. Over time, they reappear throughout the em-
bryo, until the gastrula stage where adult levels of methylation are achieved,
these will be perpetuated in all future daughter cells (183, 184). This de
novo methylation is mainly mediated by DNA (cytosine-5)-methyltransferase
3A (DNMT3A) and DNA (cytosine-5)-methyltransferase 3B (DNMT3B) (185).
Nevertheless, some sections of DNA are resistant to this demethylation wave
as well as to the de novo methylation that follows; these are imprinted genes.
Genomic imprinting is the phenomenon by which mammals express certain genes
only from the paternally or maternally supplied chromosome (186, 187 ). This
selective gene expression is achieved through differential DNA methylation of
specific regions on both chromosomes (188). During gametogenesis, the genes
will be methylated differently in the two parents and will be passed on as such to
the next generation (189). This leads to differential expression of genes depend-
ing on which chromosome they are located on. Hence inappropriate imprint-
ing of these regions will lead to disease. For instance Praeder-Willi syndrome
(PWS) is caused by deletions in the paternally inherited chromosome 15, as this
region is imprinted, the maternal chromosome will not express the same genes
as the paternal one since genes usually expressed on the paternal chromosome
are repressed (190, 191). Angelman syndrome (AS) on the other hand is caused
by a deletion in the same region but on the maternally inherited chromosome
(192). These syndromes can also arise in individuals who inherit two paternal
chromosomes for PWS and two maternal ones for AS (193).
One of the most prevalent mutations in cancer is deamination of the m5C to
a thymine (T) with the associated guanine (G) becoming an adenine (A) on the
complementary strand (194). This leads to the loss of a methylation mark and
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is usually involved in the transformation of a proto-oncogene to an oncogene or
in the inactivation of a tumour suppressor gene. Similarly, altered methylation
patterns are often found in cancers, for instance hypomethylation of an oncogene
leading to its expression and hypermethylation of a gene encoding for a tumour
suppressor causing its repression are common (172). Thus, correct methylation
patterns are essential for proper development and alterations in these motifs can
lead to disease.
1.4.2 Histone Modifications
Another form of epigenetic regulation involves histone modifications. His-
tones are proteins used to package DNA into its compact chromatin structure
(195). Due to their important role in cells, these proteins are highly conserved
over eukaryotes, one of these characteristics is a sequence of approximately 70
residues near the C-terminus of the sequence that folds into a central a-helix
flanked by a loop and a shorter a-helix on both sides. This secondary structure
forms the central histone fold found in Histone 2A (H2A), Histone 2B (H2B),
Histone 3 (H3), and Histone 4 (H4) (196), and is the dimerisation motif used
by these proteins to form a histone core around which approximately 200 bp
of DNA is wrapped to form the nucleosomes (Figure 1.6). Each nucleosome is
held together by a Histone 1 (H1) linker protein, these nucleosome filaments
coil into 30 nm thick chromatin fibres (197 ), containing about six nucleosome
cores per turn, which are packed into the condensed chromosomes that appear
at metaphase (198). When DNA is replicated in cell division, the process is also
accompanied by its packing into chromatin. During this process the parental
histone cores are distributed randomly between the daughter duplexes resulting
in the conservation of epigenetic marks associated with the histone cores.
Throughout interphase and the rest of the cell cycle, the chromatin is highly
dispersed and the individual chromosomes can’t be distinguished. There are two
types of dispersed chromatin; euchromatin, which is less dense and transcrip-
tionally expressed or with the potential to be activated, and heterochromatin
which is more densely packed and transcriptionally inert (199). The latter can
be separated into two distinct types: facultative and constitutive heterochro-
matin (200). Facultative heterochromatin varies in a tissue specific manner and
is generally located in regions coding for genes that are expressed differentially
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throughout development and differentiation. The condensation of facultative
heterochromatin transcriptionally inactivates large chromosomal blocks making
the DNA inaccessible to transcription mediating proteins (201). Facultative het-
erochromatin is found in the inactivation of stem cell maintenance genes which
are permanently switched off in terminally differentiated cells. This is also found
in X chromosome inactivation that occurs in female mammalian cells, and is as-
sociated with trimethylation of lysine 27 on H3 (H3K27me3) (202). Constitutive
heterochromatin, on the other hand, is found in gene poor and highly repetit-
ive regions such as telomeres and centromeres, which is permanently condensed
and silenced through trimethylation of lysine 9 on H3 (H3K9me3) (203). Hence
specific histone modifications are associated with the different chromatin states.
Therefore DNA methylation and histone modification regulate gene expres-
sion in a coordinated fashion. Unmethylated genes with an euchromatic histone
pattern are ready to be expressed, methylated genes with an euchromatic his-
tone pattern are poised to be silenced, and finally, methylated genes with a
heterochromatic histone pattern are silenced.
The nucleosome core is a histone octamer (Figure 1.6) composed of two H2A-
H2B dimers and an H3-H4 tetramer (204). There is no sequence specificity for
the histone-DNA binding as the histones bind to the inner face of DNA princip-
ally through the sugar-phosphate backbone with hydrogen bonds, hydrophobic
interactions, salt bridges, and helix dipoles (205). This ionic interaction occurs
as histone proteins contain a high proportion of positively charged residues such
as lysine (K) and arginine (R) which provide a positive surface charge to the
histone complex, allowing for interaction with the negatively charged phosphate
groups of DNA. The strength of this interaction determines how tightly packed
the DNA will be (206).
A flexible N-terminal tail protrudes from the core of each histone, this is a very
positively charged polypeptide which makes up around 25 % of the histone mass
(207 ). This tail extends out of the nucleosome core and past the coiled DNA,
it can interact with linker DNA and the modulation of this interaction by post-
translational modification is involved in the regulation of chromatin unfolding
and the availability of DNA for transcription, replication, recombination, and
repair (208). Post-translational modifications include acetylation, methylation,
phosphorylation, ubiquitination (Figure 1.6), on specific K, R, and serine (S)
side chains (201). Most of these modifications are reversible and, apart from
39
1 Introduction
methylation, reduce the overall positive charge of the histone, altering the DNA-
histone electrostatic interaction. Indeed, transcriptionally active chromatin is
associated with the acetylation of H3 K9, K14, and H4 K5, as well as the methyl-
ation of H3 K4 and H4 R3. Inactive chromatin is associated with acetylation
of H4 K12, and depending on the type of heterochromatin, methylation of H3
K9 or K27. Acetylation is of particular interest to us as it affects packaging of
DNA around the histones and therefore alters gene expression (209, 210).
There are five families of Histone acetyl transferases (HAT) that function
as transcriptional coactivators or silencers. The HAT proteins function in large
multi-subunit complexes of which the composition will determine the specificities
of the histone target sites (211). They use Acetyl coenzyme A (Acetyl-CoA) as
a cofactor for the acetylation of K residues in core histone tails (212). The
transfer of a COCH3 group to a positively charged lysine, neutralises its charge
thus weakening the DNA-histone interaction. This prevents tight packing of
DNA into chromatin by H1 resulting in a more open chromatin configuration
which generally leads to transcription of genes in that region (213). Acetylation
occurs predominantly on H3 and H4 histone tails and is largely targeted to
promoter regions (promoter localised acetylation). However, low levels of global
acetylation are found throughout transcribed genes (214).
Histone deacetylase (HDAC) enzymes are mainly transcriptional repressors as
they remove acetyl groups from lysine amino acids leading to DNA condensation
and gene silencing (215). There are three classes of HDACs, Class I HDACs,
HDAC 1 to 3, and 8, generally form the catalytic core of multi-subunit complexes
whilst Class II, HDAC 4 to 7, 9, and 10, tend not to be part of complexes (216).
Both families function as transcriptional corepressors (217 ). Class III HDACs
are the sirtuins; silent information regulators type (SIRT) SIRT 1 to 7. These
contain a nicotinamide adenine dinucleotide (NAD+) cofactor, therefore, after
hydrolysing the amide bond linking the acetyl group to the K, they transfer it
to NAD+ producing O-acetyl-ADP-ribose (218, 219).
Histone acetylation is tightly regulated in cells and disruption of acetylation
homeostasis has been linked to disease and cancer (220, 221). Overexpression of
HDAC enzymes has been found to be associated with poor prognosis in cancer
(215) and aberrant HDAC recruitment can lead to tumour development (222,
223) by silencing tumour suppressor genes (224, 225), and cancer progression
and metastasis (226). Loss of histone acetylation has even been suggested to be
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a common hallmark of cancer (227 ) suggesting HDAC inhibitors could have a
therapeutic use in certain cancer settings (228).
1.4.3 Epigenetic Regulation of miRNAs
As previously described, miRNA expression is under tight spatial and tem-
poral regulation. miRNAs can be characterised as intragenic or intergenic de-
pending on whether or not they are located within a gene transcription region
(229). The promoter region of intergenic miRNAs and those intragenic but
going in the inverse direction of the coded gene is still unclear.
Intragenic miRNAs are generally controlled with the same promoter as the
gene but they can also have a different promoter located in the intron in which
the miRNA is located. Their expression can be regulated by histone modifica-
tion and DNA methylation levels (114, 230). This creates a feedback loop as
certain miRNAs can regulate epigenetic modulator genes such as those involved
in methylation (231). These in turn affect miRNA expression through modi-
fication of the epigenetic pattern by DNA methylation or histone modifications
(166). CpG methylation of DNA leads to silencing of the miRNA, however
histone modifications can induce or suppress miRNA expression (232).
1.5 Summary
As HER2+ breast cancer is one of the more aggressive breast cancer sub-
types and a high number of patients develop resistance and have refractory
disease using the current HER2-targeting therapies, this highlights the neces-
sity to identify new therapeutic targets to overcome resistance. miRNAs are
often deregulated in tumours and their expression has been found to vary with
therapeutic resistance, therefore these small non-coding RNAs appear to be key
components in resistance. miRNAs however, are not suitable therapeutic targets
therefore investigating their downstream effectors could identify new therapeutic
options.
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1.6 Aims
This PhD project aims to identify miRNAs involved in lapatinib resistance
and investigate their epigenetic regulation. In addition to validating putative
targets of the miRNAs and assessing their role in clinical breast cancers and
their potential as therapeutic targets.
1.6.1 Identification of miRNAs Involved in Resistance to
HER2-Targeted Therapy
miRNAs are likely to be deregulated in cancer and their expression patterns to
be altered in resistance. Therefore we will study the miRNA expression profile
of lapatinib resistant breast cancer cells by miRNA array in order to identify
and validate miRNAs common to different cell lines by RT-qPCR. This will help
to understand the miRNA driven mechanism of resistance to lapatinib.
1.6.2 Regulation of the miRNAs Involved in Resistance
Once miRNAs altered in lapatinib resistance have been identified, we will
investigate the epigenetic mechanism controlling their upregulation in resistance.
Firstly by miRNA array of untreated cancer cells and demethylated ones. Then
we will investigate the response of our target miRNAs to demethylation and
inhibition of deacetylation. This will be followed by methylation resequencing
experiments in order to establish the methylome of the selected region.
1.6.3 Identification of Downstream Effectors of the miRNAs and
their Potential as Therapeutic Targets
As miRNAs are poor therapeutic targets we aim to identify miRNA gene
targets by gene expression array and study their effect on resistance through
knock-down assays. As well as assessing the role of these putative targets in
clinical breast cancers using data from patients on neoadjuvant HER2-targeting
based treatments from the NeoALTTO trial.
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2.1 Cell Culture Assays
2.1.1 Cell Culture
The cell lines are cultured in the appropriate medium, either in Roswell Park
Memorial Institute (RPMI)-1640 medium (Sigma-Aldrich, St Louis, MO, USA),
L-15 (Leibovitz) medium (Sigma-Aldrich), or McCoy’s 5A Modified medium
(Sigma-Aldrich). The medium is supplemented with 2 mM L-glutamine, 1 %
penicillin-streptomycin (Sigma-Aldrich), and fœtal bovine serum (FBS) (Gibco,
Carlsbad, CA, USA) as detailed in Table 2.1. All the cell lines used are derived
from HER2+ breast cancers and grow in an adherent monolayer. The cells are
cultured at 37 °C with 5 % CO2 and 95 % air in a humidified incubator. Cells
with acquired resistance to lapatinib (Selleck Chemicals, Munich, Germany) are
maintained in presence of 2 µM of the drug, twice the resistance threshold.
The cells are passaged by trypsinisation using 1x trypsin-2,2′,2′′,2′′′-(etane-
1,2-diyldinitrilo)tetraacetic acid (EDTA) (Sigma-Aldrich). Once the cells have
detached from the plastic, FBS enriched medium is added to a minimum of
Cell Line Medium FBS (%) Lapatinib (µM) Trastuzumab (mg·L-1)
BT-474 RPMI 1640 10 - -
BT-474/L RPMI 1640 10 2.0 -
BT-474/T RPMI 1640 10 - 40.0
HCC1954 RPMI 1640 10 - -
HCC1954/L RPMI 1640 10 2.0 -
SKBR-3 McCoy’s 5A 10 - -
SKBR-3/L McCoy’s 5A 10 2.0 -
JIMT-1 RPMI 1640 10 - -
MDA-MB-361 L-15 (Leibovitz) 20 - -
Table 2.1: Cell Culture Conditions.
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three times the volume of trypsin. The suspension is then centrifuged in the
Eppendorf 5415D centrifuge (Eppendorf, Hamburg, Germany) at 12000 RCF for
five minutes, the supernatant is removed and the cell pellet is re-suspended in
the appropriate culture medium. Where necessary cells are counted in presence
of trypan blue (Sigma-Aldrich) using the TC20 Automated Cell Counter (Bio-
Rad Laboratories, Hercules, CA, USA).
2.1.2 Generation of Resistant Lines
The lapatinib resistant BT-474/L cells were obtained from Liu et al. (1) as
BT-474 J4 clone. The trastuzumab resistant BT-474/T were obtained from An-
thony Kong’s laboratory (Institute of Cancer and Genomic Sciences, University
of Birmingham).
SKBR-3 and HCC1954 cells were cultured in increasing concentrations of
lapatinib, starting approximately from the IC50 value, respectively 77 nM and
165 nM, as determined by dose-response studies. Through continuous exposure
to the drug, the lapatinib sensitive cells die and the live cells are cultured un-
til they outgrow the lapatinib dose. The dose is increased and the process is
repeated until the cells are able to grow in 2 µM of lapatinib, a concentration
equal to twice the resistance threshold. The resistant cells and their isogenic
sensitive cell line are listed in Table 2.2.
Parental Line
Resistant Line
Lapatinib Trastuzumab
BT-474 BT-474/L BT-474/T
HCC1954 HCC1954/L
SKBR-3 SKBR-3/L
Table 2.2: Parental Cell Line and Derived Acquired Resistant Line.
2.1.3 Cytotoxicity Assay
Thiazolyl blue tetrazolium bromide or MTT (Alfa Aesar, Ward Hill, MA,
USA) powder is dissolved in FBS supplemented medium to a stock concentration
of 2 g·L-1 and added to each well in a 1:3 dilution, for a final concentration of
0.67 g·L-1. After 1 hour 30 minutes to 3 hours incubation at 37 °C the medium
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is removed, the cell culture plate can be stored at -20 °C or used immediately.
The MTT crystals are dissolved in dimethyl sulphoxide (DMSO) (Thermo
Fisher Scientific, Waltham, MA, USA) and absorbency is acquired on the VIC-
TOR3 Multilabel Counter (PerkinElmer, Waltham, MA, USA) at 560 nm for
0.1 seconds and corrected for background at 630 nm.
2.1.4 Baseline 50 % Inhibitory Concentration Assay (IC50)
The cells are plated in 96 well plates as detailled in Table 2.3, and are left
to adhere for 24 hours after which the medium is replaced with fresh medium
containing a serial dilution of the drug used for the IC50, as detailed in Table 2.4.
Cell Line Density (cells·mL-1)
BT-474 6.0·104
BT-474/L 6.0·104
HCC1954 6.0·104
HCC1954/L 4.0·104
SKBR-3 4.8·104
SKBR-3/L 4.0·104
JIMT-1 6.0·104
MDA-MB-361 8.0·104
Table 2.3: Baseline IC50 Plating Densities used for the Different Cell Lines.
Drug Units Doses
Lapatinib
nM
0.1, 1.0, 10.0, 50.0, 100.0,
500.0, 1000.0, 5000.0, 10000.0
Gefitinib
Dacomitinib
Trastuzumab mg·L-1 0.1, 10.0, 25.0, 50.0, 100.0
Neratinib nM
0.01, 0.1, 1.0, 10.0, 100.0,
500.0, 1000.0, 5000.0, 10000.0
Table 2.4: Drug Range used for all the IC50 Experiments.
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2.1.5 Population Doubling Assay
5.0·105 cells are plated in 5 mL in a T25 flask. Every three days, the cells are
detached with 1 mL trypsin and diluted in 3 mL of medium and counted with
the TC20 Automated Cell Counter in the presence of trypan blue. 5.0·105 cells
are then plated again in 5 mL in a T25 flask. The process is repeated until day
15.
2.1.6 Immunofluorescence Assay
Cells are plated onto coverslips (Warner Instruments, Hamden, CT, USA) in
6 well plates in FBS free media. After 1 hour 10 % FBS is added to the culture
medium. Resistant cells are grown without the addition of lapatinib. When
cells are 70 % confluent the coverslips are fixed in methanol for 20 minutes at
-20 °C. Cells are permeabilised with 0.2 % Triton-X 100 in PBS and blocked for
30 minutes in a solution of 5 % bovine serum albumin (BSA), 0.1 % Triton-X 100
in PBS. F-actin is stained with Alexa Fluor 568 Phalloidin (LifeTechnologies)
at a 1 in 250 dilution in blocking buffer for 1 hour. DNA is then stained with
Hoechst (Invitrogen) for 5 minutes at a 1 in 5000 dilution in PBS. Coverslips
are mounted using ProLong Gold antifade (Invitrogen).
2.1.7 siRNA Reverse Transfection
The small interfering RNAs (siRNAs) (Qiagen, Hilden, Germany) used are
listed below (Table 2.5) and will be referred to as siRNA 1 and siRNA 2 for
each gene throughout this document . The siRNA-lipid solution is composed
of 50 nM siRNA or negative control (-ve) (AllStars Negative Control, Qiagen)
with 1 % Lipofectamine RNAiMAX transfection reagent (Invitrogen by Life-
Technologies) in FBS free medium. The siRNA-lipid solution is incubated at
room temperature for 5 minutes to allow complexes to form. The mixture is
added to each well at 20 % of the final volume of the well, in a 96 well plate,
this is equal to 20 µL. Therefore each well has a final concentration of 10 nM
siRNA with 0.2 % lipofectamine.
Cells are seeded on top at a density of 4.0·104 cells·mL-1, in a 96 well plate,
80 µL of cell suspension are added per well. The medium is changed after 24
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Gene
siRNA 1 siRNA 2
Assay Name Sequence Assay Name Sequence
BASP1 Hs_BASP1_5 TACAGGATGTTGTCCCATCAA Hs_BASP1_6 CACATGGATCTCAATGCCAAT
KLF9 Hs_KLF9_4 CAAGAGTTATGTAGAAGGAAA Hs_KLF9_6 AACCAGCATTCTAATTAGATT
NEDD4L Hs_NEDD4L_3 TAGGCCGAACTTACTATGTCA Hs_NEDD4L_9 CTCATCCGAGAAATTACTTAA
PKIA Hs_PKIA_9 ATGATTATCATTAGAAGCTAA Hs_PKIA_10 TCACTTGATCATATGACGAAA
PREX1 Hs_PREX1_8 AAGGGCCTTCTTCCTCTTCGA Hs_PREX1_9 CACGGCGTGGTGTATGAGTAT
SH3BGRL Hs_SH3BGRL_6 TTCACACTACCTTATTACCAA Hs_SH3BGRL_9 CTCTGGCTCTACAGCGATTAA
SOCS2 Hs_SOCS2_2 CCAACTAATCTTCGAATCGAA Hs_SOCS2_8 TTGTCTAACCATGGACATAAA
Table 2.5: siRNA Sequences used for Functional Validation of Putative miRNA Gene
Targets. In further experiments the siRNAs have been renamed siRNA 1
and siRNA 2 for each gene as detailed above.
hours and the cells can be used for IC50 assays using the previously described
protocol, or the transfected cells are cultured until the appropriate time point
when they are washed in phosphate buffered saline (PBS) (Sigma-Aldrich) and
collected for RNA and protein studies.
2.1.8 miRNA Mimic or Inhibitor Reverse Transfection
The miRNA mimics (mirVana miRNA mimic, Thermo Fisher Scientific) and
miRNA inhibitors (mirVana miRNA inhibitor, Thermo Fisher Scientific), de-
tailed in Table 2.6, are used in the miRNA-lipid transfection solution. This is
composed of a given mimic, inhibitor, or scramble negative control (scramble,
scb) with 0.75 % Lipofectamine RNAiMAX transfection reagent in FBS free
medium. Mimic and scb or inhibitor and scb are added at the same concen-
tration in each experiment, however, the concentration varies across different
experiments. The mimic-lipid solution is incubated at room temperature for 5
minutes to allow complexes to form. The mixture is added to each well at 20 %
of the final volume of the well, in a 96 well plate, this is equal to 20 µL.
miRNA Mimic Assay Inhibitor Assay
Negative control #1 4464058 4464076
hsa-miR-127-3p MC10400 MH10400
hsa-miR-409-3p MC12446 MH12446
hsa-miR-495-3p MC11526 MH11526
Table 2.6: mirVana miRNA Mimic and Inhibitor Assays Used for Transfections.
Cells are seeded on top, in a 96 well plate, 80 µL of cell suspension are added
per well. The medium is changed after 24 hours and the cells can be drugged
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for IC50 assays using the previously described protocol, or the transfected cells
are cultured until the appropriate time point when they are washed in PBS and
collected for RNA and protein studies.
2.2 RNA Studies
2.2.1 RNA Samples for mRNA Study
Cells to be used for mRNA extractions are washed in PBS before being
stored at -20 °C until total RNA is extracted using a phenol based extraction
protocol. The cells are lysed in TRI Reagent (Sigma-Aldrich) and 1-bromo-
3-chloropropane (Sigma-Aldrich) is added to each sample at a 1:10 ratio. This
solution is vortexed for 10 seconds and centrifuged at 12000 RPM for 10 minutes
at 4 °C. The upper aqueous phase is transferred to a new tube whilst the organic
phase is discarded. One volume of propan-2-ol is added to the aqueous phase
to precipitate the RNA. This solution is vortexed for 10 seconds and incubated
at room temperature for 10 minutes before being centrifuged at 12000 RPM
for 5 minutes. The supernatant is removed without dislodging the RNA pellet
and impurities are cleared with a 75 % ethanol wash centrifuged at 7500 RPM
for 5 minutes. The supernatant is removed and the pellet is air dried prior to
being re-suspended in RNase free H2O. The RNA is then quantified using either
the NanoDrop 1000 or NanoDrop 2000 spectrophotometer (Thermo Fisher Sci-
entific).
The High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems by
Thermo Fisher Scientific) containing random primers is used according to the
manufacturer’s instructions. 100 ng of RNA is added to each reaction as detailed
in Table 2.7, and is incubated in the Veriti Thermal Cycler (Applied Biosystems)
with the steps detailed in Table 2.8.
2.2.2 Sybr Green Real Time Quantitative Polymerase Chain
Reaction (RT-qPCR) and Quantification
Primers for each of the target genes are designed using Primer3web (233,
234) to be compatible with Sybr green technologies and are detailed in Table
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Reagent Volume (µL)
10x RT Buffer 2.0
25x dNTP Mix (100 mM) 0.8
10x RT Random Primers 2.0
MultiScribe RT 1.0
RNase Free H2O 4.2
RNA (10 ng·µL-1) 10.0
Total Reaction Volume 20.0
Table 2.7: cDNA Reverse Transcription Reaction for mRNA using the High-Capacity
cDNA Reverse Transcription Kit.
Step Temperature (°C) Time (minutes)
1 25 10
2 37 120
3 85 5
4 4 ∞
Table 2.8: cDNA Reverse Transcription Thermal Cycler Conditions for mRNA using
the High-Capacity cDNA Reverse Transcription Kit.
2.9. Previously generated cDNA diluted to 1 ng·µL-1 is used as template in the
RT-qPCR reactions. The SYBR green PCR master mix (Applied Biosystems) is
used in 10 µL reactions as detailed in Table 2.10 and optimal primer concentra-
tions are determined according to the Applied Biosystems guidelines; selected
concentrations are listed in Table 2.11. Default SYBR green setting are used
on the ABi 7500 thermal cycler or on the QuantStudio 5 (Applied Biosystems)
(Table 2.12) and the PCR cycles are followed by melt curve acquisition. Primer
efficiency was determined from standard curves generated for each primer pair.
The efficiency (E) is calculated as follows:
E = 10
− 1
slope − 1
giving a scale from 0, no amplification of product per cycle, to 1, perfect doubling
each cycle. The efficiency has been calculated as a percentage as for each primer
used as detailed in Table 2.9 as a percentage.
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Gene Forward Sequence Reverse Sequence Efficiency
RPLP0 GCGACCTGGAAGTCCAACTA GGATCTGCTGCATCTGCTTG 100 %
AHNAK CGAGCCGGAGTTACAAGAGC CATCATCCCCGCTCAGAACC 82 %
BASP1 GCCAGCCGAGAACTCCAA TCCCTCCCTTGATGGGACAA 95 %
EMP1 TATAACCTCGGGAGGCAGGT GGAAACCAACCAGACATTGGC 96 %
FADS1 GTGAGTTGCCCAAGACCCAC TGTTTCCCAAGCTCCACAGAG 106 %
KLF9 AGAGTGCATACAGGTGAACGG TGATCATGCTGGGGTGGAAC 109 %
NEDD4L TCATCAACTGTCACGGGTGG GTGTAGTTGTCCGTGGCAGA 90 %
NRCAM GTCAATGGGAAAGGGGAGGG GCCATCGCTTCATCCACAGT 103 %
PKIA CGGGGAAGTCCCTGCTATGT AAGCAATCAGAGAAGGGGGC 100 %
PREX1 CTCAACGAGATCTTGGGCAC CTGGAACTGTAAGAGGAGGC 92 %
SH3BGRL ATCTCGCGGTGCTATTCGAG GAAGGCATCATAGTCCCCGC 96 %
SOCS2 TCATCAACTGTCACGGGTGG GTGTAGTTGTCCGTGGCAGA 91 %
STC2 AATACAGCGGAGATCCAGCAC CGAGGTGCAGAAGCTCAAGA 92 %
Table 2.9: SYBR Green Primer Sequences used for Validation of the Gene Expression
Array.
Reagent Volume (µL)
2x SYBR Green PCR Master Mix 5.00
Forward Primer (10 mM) 0.05 to 0.50
Reverse Primer 0.10 to 0.50
cDNA (1 ng·µL-1) 1.00 to 2.00
RNase Free H2O 2.00 to 3.85
Total Reaction Volume 10.00
Table 2.10: Sybr Green RT-qPCR Reaction.
2.2.3 RNA Samples for miRNA Study
Cells to be used for total RNA extractions are washed in PBS before being
stored at -20 °C until total RNA is extracted using either the mirVana miRNA
Isolation kit (Ambion by Thermo Fisher Scientific) as per the manufacturer’s
instructions, or a column-free adaptation of the protocol detailed below.
The column free miRNA extraction uses reagents from the mirVana miRNA
Isolation kit. The cells are disrupted in 600 µL of Lysis/Binding Buffer and
miRNA Homogenate Additive is added to each sample at a 1:10 ratio. This
solution is vortexed for 10 seconds and incubated on ice for 10 minutes. One
volume of Acid-Phenol:Chloroform is added to the tubes and the samples are
vortexed for 30 seconds before being centrifuged at 12000 RPM for 5 minutes.
The upper aqueous phase is transferred to a new tube whilst the organic phase
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Gene
Primer Concentration (nM)
Forward Reverse
RPLP0 0.50 0.50
AHNAK 0.05 0.10
BASP1 0.10 0.10
EMP1 0.05 0.10
FADS1 0.10 0.10
KLF9 0.30 0.30
NEDD4L 0.10 0.10
NRCAM 0.05 0.10
PKIA 0.10 0.10
PREX1 0.50 0.50
SH3BGRL 0.10 0.10
SOCS2 0.10 0.10
STC2 0.10 0.10
Table 2.11: Final SYBR Green Primer Concentrations used per Reaction for RT-qPCR
Gene Expression Analysis.
Step Temperature (°C) Time
Enzyme Activation Hold 95 10 minutes
40 cycles
Denature 95 15 seconds
Anneal/Extend 60 60 seconds
Table 2.12: Sybr Green RT-qPCR Cycling Conditions.
is discarded. One volume of propan-2-ol is added to the aqueous phase to
precipitate the RNA. This solution is vortexed for 10 seconds and incubated at
room temperature for 10 minutes before being centrifuged at 12000 RPM for 8
minutes. The supernatant is removed without dislodging the RNA pellet and
impurities are cleared with a 75 % ethanol wash centrifuged at 7500 RPM for 5
minutes. The supernatant is removed and the pellet is air dried prior to being
re-suspended in RNase free H2O. The RNA is then quantified using either the
NanoDrop 1000 or NanoDrop 2000 spectrophotometer.
The TaqMan miRNA Reverse Transcription Kit (Applied Biosystems) is used
according to the manufacturer’s instructions, with predesigned TaqMan primers
(Applied Biosystems) for the selected mature miRNA and small nucleolar RNA,
C/D box 44 (SNORD44 or RNU44), used as the housekeeping control, detailed
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in Table 2.15. 10 ng of RNA is added to each reaction as detailed in Table 2.13,
and is incubated in the Veriti Thermal Cycler with the steps detailed in Table
2.14.
Reagent Volume (µL)
dNTPs with dTTP (100 mM) 0.15
MultiScribe RT (50 U·µL-1) 1.00
10x RT Buffer 1.50
RNase Inhibitor (20 U·µL-1) 0.19
RNase Free H2O 4.16
5x RT Primer (miRNA specific) 3.00
RNA (2 ng·µL-1) 5.00
Total Reaction Volume 15.00
Table 2.13: cDNA Reverse Transcription Reaction for miRNA using the TaqMan
miRNA Reverse Transcription Kit.
Step Temperature (°C) Time (minutes)
1 16 30
2 42 30
3 85 5
4 4 ∞
Table 2.14: cDNA Reverse Transcription Thermal Cycler Conditions for miRNA using
the TaqMan miRNA Reverse Transcription Kit.
2.2.4 TaqMan Real Time Quantitative Polymerase Chain Reaction
(RT-qPCR) and Quantification
cDNA previously generated using miRNA specific primers is used as template
in the RT-qPCR reactions. The TaqMan Universal Master Mix II (Applied
Biosystems) is used in 20 µL reactions as detailed in Table 2.16. Default Taq-
Man setting are used on the ABi 7500 thermal cycler or on the QuantStudio 5
(Applied Biosystems).
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miRNA Assay Name Assay ID
RNU44 NR_002750 001094
miR127 hsa-miR-127 000452
miR409 hsa-miR-409-3p 002332
miR411 hsa-miR-411 001610
miR433 hsa-miR-433 001028
miR495 mmu-miR-495 001663
miR539 hsa-miR-539 001286
Table 2.15: TaqMan RNU44 MicroRNA Control Assay and MicroRNA Assays used
for miRNA RT-qPCR Analysis of Expression Levels.
Reagent Volume (µL)
2x TaqMan Master Mix 10.0
20x TaqMan miRNA Assay 1.0
cDNA (2 ng·µL-1) 2.0
RNase Free H2O 7.0
Total Reaction Volume 20.0
Table 2.16: TaqMan RT-qPCR Reaction.
Step Temperature (°C) Time
Enzyme Activation Hold 95 10 minutes
40 cycles
Denature 95 15 seconds
Anneal/Extend 60 60 seconds
Table 2.17: TaqMan RT-qPCR Cycling Conditions.
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2.2.5 RT-qPCR Analysis using the DDCt Method
For every experiment, a threshold of 0.1 is set for determining the threshold
cycle (Ct) values generated from RT-qPCR runs and technical duplicates are
averaged. A comparative Ct analysis is performed using the DDCt method. Ct
values for the reference gene (CtRef ), either RPLP0 for mRNA experiments,
or RNU44 for miRNA expression, are subtracted from those of the gene of
interest (CtGoI) giving the DCt value (2.1). The DCt values for each biolo-
gical replicate are then averaged. Next, the DCt average value of the reference
sample (∆CtControl) is subtracted to each DCt average (∆CtTreatment), giving
the DDCt average (2.2). This value is then utilised to calculate the fold change
(Fch) giving the expression of the gene of interest relative to the control for each
sample (2.3).
CtGoI − CtRef = ∆Ct (2.1)
∆CtTreatment −∆CtControl = ∆∆Ct (2.2)
Fch = 2
−∆∆Ct (2.3)
2.2.6 miRNA Array and Analysis
cDNA, prepared using the Megaplex Primer Pools (Applied Biosystems) as
per manufacturer’s instructions, is loaded onto the TaqMan low density miRNA
Human A and B Array cards as per the manufacturers instructions and run on
the ViiA 7 Real-Time PCR System (Applied Biosystems). The data is analysed
using the DDCt method and fold change analysis with DataAssist Software
(235). A 10-fold cut-off is selected to obtain values in top quartile of upregula-
tion for the BT-474 vs BT-474/L array. This cut-off was conserved for analysis
of the other miRNA array.
2.2.7 Gene Expression Array and Analysis
Two independent array experiments (one with technical duplicates and an-
other with triplicate), were completed with the Illumina Human HT12 v4.0
array on the lapatinib sensitive BT-474 and corresponding resistant cell line
(BT-474/L). The arrays were combined in order to make the data more robust,
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and were analysed to compare genes differentially expressed between the sensit-
ive and resistant cells. To cross-reference these results, they were combined with
the DMSO control conditions from the array used in the original publication of
the BT-474/L cell line (1) using the Affymetrix Human Genome U133 Plus 2.0
Array platform (GEO accession number: GSE16179). Using this extra data set
increase the number of replicates analysed, which should contribute to making
the analysis more robust.
The bioinformatic analysis was performed by members of the Chelela group,
Ai Nagano and Natasha Saghal. Normalisation and quality control of the ex-
pression data are performed on the upgraded version of o-miner transcriptomics
analysis platform (236), adapting LUMI (237–239) in the R statistical envir-
onment via Bioconductor packages (240). Expression data is analysed using
LIMMA (241) to fit a linear model to the expression data for each gene in or-
der to detect differentially expressed genes between two groups. Differentially
expressed genes are gauged using LIMMA empirical Bayes statistics module.
The adjusted p-values (false discovery rate) are estimated by Benjamini and
Hochberg procedure (242). The differentially expressed genes are selected when
the adjusted p-value is less than 0.05 and the absolute value of log fold change
is more than 1. Unsupervised hierarchical clustering (method: Ward, distance:
Pearson correlation) is performed on the heat map to assess the reproducibility
of the groupings. Once data from the different platforms have been analysed
independently, the results are combined, comparing the differently expressed
genes in both arrays.
2.3 Epigenetic Analysis
2.3.1 DNA Methylation and Histone Modification Reversal
The cells are grown until they are 60 % confluent. They are then treated with
5 µM 5-aza-2′-deoxycytidine (Aza) (Sigma-Aldrich) for 5 days. For the final
16 hours before collection of the cells, some samples are treated with 0.3 nM
Trichostatin A (TSA) (Sigma-Aldrich). On day 5 the cells are trypsinised and
washed with PBS before being pelleted and stored at -20 °C for use in further
experiments.
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Aza is a chemical analogue of cytidine (C) (Figure 2.1a) that can be integrated
into the DNA of proliferating cells instead of C (243). The Azacytosine-Guanine
dinucleotide is recognised by the methyltransferase and the nucleophilic attack
for the methylation process occurs. This causes the formation of a covalent
bond between the Azacytosine base and the enzyme (244). However, due to the
presence of the nitrogen group in position 5 in the cytosine base, the reaction
cannot proceed and the methylation mark is lost during replication causing
hypomethylation of DNA (245). TSA (Figure 2.1b) is an anti-fungal antibiotic
that inhibits class I and II mammalian HDACs (246, 247 ). It prevents the
removal of acetyl groups from core histone tails leading to the accumulation of
hyperacetylated histones which causes the DNA to become de-condensed.
(a)
(b)
Figure 2.1: Chemical Structure of Aza and TSA. (a) Chemical structure of 2′-
deoxycytidine and 5-aza-2′-deoxycytidine. Aza is a chemical analogue of
cytidine that can get integrated into the DNA of proliferating cells. How-
ever the aza analogue contains a nitrogen in position 5 in the cytosine base
leading to the methylation mark being lost during replication, leading to
hypomethylation of DNA. (b) inhibits class I and II mammalian HDACs
leading to the accumulation of hyperacetylated histones and to DNA be-
coming de-condensed
2.3.2 Bisulphite Conversion and Next Generation Sequencing
Multiplex bisulphite PCR assays was completed in Darren Korbie’s laboratory
as described by Korbie et al. (248). The regions selected for analysis are detailed
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in Table 2.18. Aligned sequences were computationally analysed by the BCI
Bioinformatics Core Team.
Region Start Position Stop Position Length (bp)
IG-DMR 101276905 101277735 830
MEG3-DMR 101293428 101294433 1005
CpG 1 101348386 101348698 312
CpG 2 101349373 101349860 487
Table 2.18: CpG Regions Selected for Methylation Analysis. The regions are located
on chromosome 14 using coordinates from the GRCh37/hg19 genome as-
sembly.
2.4 Protein Assays
2.4.1 Protein Quantification
Samples are lysed from a 24 well plate in 100 µL radioimmunoprecipitation
assay (RIPA) buffer and cell pellets collected after trypsinisation are washed in
PBS and lysed in up to 1.5 mL of RIPA buffer. The samples are centrifuged for
10 minutes at 12500 RPM at 4 °C and boiled for 5 minutes at 98 °C in laemmli
buffer.
2.4.2 Western Blotting
10 µg of protein are loaded onto either a 4-20 % gradient minigel (Bio-Rad,
Hercules, CA, USA), a 10 %, or 12 % acrylamide gel depending on the size of the
protein of interest. Lysates are separated by gel electrophoresis in tris-glycine
SDS running buffer and the samples are transferred to a polyvinylidene difluoride
(PVDF) membrane (GE Healthcare, Little Chalfont, Buckinghamshire, UK) in
tris-glycine buffer. Running and transfer conditions are described in Table 2.19.
The membrane is blocked for 45 minutes in the same buffer used for the primary
antibody. Primary antibodies and their details are listed in Table 2.20.
The primary antibody is incubated at 4 °C overnight, washed prior to sec-
ondary anti-rabbit antibody (Cell Signalling Technology, 7074) incubation for
45 minutes at room temperature. After a final wash, the membrane is incub-
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Running Transfer
Voltage (V) Time (minutes) Amperage (mA) Time (minutes)
110 10 300 60
140 60
Table 2.19: Running and Transfer Conditions Used for Western Blotting.
Protein Host Species Dilution Buffer Antibody
GAPDH Rabbit 1:5000 5 % milk in TBST CST2118
NEDD4L Rabbit 1:1000 5 % milk in PBST CST4013
PREX1 Rabbit 1:1000 5 % milk in PBST ab102739
SH3BGRL Rabbit 1:1000 5 % milk in PBST ab80865
Table 2.20: Antibody Dilutions and Species used for Secondary Antibody. CST: Cell
Signaling Technology, ab: abcam.
ated for 5 minutes with enhanced chemiluminescence (ECL) buffer. Detection is
carried out by using the G:BOX Chemi XT system (Syngene, Cambridge, UK).
2.5 Statistical Analysis
Analysis was performed using GraphPad Prism version 5.03 for Windows
(GraphPad Software, La Jolla, CA, USA, www.graphpad.com) normalised non-
linear regression protocol for dose-response curves from IC50 data. Statistical
significance was determined using a one-way ANOVA with a Dunnett’s post-test
comparing all conditions to the control condition. RT-qPCR data was analysed
using the ΔΔCt relative quantification method with normalisation to RNU44
expression and scb control. Statistical significance was determined either using
a one-way ANOVA with a Dunnett’s post-test comparing all conditions to the
control condition or a student’s t-test. For all tests, p ≤ 0.05 was considered
statistically significant.
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Region are Upregulated in Acquired
Resistance to Lapatinib
3.1 Sensitivity of HER2+ Cell Lines to Lapatinib
A panel of HER2+ breast cancer cell lines (Table 3.1) was screened to de-
termine the sensitivity of their response to lapatinib (Figure 3.1). The average
IC50 values for the cell lines are listed in Table 3.2, cell lines with an IC50 greater
than 1 µM were considered resistant. Determination of IC50 values confirmed
lapatinib sensitivity of BT-474, SKBR-3, and HCC1954 cells as well as intrinsic
resistance of JIMT-1 and MDA-MB-36.
Cell Line Site Morphology
Receptor Status
ER PR HER2
BT-474 Primary Epithelial + + +
HCC1954 Primary Epithelial - - +
SKBR-3 Metastasis: pleural effusion Epithelial - - +
JIMT-1 Metastasis: pleural effusion Epithelial - - +
MDA-MB-361 Metastasis: brain Epithelial + - +
Table 3.1: Cell Line Characteristics (249–252). These cell lines are all derived from
female breast cancers. ER: Œstrogen Receptor, PR: Progesterone Receptor,
HER2: Human Epidermal Growth Factor Receptor 2.
In order to examine the mechanism driving acquired resistance to lapatinib the
sensitive cell lines were made resistant to the drug through continuous exposure
to increasing concentrations of lapatinib. BT-474/L resistant cells have been
previously published (1) and SKBR-3/L and HCC1954/L cells were generated
during the course of this research. IC50 determination showed a clear shift, with
over a 20-fold increase in IC50 value for SKBR-3/L compared to SKBR-3, and
59
3 14q32 miRNAs are Upregulated in Resistance to Lapatinib
IC
5
0
 [
L
a
p
a
ti
n
ib
] 
(n
M
)
B
T-
47
4
B
T-
47
4/
L
SK
B
R
-3
SK
B
R
-3
/L
H
C
C
19
54
H
C
C
19
54
/L
M
D
A
-M
B
-3
61
JI
M
T-
1
0
200
400
600
800
1000
Acquired Intrinsic
Figure 3.1: Lapatinib IC50 values for a Panel of HER2+ Breast Cancer Cell Lines.
Three lapatinib sensitive cell lines were cultured in increasing concentra-
tions of lapatinib to generate cell lines with acquired resistance to the
drug; BT-474/L, SKBR-3/L, and HCC1954/L. Cell lines with an IC50
value greater than 1 µM are considered resistant. This value was used as
the cut-off for the y-axis of the graph as the assay was designed to obtain
IC50 values for the sensitive cell lines and mainly uses drug concentrations
< 1 µM (Table 2.4). Higher IC50 values are, therefore, not accurate as
they are extrapolated from the data. The IC50 values are obtained from
non-linear regression analysis of cytotoxicity experiments, average of at
least four experiments. MDA-MB-361 and JIMT-1 display intrinsic resist-
ance to the drug with an IC50 greater than 1 µM; they were not grown in
presence of the drug to develop resistance.
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more than a 50-fold increase for HCC1954/L relative to HCC1954, confirming
the cell lines have acquired resistance to lapatinib (Figure 3.1).
3.2 Cross-Resistance to Other Targeted Therapies
Having identified the lapatinib sensitive and resistant cells we decided to in-
vestigate how the cell’s response to lapatinib affected cross-resistance with other
HER targeting agents (Table 3.2) as other targeted therapies can be used to over-
come resistance to a prior treatment as they may work via different pathways.
Cell Line
Lapatinib
EGFR, HER2
(nM)
Trastuzumab
HER2
(mg·L-1)
Neratinib
pan-HER
(nM)
Dacomitinib
pan-HER
(nM)
Gefitinib
EGFR
(µM)
BT-474 28 0.4 4 68 5
BT-474/L 17938 89 11996 16364 26
SKBR-3 77 0.2 21 151 13
SKBR-3/L 1567 0.4 78 205 16
HCC1954 165 39 21 246 15
HCC1954/L 8599 27 2049 551 5
MDA-MB-361 2652 - 21 536 59
JIMT-1 2270 - 344 14311 224
Sensitive Resistant
Table 3.2: Average IC50 Values for a Panel of HER2+ Breast Cancer Cell Lines to
Various HER-Targeting Agents. The IC50 values are obtained from non-
linear regression analysis of cytotoxicity experiments, average of at least
three biological replicates. Sensitivity to the drug is shown in green and
resistance in red.
3.2.1 Trastuzumab
BT-474 is sensitive to the HER2-targeting monoclonal antibody, trastuzumab;
BT-474/L, however, is resistant to this treatment as it does not respond to
doses under 10 mg·L-1. This threshold value was selected based on previously
published data, as concentrations ranging from 4 mg·L-1 to 15 mg·L-1 are used
to generate trastuzumab resistant cell lines (253–257 ). SKBR-3 is also sensitive
to trastuzumab and, although the SKBR-3/L cells are still sensitive to the drug,
they are less so than their parental line. HCC1954 cells are intrinsically resistant
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to trastuzumab and this is conserved in the lapatinib resistant HCC1954/L
(Figure 3.2a). MDA-MB-361 and JIMT-1 have been previously reported to be
resistant to trastuzumab and they were not tested here (66, 77 ).
3.2.2 Neratinib
Neratinib is a pan-HER inhibitor therefore it targets all the members of the
HER family preventing compensation signalling through other HER receptors.
Hence its effectiveness as a treatment on the sensitive and de novo resistant lines
as their IC50s are all brought under the 1 µM threshold. The lapatinib sensitive
cells and SKBR-3/L also have low IC50 values with neratinib. The other two
acquired resistant lines, BT-474/L and HCC1954/L, are resistant to this drug
(Figure 3.2b).
3.2.3 Dacomitinib
Dacomitinib, another pan-HER inhibitor, on the other hand seems to be more
effective on the acquired resistant lines as both IC50 values for SKBR-3/L and
HCC1954/L are under the 1 µM resistance threshold. MDA-MB-361 is also
sensitive to the inhibitor as are the lapatinib sensitive lines; BT-474/L and
JIMT-1 however are not (Figure 3.2c).
3.2.4 Gefitinib
Since lapatinib targets both HER2 and EGFR, to confirm the sensitivity
observed in the cell lines was due to the HER2 targeting, rather than blocking
EGFR, the cells were also treated with an EGFR inhibitor, gefitinib. None of
the cell lines responded to gefitinib treatment (Figure 3.2d) and all the cell lines
have IC50 values greater than 1 µM. This confirms their dependence on HER2
signalling for survival and proliferation.
3.2.5 Summary
These results show there is some cross-resistance occurring with other HER2-
targeting therapies as the lapatinib resistant cells are less responsive to other
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Figure 3.2: IC50 Values for a Panel of HER2+ Breast Cancer Cell Lines to Various
HER-Targeting Agents. The IC50 values are obtained from non-linear re-
gression analysis of cytotoxicity experiments, average of at least three ex-
periments. (a) IC50 values for trastuzumab treatment in the paired sens-
itive and resistant cells. The y-axis is cut off at 10 mg·L-1. (b) IC50 values
for neratinib, and (c) IC50 values for dacomitinib in the paired cell lines as
well as two lines intrinsically resistant to lapatinib. The y-axis is cut off at
1000 nM. (d) IC50 values for gefitinib in the paired cell lines as well as two
lines intrinsically resistant to lapatinib. For (a, b, and c) the y-axis is cut
off at the generally accepted threshold for resistance. This value was used
as the cut-off for the y-axis of the graph as the assay was designed to obtain
IC50 values for the sensitive cell lines and mainly uses drug concentrations
< 1 µM (Table 2.4). Higher IC50 values are, therefore, not accurate as
they are extrapolated from the data.
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HER2-targeting treatments than the parental lines. Only BT-474/L cells were
resistant to all the HER2 inhibitors tested, HCC1954/L is only sensitive to
Dacomitinib while SKBR-3/L is sensitive to all the other HER2-targeting agents
tested, although it is always less sensitive to the drug than SKBR-3, its parental
line.
Similarly the de novo resistant lines behave differently, with MDA-MB-361
being sensitive to both pan-HER inhibitors, whilst JIMT-1 is only sensitive to
neratinib.
3.3 Phenotypic Differences Between the Paired Cell
Lines
3.3.1 Resistant Cells can Have More Filopodia and a Greater
Surface Area than Sensitive Lines
To investigate phenotypic changes observed between the sensitive and resist-
ant cells, the paired lines were stained with Hoechst and Phalloidin for immun-
ofluorescence (Figure 3.3a). The resistant cells have more stress fibres visible
in the cytoplasm, the cells also have a more irregular appearance with many
lamellipodia and filopodia (white arrows in Figure 3.3a). This demonstrates
that the resistant lines are phenotypically divergent to the sensitive line they
are derived from; with the resistant lines appearing more motile and invasive.
Additionally, both BT-474/L and HCC1954/L cells are significantly bigger
than their sensitive counterpart. BT-474 cells have a mean area of 300 µm2
whilst BT-474/L cells are on average 1930 µm2. HCC1954 cells are generally
634 µm2 and the resistant HCC1954/L are 846 µm2. SKBR-3 and SKBR-3/L
cells are of a similar size, on average 357 and 325 µm2 (Figure 3.3b). BT-474/L
has a slightly bigger nucleus than its paired BT-474 line. The other two isogenic
pairs have a similar nucleus size between sensitive and resistant (Supplementary
Figure 7.8).
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Figure 3.3: Comparison of Paired Lapatinib Sensitive and Acquired Resistant HER2+
Breast Cancer Cell Lines. (a) Hoechst (blue) and Phalloidin (red) staining
of the paired sensitive and resistant lines. The resistant lines appear to have
more stress fibres and filopodia, indicated by white arrows. This suggest
resistant cells could be more motile and invasive. (b) Cell area measured
for two to four frames per cell line. BT-474/L and HCC1954/L have a
bigger cell area than their sensitive counterparts. Mean and standard error
are shown, statistical significance is obtained from a one-way ANOVA with
Bonferroni’s Multiple Comparison post-test. Where results are statistically
significant p-values are shown on the graph, with ? for p ≤ 0.05, and
???? for p ≤ 0.0001.
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3.3.2 Lapatinib Sensitive and Acquired Resistant Cells do not Have
the Same Population Doubling Rate Rate
After showing the acquired resistant cells were might be invasive, although
invasion assays would be needed to confirm this, we investigated whether there
may also be a difference in the growth rate of the sensitive and resistant cells. To
determine how acquired resistance influenced cell growth, population doubling
studies were carried out. These showed BT-474 sensitive and BT-474/L resistant
lines grew very differently, with the resistant cells growing almost three times
faster than the sensitive ones. This, however, was not observed in the other two
acquired resistant lines, which grew slower compared to their paired parental
line. HCC1954 cells showed the most difference with a two fold decrease in
doubling rate in the HCC1954/L (Figure 3.4).
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Figure 3.4: Comparison of the Population Doubling Rate of Paired Lapatinib Sensitive
and Acquired Resistant HER2+ Breast Cancer Cell Lines without Lapat-
inib. BT-474/L cells are the fastest growing cell line with a doubling rate
almost three times higher than its paired parental line. HCC1954 cells
have a faster doubling rate than the paired HCC1954/L line. SKBR-3 and
SKBR-3/L lines have similar population doubling rates with the sensit-
ive cells growing slightly faster than the resistant ones. The population
doubling was carried out over 15 days and cells were counted and re-plated
every three days, an average of 3 biological replicates is shown. Statistical
significance is displayed for each pair of cell lines at day 15 and obtained
from a one-way ANOVA with Bonferroni’s Multiple Comparison post-test,
with ? for p ≤ 0.05, and ???? for p ≤ 0.0001.
66
3 14q32 miRNAs are Upregulated in Resistance to Lapatinib
3.4 miRNA Expression Across HER2+ Breast Cancer
Cell Lines
miRNAs have increasingly been linked to cancer and, in patients, changes in
miRNA expression profiles have been found to occur with resistance to therapies.
To identify the role of miRNAs in resistance to lapatinib, we investigated miRNA
levels in our panel of HER2+ breast cancer cell lines.
3.4.1 miRNA Expression in BT-474 Sensitive vs BT-474/L Resistant
Cells
In order to determine which miRNAs are involved in acquired resistance to
lapatinib, we compared changes in expression between sensitive and resistant cell
lines using a miRNA array. This showed many changes in miRNA expression
levels between the two cell lines.
Numerous miRNAs were significantly upregulated in the resistant cells, with
164 miRNAs having over a 2-fold upregulation in the BT-474/L cells compared
to the BT-474. The data was analysed using the DDCt method and fold change
analysis with DataAssist Software (235). Using a 10-fold change cut-off, 43
miRNAs were found to be upregulated in the resistant cells (Figure 3.5a). Fewer
miRNAs were downregulated in BT-474/L, with only 12 targets displaying over
a 10-fold downregulation compared to BT-474 (Figure 3.5b).
Of the most upregulated miRNAs, 44 % occupy the same genomic region: the
14q32, this region contains two miRNA clusters: the 14q32.2 and the 14q32.31.
This was the most represented genomic region, the second most represented re-
gion with 8 upregulated miRNAs was the 19q13.42. There are nine other regions
represented in the upregulated miRNAs which have on average 1.8 upregulated
miRNAs (Figure 3.6a). As miRNAs from a same genomic locus have been
shown to be involved in regulating similar pathways, we decided to investigate
the 14q32 miRNAs.
The 19q13.42 is the second most upregulated miRNA region, with 8 miRNAs
overexpressed in the resistant compared to the sensitive line. The 19q13.42
contains 34 known coding genes and a miRNA cluster of 50 miRNAs (258) There
are few reports of this region’s role in cancer. miRNAs in the 19q13.42 region
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Figure 3.5: miRNA Expression in BT-474/L Relative to BT-474 Cells Measured by
miRNA Array. miRNA profiling using the Human TaqMan Array Card
for the lapatinib sensitive HER2+ BT-474 cell line and the paired lapat-
inib resistant cells BT-474/L, results are averaged for two replicates. This
array identified a panel of differentially expressed miRNAs in the resist-
ant compared to the sensitive cells. After fold change analysis a cut-off
of 10-fold was selected. (a) 43 miRNAs were found to be significantly up-
regulated of which 44 % are located in the 14q32 locus (pink and red).
miR127, miR409, miR411, miR433, and miR495 (red) were selected for
further validation of their role in resistance; miR539 was also added to this
list as it was upregulated in the resistant cells, with an 8-fold increase in
expression. (b) 12 miRNAs were significantly downregulated with over a
10-fold decrease in expression.
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Figure 3.6: Analysis of the miRNA Array (a) Chromosomal location of miRNAs up-
regulated in the array. The 14q32 region is the most represented region,
the second region is the 19q13.42 with less than half as many miRs as the
14q32 upregulated over 10-fold. (b) Comparison of the probes present in
the array to miRNAs in 14q32 Region. Out of the individual 671 probes in
the TaqMan miRNA array, 61 corresponded to 43 out of 52 miRNA genes
found in the 14q32 miRNA clusters.
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14q32.2 14q32.31
miR-493 miR-337 miR-665 miR-379 miR-411 miR-299 miR-380
miR-431 miR-433 miR-127 miR-1197 miR-323a miR-758 miR-329-1
miR-432 miR-136 miR-370 miR-329-2 miR-494 miR-1193 miR-543
miR-495 miR-376c miR-376a-2 miR-654
miR-376b miR-376a-1 miR-300 miR-1185-1
miR-1185-2 miR-381 miR-487b miR-539
miR-889 miR-544a miR-655 miR-487a
miR-382 miR-134 miR-668 miR-485
miR-323b miR-154 miR-496 miR-377
miR-541 miR-409 miR-412 miR-369
miR-410 miR-656 miR-1274
Table 3.3: miRNAs from the 14q32.2 and 14q32.31 Clusters. The miRNAs are listed in
the order they are encoded in the genome within each cluster. The miRNAs
selected for further validation are highlighted, two are in the 14q32.2 and
four in the 14q32.31 cluster.
have been suggested to be oncogenes (259). The 19q13.42 miRNAs have been
found to be upregulated in 10 % of pancreatic cancers and high expression of the
miRNAs correlates to poor survival (260). Mainly, amplifications in this region
have been linked to embryonal tumours with ependymoblastic rosettes (261). In
these cancers amplification of the region can be used a diagnostic maker (262).
The 19q13.42 region was not selected for further investigation due to the lack
evidence of a role in either breast cancer or resistance to therapies. Moreover,
even though both the 14q32 and 19q13.42 regions contain similar numbers of
miRNAs, there are more than double the number of miRNAs upregulated in
the 14q32 than in the 19q13.42 (Figure 3.6a).
There are 52 annotated miRNA genes in the 14q32 region (Table 3.3), not
all of which were represented in the array (Figure 3.6b), and two protein cod-
ing genes. Expression levels of the genes was not significantly altered between
the sensitive and resistant lines. This will be discussed further in Chapters 4
and 5. Six miRNAs from the 14q32 region were selected for further validation
of their role in resistance: miR-127-3p (miR127), miR-409-3p (miR409), miR-
411 (miR411), miR-433 (miR433), miR-495 (miR495), and miR-539 (miR539).
Their sequence and miRBase accession number are listed in Table 3.4. The first
five miRNAs have a fold change greater than 10 in the resistant cells compared
to BT-474.
There are 9 miRNAs in the14q32.2 cluster, 5 of these, miR127, miR-431, miR-
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miRNA Sequence miRBase Accession Name
hsa-miR-127-3p UCGGAUCCGUCUGAGCUUGGCU MIMAT0000446 miR127
hsa-miR-409-3p GAAUGUUGCUCGGUGAACCCCU MIMAT0001639 miR409
hsa-miR-411-5p UAGUAGACCGUAUAGCGUACG MIMAT0003329 miR411
hsa-miR-433-3p AUCAUGAUGGGCUCCUCGGUGU MIMAT0001627 miR433
hsa-miR-495-3p AAACAAACAUGGUGCACUUCUU MIMAT0002817 miR495
hsa-miR-539-5p GGAGAAAUUAUCCUUGGUGUGU MIMAT0003163 miR539
Table 3.4: Mature miRNA Sequences and miRBase Accession Numbers for the Selected
miRNAs and abbreviation used.
370, miR433, and miR-432 are upregulated over 10-fold. miR127 is the most
upregulated miRNA from the array so it was selected for further analysis. It
has been shown to be epigenetically regulated in prostate, bladder, and colon
tumours (263) and can be silenced by CpG hypermethylation. In many cancer
types miR127 has been found to be a tumour suppressor miRNA as it is often
downregulated in tumours. miR127 expression can lead to inhibition of cell
cycle progression, proliferation, and migration (264). miR127 has been seen
to inhibit B-Cell chronic lymphocytic leukaemia (CLL)/Lymphoma 6 (BCL6)
translation and lead to senescence (265). In breast cancer, miR127 is generally
expressed at low levels, probably because of its tumour suppressive role. Indeed,
low levels of the miR127 have been associated with poor prognosis and lymph
node metastasis (266). Contrastingly, higher levels of miR127 have also been
observed in patients with breast cancer compared to healthy (267 ). Most of the
studies listed here haven’t established differences in the breast cancer subtypes,
thus it is impossible to confirm whether the affirmations made about miR127
are applicable to all subtypes equally. Due to these opposing findings, it is
necessary to study miR127 more in detail to conclude on its role in resistance.
The average expression of the remaining 4 miRNAs from the 14q32.2 cluster
is closest to levels of miR433. This miRNA was, therefore, selected as rep-
resentative for this region. miR433 has been reported to be downregulated in
breast cancer cell lines where it can inhibit AKT (268), and lead to inactivation
of MAPK signalling causing apoptosis (269). These studies, however, did not
look at variation of miR433 between different subtypes and no HER2+ cell lines
were included in their work. The miRNA has also been shown to regulate the
AKT b-catenin pathway in cervical cancer (270) and reduce EMT in bladder
cancer by inhibiting AKT, GSK3, and Snail signalling (271). miR433 has been
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shown to inhibit Notch signalling in retinoblastoma (272) and in ovarian cancer
where the miRNA was linked to inhibition of invasion (273). In colorectal can-
cer, miR433 can suppress migration and proliferation (274) and reduce viability
through Metastasis-Associated In Colon Cancer Protein 1 (MACC1) regulation
(275). The microRNA has also been found to inhibit proliferation in oesopha-
geal squamous cell carcinoma by targeting GRB2 (276). These results point
towards miR433 acting as a tumour suppressive miRNA, however, this miRNA
was also shown to be upregulated in resistance to certain cancer therapies. In
ovarian cancer, miR433 was overexpressed in paclitaxel resistance, where it in-
hibits Cyclin Dependent Kinase 6 (CDK6) leading to a senescent phenotype
(277 ). The miRNA was also found to be upregulated in gemcitabine acquired
resistance in patients with gallbladder cancer, where increased serum levels of
miR433 were observed in patients with drug resistant tumours (278). Due to
the disparate roles identified for miR433 and the lack of data about its function
in HER2+ breast cancer, it is necessary to further study this miRNA.
The other four miRNAs selected are encoded in the 14q32.31, this regions con-
tains more miRNAs than the 14q32.2 which is why more miRNAs were selected
from the 14q32.31 region.
miR409 functions in a context dependant manner acting either as a tumour
suppressive or an oncogenic miRNA. In colorectal, gastric, and lung cancers,
miR409 expression is generally reduced, backing its role as a tumour suppressor
in those settings. Indeed, the miRNA is a negative regulator of cell migration,
invasion, and metastasis in colorectal cancer (279) where it targets GRB2 Asso-
ciated Binding Protein 1 (GAB1) leading to reduced levels of the protein (280).
In gastric cancers, miR409 exerts it function as a tumour suppressor by bind-
ing the pro-metastatic gene Radixin (RDX) (281) as well as causing apoptosis
by targeting the transcriptional regulator Plant homeodomain (PHD) Finger
Protein 10 (PHF10) (282). This prevents PHF10 from binding to the Caspase
3, Apoptosis-Related Cysteine Peptidase (CASP3) promoter region leading to
activation of the apoptosis caspase cascade. In lung adenocarcinoma miR409
is also involved in CASP3 dependant apoptosis, as the miRNA represses ex-
pression of the Mesenchymal Epithelial Transition Proto-Oncogene, Receptor
Tyrosine Kinase (MET) which leads to a decrease in AKT phosphorylation, in
turn causing the downregulation of B-Cell CLL/Lymphoma 2 (BCL2) and an
increase in BCL2 Associated X, Apoptosis Regulator (BAX) levels eventually
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leading to apoptosis (283). Similarly, in breast cancer, the miRNA was found
to target AKT Serine/Threonine Kinase 1 (AKT1). This leads to inhibition of
cancer cell growth and metastasis (284). This work was carried out in triple
negative and luminal A cell lines, which are all HER2 negative. miR409 has
also been suggested to reduce cell growth and invasion by targeting Zinc Finger
E-Box Binding Homeobox 1 (ZEB1) (285). This work was done in a triple neg-
ative cell line and might thus not be relevant in HER2+ breast cancer. miR409
levels were also seen to be lower in breast cancer compared to healthy tissue
(286), however, this study did not look at levels in the individual subtypes nor
how this influenced survival. Conversely, in prostate cancer, miR409 was found
to act as oncogenic miRNA by promoting metastasis and EMT (287 ). Indeed
high levels of miR409 in patients has been associated with poor prognosis and
reduced progression-free survival. The miRNA has been found to target tumour
suppressor genes such as RAS Suppressor Protein 1 (RSU1) which is involved in
inhibition of the RAS/MAPK pathway (288). Due to the dual role of miR409
depending on the context and the lack of evidence in HER2+ breast cancer,
further validation is necessary to conclude on its role in resistance.
miR411 has been reported to be a tumour suppressive miRNA in renal cell
cancer (289), in ovarian cancer (290), and in gastric adenocarcinoma (291) as
its expression downregulated. In breast cancer it has also been suggested to act
as a tumour suppressor as it was found to be downregulated in patients (292),
however, this study did not correlate levels of the miRNA with the different
subtypes so it is not possible to say whether this data is relevant to HER2+
breast cancers. miR411 was reported to prevent proliferation and migration
of cells by inhibiting Specificity Protein 1 (SP1) (293) as well as GRB2, and
therefore RAS, signalling (292). Again, none of these papers specifically invest-
igated how miR411 expression was altered in HER2+ breast cancer compared
to other subtypes. miR411 was found to be expressed at lower levels in drug
resistant malignant pleural mesothelioma when compared to sensitive (294).
In lung cancer however, miR411 was found to act as an oncogenic miRNA as
it targets Sprouty Receptor Tyrosine Kinase Signalling Antagonist 4 (SPRY4)
and Thioredoxin Interacting Protein (TXNIP) (295) as well as the tumour sup-
pressor Forkhead Box O1 (FOXO1) which leads to increased proliferation of
the cancer (296). In hepatocellular carcinoma the miRNA targets Itchy E3
Ubiquitin Protein Ligase (ITCH) which leads to upregulation of CCND and c-
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MYC which promotes proliferation (297 ). As there is no conclusive evidence for
the role of miR411 in resistance in HER2+ breast cancer, further investigation
of the miRNA is necessary.
miR495 has a context dependant role; it can act as both a tumour suppressor
or an oncogene. The miRNA has been reported to be downregulated in mixed
lineage leukaemia (MLL) (298) suggesting it acts as a tumour suppressor in
this cancer. miR495 has been shown to target CDK6 in glioblastoma (299), and
inhibit migration by downregulating Protein Tyrosine Phosphatase Type IVA,
Member 3 (PTP4A3) in gastric cancer (300, 301). It also leads to downregu-
lation of Metastasis Associated 1 Family, Member 3 (MTA3) in non-small cell
lung carcinoma (NSCLC) (302). In cisplatin (DDP) resistant NSCLC upregula-
tion of the miRNA has been shown to lead to downregulation of anti-drug genes
ATP Binding Cassette Subfamily G Member 2 (Junior Blood Group) (ABCG2)
and Excision Repair Cross-Complementing 1, Endonuclease Non-Catalytic Sub-
unit (ERCC1) (303). miR495 has been found to be downregulated in breast
cancer cells after induced EMT (304). Contrastingly, miR495 has also been
found to act as an oncogenic miRNA in hepatocellular carcinoma where it is
upregulated leading to increased proliferation. By artificially decreasing levels
of the miRNA, miR495 was found to target Menage A Trois Cyclin Dependent
Kinase-Activating Kinase Assembly Factor 1 (MNAT1) leading to decreased
tumour growth (305). The miRNA has been found to be significantly upregu-
lated in breast cancer compared to normal tissue. It also promotes cell mobility
and migration through inhibition of the junctional adhesion molecule F11 Re-
ceptor (F11R) and is associated with increased breast cancer progression (306).
miR495 has been found to be upregulated in breast cancer stem cell popula-
tions as well as to promote oncogenesis and hypoxia resistance (307 ). Due to
the available data on miR495, it appears to be a promising target to investigate
resistance in HER2+ breast cancers.
miR539 is expressed approximately eight times higher in BT-474/L compared
to BT-474 and is therefore not represented in Firgure 3.5a. It was selected to
represent the other 14q32 miRNAs, the ones that are not upregulated more than
10-fold but are still expressed at higher levels in the resistant cells compared to
the sensitive ones. miR539 has been found to act as a tumour suppressor.
In colorectal cancer, miR539 targets the oncogene Runt Related Transcription
Factor 2 (RUNX2) thus low levels of the miRNA have been found to correl-
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ate with a more advanced stage and lymph node metastasis (308). High levels
of miR539 have been shown to reduce tumour growth in xenograft models,
where the miRNA was found to inhibit SRY (Sex Determining Region Y)-Box
4 (SOX4). This miRNA has been linked to reduced proliferation and invasion
in glioma cells where it targets DIX Domain Containing 1 (DIXDC1) which is
a positive regulator of Wingless-Type MMTV Integration Site (Wnt) signalling
(309). In prostate cancer, miR539 also inhibits progression by targeting the on-
cogene Sperm Associated Antigen 5 (SPAG5), which is required for progression
into anaphase (310). miR539 has also been found to inhibit thyroid cancer meta-
stasis by targeting Caspase Recruitment Domain Family Member 11 (CARD11)
thus preventing activation of Nuclear Factor Kappa B Subunit (NF-kB) sig-
nalling and of the Inhibitor Of Nuclear Factor Kappa B Kinase (IKK) complex
(311). Breast cancer tissue was identified as having lower levels of miR539 than
normal tissue, where low levels of the miRNA correlated with lymph node meta-
stasis. miR539 was found to lead to a decrease in EGFR levels in luminal and
triple negative cell lines (312). In triple negative breast cancers, the miRNA was
found to lead to downregulation of Laminin Subunit Alpha 4 (LAMA4) which
appears to be involved in proliferation and migration (313). In melanoma, mi539
has been observed to be upregulated by the Androgen Receptor (AR) which
causes increased Melanocyte Inducing Transcription Factor (MITF) protein de-
gradation leading to increased invasiveness (314). miR539 has been reported to
be involved in resistance to therapy where it was reported to be both down- and
upregulated. miR539 was downregulated in DDP resistant compared to sensit-
ive NSCLC where loss of the miRNA leads to increased levels of Doublecortin
Like Kinase 1 (DCLK1) as it is no longer repressed by miR539. This upreg-
ulation allows for increased pro-survival PI3K/AKT/mTOR signalling (315).
miR539 was also found to overcome arsenic trioxide resistance in hepatocellular
carcinoma, where overexpression of the miRNA leads to decreased expression
of the anit-apoptotic factors BCL2 and BCL2 Like 1 (BCL2L1), leading to cell
death (316). None of these studies investigated the role of miR539 in HER2+
breast cancer therefore further investigation of the miRNA would be necessary.
Due to the conflicting reports on these miRNAs, and the lack of evidence
in HER2+ breast cancer, the 14q32 region necessitates further investigation to
conclude on the role of these miRNAs in resistance to therapy.
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3.4.2 Baseline miRNA Expression in Other HER2+ Breast Cancer
Cell Lines
The changes in miRNA expression observed in BT-474 paired cell lines were
validated by stem-loop RT-qPCR on the HER2+ breast cancer panel with paired
lapatinib sensitive and acquired resistant cell lines as well as intrinsically resist-
ant lines (Figure 3.7). miRNA levels in all the cell lines represented in Figure
3.7 are shown relative to BT-474, to allow comparison between all the different
cell lines.
In the sensitive cell lines, we compared the expression of the miRNA to the
sensitive BT-474 cell line in order to determine the variability of miRNA ex-
pression across our panel. SKBR-3 sensitive cells have similar levels of miRNA
expression than BT-474, HCC1954 cells also express miR127 and miR539 at
similar levels to BT-474. However, in the HCC1954 line, the other miRNAs
are present at higher levels with miR409 and miR495 having approximately a
2-fold overexpression, and miR411 and miR433 about a 14- and 10-fold increase
respectively when compared to BT-474 expression levels (Figure 3.7a).
The de novo resistant lines MDA-MB-361 and JIMT-1 show quite different
miRNA expression patterns, with MDA-MB-361 having high miRNA expression
with levels very similar to those of BT-474/L. Conversely, JIMT-1 has very low
levels of miRNAs (Figure 3.7b). Further investigating gene targets and signalling
pathways altered between these cells lines could highlight similarities between
them.
3.4.3 Baseline miRNA Expression in Lapatinib Acquired Resistant
HER2+ Breast Cancer Cell Lines
In the acquired resistant lines, a greater than ten-fold upregulation for all six
of the miRNAs was confirmed in the BT-474/L cells compared to the BT-474.
SKBR-3/L cells showed a slight increase in miR127 and miR539 expression
compared to SKBR-3. The other four miRNAs have at least a ten-fold upregu-
lation, with miR409 having the greatest increase in expression in the acquired
resistant line.
In HCC1954/L there is an upregulation in all miRNA expression compared
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Figure 3.7: Baseline miRNA Expression in Sensitive and Resistant HER2+ Breast
Cancer Cell Lines. Results are obtained by stem-loop RT-qPCR, are ana-
lysed by fold change analysis, and are averaged for at least three replic-
ates. Expression for all cell lines is relative to BT-474 cells. (a) Overlay
of miRNA expression in paired sensitive and acquired resistance lines re-
lative to BT-474. (b) miRNA expression in cells intrinsically resistant to
lapatinib relative to BT-474. Endogenous levels of miRNA expression were
obtained by RT-qPCR and results analysed using the DDCt relative quan-
tification method, miRNA expression was normalised to RNU44 for each
cell line. Baseline miRNA expression is similar between BT-474, SKBR-3,
and JIMT-1 cell lines.
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to the sensitive HCC1954 line. miR433 has the smallest change with only a
2.3-fold increase in the resistant cells, with levels ranging from approximately
10 to 23. miR409 and miR495 have the highest upregulation in HCC1954/L
cells with a 14-fold increase in expression (Figure 3.7a).
3.5 Summary
These results indicate that the adaptive mechanisms of non-isogenic cells dif-
fer. Lapatinib resistance was found to decrease sensitivity to other HER2-tar-
geting agents, however the cells do not all exhibit the same cross-resistance pat-
terns suggesting they may have adapted to lapatinib in different ways. SKBR-
3/L is the only cell line to show decreased sensitivity to other HER2-targeting
agents without it being resistant to any of them. The other lapatinib acquired
resistant cell lines display varying patterns of resistance to the HER2-targeting
agents. Some cross-resistance was also observed in the intrinsically resistant
HER2+ cells.
We also showed the acquired resistant lines had a different appearance, with
both BT-474/L and HCC1954/L cells having a significantly bigger surface area
than their parental line, with BT-474/L also displaying an enlargement in nuc-
leus size. The resistant cell lines also have an increase in stress fibres as well
as protrusions and filopodia, suggesting these cells could be more motile and
invasive. Additionally, the acquired resistant cells do not have the same growth
pattern, with the BT-474/L cells having the fastest population doubling rate,
SKBR-3/L a similar rate to its parental line, and HCC1954/L cells growing
slower than the HCC1954 line. Again, these differences suggest the cells have
developed different mechanisms of adaptation to lapatinib.
miRNAs have been found to play an important role in resistance to therapies,
with expression profiles being altered over time leading to differing levels of
individual miRNAs in resistant cells compared to sensitive cells. To get insight
into the changes occurring in the resistant cells we decided to investigate shifts
in miRNA expression. Levels of many miRNAs were changed in the BT-474/L
cells, with the majority of the most significantly upregulated targets located
in the 14q32 region which contains two miRNA clusters. A similar pattern of
miRNA overexpression in the other acquired resistance lines was observed.
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Resistance is multi-factorial, thus it is not surprising that cells intrisically
resistant to lapatinib do not have the same miRNA changes. Intrinsic resistance
to lapatinib may not rely on changes in miRNA expression since JIMT-1 and
MDA-MB-361 have opposing miRNA expression patterns. However, although
the acquired resistant lines behave differently, they all have miRNA upregulation
as a common finding of acquired resistance to lapatinib.
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4.1 The 14q32 Cluster
4.1.1 Imprinting
The 14q32 region is located on chromosome 14 at band 32 and is an imprinted
region which is highly conserved in mammals. It contains paternally expressed
genes (PEGs), Delta, drosophila like homologue 1 (DLK1) and Retrotransposon-
like gene 1 (RTL1), which are protein coding, and maternally expressed genes
(MEGs), MEG3, or Gtl2 in mice, RTL1as, and MEG8, which are non coding
genes (317, 318) (Figure 4.1). The function of MEG3 is not clear, however,
it produces a long non-coding RNA (lnRNA) (319). DLK1 is a member of the
delta-notch family of proteins (320) involved in cellular differentiation signalling
(321, 322) and is important in early embryonic development, postnatal growth,
and fat deposition (323).
Imprinting of this region is thought to be controlled by three differentially
methylated regions (DMRs) (324, 325) with the intergenic-differentially methyl-
ated region (IG-DMR) (325, 326) acting as the imprinting control region. Two
secondary DMRs also contribute to regulate the imprinted genes; the DLK1-
DMR (327 ) and the MEG3-DMR which overlaps the MEG3 promoter region as
well as the MEG3 gene body (326, 328, 329). Contrary to imprinted methyla-
tion on the IG-DMR, which is inherited from the gametes (330), methylation on
the MEG3-DMR appears post-fertilisation. This region contains seven putative
CCCTC-binding factor (CTCF) binding sites (324, 331), CTCF is an enhancer
blocking protein which has been implicated in transcriptional activation or re-
pression and imprinting, this protein binds to unmethylated DNA in an allele
specific manner preventing target gene expression (332, 333).
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Figure 4.1: Schematic of the 14q32 Locus. miRNAs in the 14q32 domain are mater-
nally imprinted. The intergenic-differentially methylated region (IG-DMR)
is methylated on the paternal chromosome preventing expression of the ma-
ternally expressed genes (MEG) as well as the miRNA clusters. miR127
is located in the 14q32.2 miRNA cluster, while miR409 and miR495 are in
the 14q32.31 miR cluster. miRNAs in both clusters are polycistronic how-
ever it is unclear whether both clusters are regulated by the same promoter
region or if their transcription is regulated individually.
4.1.2 miRNA Regulation
The 14q32 region contains one of the largest polycistronic miRNA clusters
identified, with 52 miRNAs in humans (334). It is syntenic to the distal region
of the mouse chromosome 12 which contains 61 miRNAs (318).
This region is separated into two different miRNA clusters: 14q32.2 and
14q32.31 (Figure 4.1); it is unclear whether both miRNA clusters are tran-
scribed as one long polycistronic RNA or as two separate smaller polycistronic
RNAs (334). These miRNAs could be processed as long transcripts originating
form the MEG3 promoter, thus they would be controlled by both the MEG3-
and IG-DMRs. If the miRNA clusters are transcribed separately, it has been
speculated that the 14q32.2 miRNAs could be controlled by a separate promoter
region (334, 335).
Expression of the miRNAs is negatively correlated to methylation of the IG-
DMR, thus on the paternal allele where the IG-DMR is methylated, the miRNAs
are not expressed (326). The role of the MEG3-DMR on the other hand is not
as straight forward; it has a bivalent pattern where methylation of the MEG3
promoter region positively correlates with miRNA expression, and methylation
of the gene body region is predominantly negatively correlated to miRNA ex-
pression (327 ).
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4.1.3 Role of the 14q32
The primary role of this region has been found to be regulation of neovascu-
larisation after injury (336) with most miRNAs silenced in healthy adult tissue
(327 ). Other genes expressed in early developmental stages are expressed from
the paternal allele (337, 338). miRNAs from this region have also been involved
in oncogenesis and malignant growth through increased proliferation and cell
survival signalling (339, 340). Loss of imprinting, leading to increased miRNA
signalling has been identified in leukaemia (327 ) and has been found to promote
metastasis in lung adenocarcinoma (341).
This region is involved in disease in the form of maternal and paternal unipar-
ental disomies (UPDs), respectively upd(14)mat and upd(14)pat. Both UPDs
have distinct phenotypes with various congenital anomalies and with deleterious
phenotypes resulting from loss or overexpression of imprinted genes, suggesting
that, here, gene copy number is a factor in regulating gene function (342, 343).
upd(14)mat, also known as Temple Syndrome, is the most common UPD of the
two, with affected individuals having two maternal copies of the region (344,
345), upd(14)pat, or Kagami-Ogata Syndrome, has a more severe phenotype
and occurs less frequently (344, 346, 347 ). This suggests that genes expressed
from the maternal allele play an important role in development.
4.2 14q32 miRNA Expression is Controlled by DNA
Methylation and Histone Acetylation
The miRNA array showed that the region with the highest number of differ-
entially expressed miRNAs in the acquired resistant BT-474/L line the 14q32
region. The miRNA are all expressed from the maternal allele. The paternal
allele expresses the PEGs DLK1 and RTL1, which are the only coding genes of
this chromosomal section. Their expression was not significantly altered between
the sensitive and resistant lines (discussed in Chapter 5). Due to the substantial
role of epigenetics in controlling gene expression in this region, and that only ex-
pression of the MEGs was altered, we investigated how epigenetic modifiers were
involved in the difference of miRNA expression observed between the sensitive
and resistant cell lines.
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4.2.1 miRNA Expression is Increased in 5-Aza-2′-deoxycytidine
(Aza) Treated Cells
To study how miRNAs are affected by methylation, BT-474 cells were treated
with the global demethylating agent 5-Aza-2′-deoxycytidine (Aza). Altered
levels of miRNA expression were measured by miRNA array and compared to
untreated BT-474 cells.
Aza is a chemical analogue of C that can be integrated into the DNA of pro-
liferating cells instead of C. The chemical structure of the analogue prevents
methylation resulting in the hypomethylation of DNA. If promoter regions con-
trolling the expression of the miRNAs are methylated, then treatment with a
demethylating agent should lead to an increase in target expression.
When comparing the hypomethylated BT-474 Aza to the untreated BT-474
samples, there are 45 miRNAs with more than a 10-fold increase (Figure 4.2) and
13 with between 5 and 10-fold increase (data not shown) in the Aza compared
to untreated sample.
Other
Other miRs in 14q32
Selected miRs in 14q32
m
iR
-1
3
5
b
m
iR
-4
5
0
a
m
iR
-5
1
7
a
m
iR
-1
3
9
-3
p
m
iR
-6
7
5
m
iR
-3
7
6
c
m
iR
-3
8
2
m
iR
-4
1
1
m
iR
-4
9
9
-5
p
m
iR
-5
1
9
d
m
iR
-9
2
b
*
m
iR
-5
0
8
-3
p
m
iR
-1
3
4
m
iR
-5
1
8
b
m
iR
-3
8
3
m
iR
-5
7
6
-5
p
m
iR
-1
2
7
-3
p
m
iR
-4
8
7
b
m
iR
-3
6
3
m
iR
-5
1
1
m
iR
-6
2
7
le
t-
7
e
*
m
iR
-4
5
1
m
iR
-2
2
0
b
m
iR
-5
4
2
-5
p
le
t-
7
b
*
m
iR
-1
9
8
m
iR
-1
3
6
*
m
iR
-6
2
9
m
iR
-3
7
4
b
*
m
iR
-2
1
9
-2
-3
p
m
iR
-4
4
9
b
m
iR
-5
2
6
b
*
m
iR
-1
2
4
*
m
iR
-4
3
3
m
iR
-3
0
2
c
m
iR
-2
9
8
m
iR
-1
8
2
*
m
iR
-4
1
1
*
m
iR
-5
9
2
m
iR
-2
1
1
m
iR
-5
6
9
m
iR
-1
3
6
m
iR
-8
9
1
a
m
iR
-9
4
4
1
10
100
1000
10000
F
o
ld
 c
h
a
n
g
e
 n
o
rm
a
li
s
e
d
 t
o
R
N
U
4
4
 R
N
U
4
8
Figure 4.2: miRNA Expression in BT-474 Cells Treated with 5-Aza-2′-deoxycytidine
(Aza) Relative to Untreated BT-474. miRNA profiling using the Human
TaqMan Array Card for a single replicate of Aza treated and untreated
BT-474 cells. This screen highlights the vast number of miRNAs affected
by DNA demethylation. After fold change analysis a cut-off of 10 fold was
selected.
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4.2.2 14q32 miRNA Expression Changes in Aza and Trichostatin A
(TSA) Treated Cell Lines
The results from the array suggests that expression of the miRNAs in the
imprinted region can be altered by changes in methylation levels. To determine
how epigenetic changes are involved in regulating miRNA expression in the
lapatinib sensitive and acquired resistant lines, the samples were treated with the
global demethylating agent Aza, the Histone deacetylase inhibitor Trichostatin
A (TSA), or a combination of both agents.
Aza treatment should only lead to demethylation and increased expression
of previously methylated genes. Histone acetylation is involved in chromatin
structure, therefore by adding the HDAC inhibitor, the DNA is maintained in
an open configuration. Nonetheless if the DNA is methylated, the open con-
figuration will not affect gene expression. Thus the combination of both de-
methylation and an open chromatin structure, should lead to even higher levels
of target gene expression than the single agent conditions. Due to the nature
of these agents, the changes caused by both Aza and TSA are random. This
leads to high variability between replicates. For this reason, the results shown
in Figure 4.3 are of one representative experiment. Additional experiments are
shown in Supplementary Figures 7.9 and 7.10.
In BT-474 cells treated with Aza, an increase in miRNA expression is observed
relative to untreated BT-474 cells. This increase in miRNA is not observed in the
BT-474/L cell line where there is less than a 3-fold increase in miRNA expression
in the Aza treated cells compared to untreated BT-474/L cells. When the cells
are treated with TSA alone, there is little variability in miRNA expression for
miR127 and miR409 both in BT-474 and BT-474/L cells. A 10-fold increase is
observed for miR495 in BT-474 cells, however, this is not the case in BT-474/L.
The combination of Aza and TSA appears to have a synergistic effect in the
sensitive BT-474 cells for miR127 and an additive effect for the other miRNAs
(Figure 4.3a).
In HCC1954 and HCC1954/L cells, there is not much change in miR127 ex-
pression irrespective of the treatment, although an increase is observed in the
Aza and TSA combination in the resistant cell line. For miR409 and miR495
and increase in miRNA expression is detected after Aza treatment and a syn-
ergistic effect is obtained after addition of both Aza and TSA, with little effect
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Figure 4.3: miRNA Expression after 5-Aza-2′-deoxycytidine (Aza) and Trichostatin A
(TSA) Treatment. The data shown here is for one representative experi-
ment of at least two replicates. Stem-loop RT-qPCR is expressed as fold
change relative to RNU44 and normalised to the untreated condition for
each cell line. This does not permit direct comparison of miRNA levels
between the sensitive and resistant cells but shows the effect of each treat-
ment on miRNA expression levels. (a) In BT-474 cells, after Aza treatment
there is an upregulation of all three miRNAs compared to BT-474/L cells.
This increase is greater when Aza and TSA are combined. (b) In HCC1954
cells there is some upregulation of the miRNAs in the sensitive cells after
treatment with Aza, a further upregulation is observed when both Aza and
TSA are combined. There is little change in HCC1954/L. (c) In SKBR-3
cells there is upregulation of the miRNAs in the Aza samples.
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seen in the TSA single treatment in HCC1954. For these two miRNAs, there is
little increase in expression with any of the treatments for HCC1954/L cells. A
decrease in miRNA levels is even observed for the Aza or TSA alone conditions
going up to a 90 % decrease for miR495 when treated with TSA (Figure 4.3b).
SKBR-3 cells respond to Aza treatment with an increase in expression of all
three miRNAs, and the combination of Aza and TSA has a synergistic effect
as greater miRNA overexpression of miR495 is observed. In this cell line TSA
treatment alone also causes upregulation of the miRNAs. In the SKBR-3/L cell
line, some upregulation of miR127 is detected after addition of Aza. Negligible
changes in miRNA expression are observed in the other conditions (Figure 4.3c).
These results suggest that for all the cell lines, the expression of the 14q32
miRNAs is regulated by epigenetic marks which are lost in the resistant cells,
leading to increased expression of the miRNAs.
4.3 Methylation Levels are Altered in the 14q32 Region
The alterations in miRNA levels following methylation reversal indicated a
role for methylation in controlling the expression of these miRNAs. To fur-
ther investigate the role of methylation we examined the methylation levels in
lapatinib sensitive and resistant cell lines.
4.3.1 Demethylation of the 14q32 Region Occurs after Aza
Treatment in the Sensitive Cell Lines
To validate that Aza treatment led to the demethylation of the 14q32 re-
gion, bisulphite conversion followed by DNA re-sequencing was performed in
the isogenic cells. During bisulphite conversion, unmethylated C residues are
chemically modified to uracil (U) whilst m5C remains unchanged. Through sub-
sequent PCR the U is replaced with Tymidine (T) and m5C with C; analysis of
the sequencing data will identify the sites where C has remained unchanged and
where it has been replaced by T, giving the methylation pattern of the region.
Four different CpG regions; the IG-DMR, the MEG3-DMR, CpG region 1, and
CpG region 2 (Figure 4.1) were interrogated.
The differences in methylation levels observed between the treated and un-
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(a) (b)
Figure 4.4: Methylation Changes in the 14q32 Region after Aza Treatment Measured
by Methylation Resequencing. Each column of the heatmap represents one
replicate, and each line a CpG site. (a) Heatmap of BT-474 and BT-474
with Aza treatment, (b) heatmap of HCC1954 and HCC1954 with Aza
treatment. Both experiments show high levels of demethylation in the Aza
treated samples.
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treated samples reflects the changes in miRNA expression observed previously
in the treated samples. Indeed, the Aza treated samples have lost most methyl-
ation marks at these sites (Figure 4.4). Methylation levels for each individual
CpG site shown here is significantly changed in 3 to 4 replicates.
4.3.2 Lapatinib Resistant Cell Lines with Increased miRNA
Expression Display Demethylation of the 14q32 Region
Since the use of a demethylating agent in the sensitive cells led to an increase
in miRNA expression; differential methylation of this region could lead to the
increase in miRNA levels observed in the resistant cells. To directly validate
the control of methylation for the 14q32 region, bisulphite conversion and DNA
re-sequencing was undertaken.
Globally, changes in the methylation patterns were observed between the sens-
itive and resistant pairs: BT-474 and BT-474/L, and HCC1954 and HCC1954/L
cells (Figure 4.5). The CpG sites shown here were significantly changed between
the lines in the 3 to 4 replicates used for analysis.
In BT-474 cells, the IG-DMR is methylated at levels higher than 75 %, these
methylation marks are lost in the BT-474/L cells with levels reducing to 50 %
or less. In the HCC1954 cell line, baseline levels of methylation are lower than
10 % on average, and in HCC1954/L cells methylation levels are increased to
50 %. There were no significant alterations between SKBR-3 and SKBR-3/L
cells where methylation levels were altered more than 20 % (Figure 4.6a). The
sites shown here were significantly changed between 3 or 4 replicates and dis-
played methylation level changes greater than 20 %.
In the MEG3-DMR methylation levels are altered in the distal region of the
CpG island, changes in this region are observed in all three cell line pairs (Fig-
ure 4.6b and Table 4.1). Decreases in methylation levels are observed in both
the CpG1 (Figure 4.6c) and CpG2 (Figure 4.6d) region between BT-474 and
BT-474/L cell lines. Between HCC1954 and HCC1954/L lines there are few
statistically significant decreases in methylation.
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(a) (b)
Figure 4.5: Methylation Changes in the 14q32 Region in Paired Sensitive and Resistant
Cell Lines Measured by Methylation Resequencing. Each column of the
heatmap represents one replicate, and each line a CpG site. (a) Heatmap
of BT-474 and BT-47/L, (b) heatmap of HCC1954 and HCC1954/L. Both
experiments show changes in methylation levels in the paired cell lines.
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(a)
(b)
(c)
(d)
Figure 4.6: Significant Methylation Changes in the 14q32 Region Measured by Methyl-
ation Resequencing. Statistically significant changes, greater than 20 %,
are represented here along with the neighbouring sites that are also sig-
nificant but might have less than a 20 % change. (a) The intergenic-
differentially methylated region (IG-DMR) is methylated in the BT-474
cells and demethylated in the BT-474/L cells, whereas it is mostly de-
methylated in HCC1954 cells and more methylated in the HCC1954/L
line. (b) The differentially methylated region located on the MEG3 gene
(MEG3-DMR) is mostly methylated in both BT-474 and HCC1954 and is
demethylated in the resistant BT-474/L and HCC1954/L cells. In SKBR-3
and SKBR-3/L cells, methylation levels vary across the region. (c) The first
CpG island located in the 14q32.2 cluster is shown here, for both sensitive
cell lines the region is methylated and it is less methylated in the resistant
cells. (d) The second CpG island located in the 14q32.2 cluster is shown
here, it is mostly methylated in BT-474 cells and less in the BT-474/L
cells. There are few significant changes in methylation in the HCC1954
cells. 90
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Cytosine
Position
BT-474 BT-474/L HCC1954 HCC1954/L SKBR-3 SKBR-3/L
(%) (%) (%) (%) (%) (%)
823 62 39
826 96 81
844 95 69
887 93 41
900 96 69 90 70
909 95 65 97 79 12 40
918 97 67 97 91 23 37
922 99 95
Table 4.1: Percentage of Methylation in the MEG3-DMR. Results are shown for the
individual CpG sites of the distal MEG3-DMR represented in Figure 4.6b.
The cytosine position is given in reference to the starting position of
the MEG3-DMR, listed in Table 2.18, which uses coordinates from the
GRCh37/hg19 genome assembly.
4.4 Summary
Expression of genes in the 14q32 region is highly controlled by epigenetic
changes. Through demethylation experiments we have identified DNA methyl-
ation as a mechanism controlling miRNA expression in this region. HDAC
inhibition had a synergistic effect suggesting that histone acetylation is also in-
volved in regulation of gene expression in this region. Methylation resequencing
revealed demethylation with Aza treatment lead to the significant loss of methyl
groups in the 14q32 region which resulted in an increase in miRNA expression.
Methylation changes were also observed between the isogenic sensitive and
resistant cells, with different patterns reported within the pairs of cell lines. BT-
474/L and HCC1954/L both displayed methylation levels in the IG-DMR lower
than 50 %. This suggests that imprinted methylation levels are lost in these cells.
HCC1954 also has low levels of methylation in this region. Moreover, both BT-
474/L and HCC1954/L also displayed a decrease in methylation marks in the
distal region of the MEG3-DMR; methylation changes in this region have been
inversely correlated to alterations in miRNA expression (327 ). This indicates
the decreased methylation in these regions could lead to the increased miRNA
expression observed in the lapatinib resistant lines.
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and Their Role in Resistance
5.1 Target Selection from Gene Expression Array
Comparing BT-474/L to BT-474 Cells
Having shown the miRNAs were upregulated by epigenetic changes in ac-
quired resistance to lapatinib, we wanted to investigate whether the increase in
miRNA was leading to resistance. Since miRNAs target the 3′UTR of mRNAs
we therefore decided to study how gene expression between lapatinib sensitive
and resistant BT-474 cells had changed. A combination of genome wide and
in silico analysis was used to identify differentially expressed genes that were
targets of the miRNAs.
5.1.1 Gene Expression Array Analysis
A first set of gene expression arrays was analysed identifying 261 significantly
differentially expressed genes in BT-474/L compared to BT-474, with 142 up-
and 119 downregulated (Figure 5.1). To increase the significance of these hits,
the results were combined with the analysis of the gene expression array pub-
lished by Liu et al. (1) (GSE16179). As there were no untreated controls in
this data set, the DMSO controls were analysed instead. The samples were
treated with a small amount of DMSO. DMSO is used as a vehicle to dissolve
lapaintib for use in the IC50 experiments. There should, therefore, be very little
change between the untreated and DMSO treated conditions. This comparison
generated a list of 87 genes that were significantly differentially expressed in
BT-474/L compared to BT-474 (Figure 5.2), with 41 up- and 46 downregulated
genes. It is interesting to note that none of the 14q32 PEGs were found to be
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Figure 5.1: Heat Map of a Gene Expression Array Comparing BT-474 and BT-474/L
cells. Cells were analysed using the Illumina Human HT12 v4.0 array, each
column of the heatmap represents one replicate, and each line a gene. 261
genes (142 up- and 119 downregulated), with an adjusted p-value <0.05,
were found to be differentially expressed between BT-474/L and BT-474
cells. Two independent arrays batch 1 and batch 2 were combined for this
analysis.
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GSE16179
1555
Batch 1
125
Batch 2
391
34 81
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87
Figure 5.2: Comparison of the Number of Differentially Expressed Genes Between Ar-
ray Batches 1, 2, and GSE16179. 87 genes were found to be significantly
differentially expressed in BT-474/L cells compared to BT-474 which were
common to all three arrays. The individual arrays were performed on dif-
ferent dates which could explain some of the difference between the arrays.
The main difference is between the arrays performed on different platforms,
this could be caused by the different arrays used as they don’t have the
same probes or be due to the fact that the experiments on the different
platforms were performed in different laboratories. These factors introduce
variation between the arrays which could cause variation in the results.
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differentially expressed between the cell lines.
As there were more miRNAs that were highly upregulated than downregulated
and here there were more downregulated genes compared to upregulated, we
investigated downregulated genes as this could be caused by repression due to
the increase in miRNA expression. However, it could also be interesting to
look at upregulated genes as this could be caused by loss of repression due to a
decrease in miRNA levels.
5.1.2 In Silico Analysis
In order to determine direct mRNA targets of the miRNAs upregulated in
the resistant BT-474/L cells, only the downregulated genes were selected from
the list of differentially expressed genes. This data was then compared to in
silico predictions of putative miRNA targets obtained from miRWalk (348),
TargetScan (110), RNA22 (349), and miRanda (350). These four databases
were used to reduce the number of false negatives obtained. This identified 27
genes as being putative miR127, miR409, or miR495 targets, with 2 hits for
miR127, 17 for miR409, and 23 for miR495 (Figure 5.3). The analysis found
few miR127 targets but those identified were common to either two, miR127
and miR495, or all three miRNAs. miR409 and miR495 had the most overlap,
with 12 genes being common to both miRNAs, 4 were miR409 targets only and
another 9 were miR495 targets only.
miR495 was selected as it had the most downregulated putative targets in the
gene set. Following mechanistic considerations, 13 targets, highlighted in Table
5.1, out of the 23 miR495 downregulated targets were selected for expression
level validation by RT-qPCR in BT-474 and BT-474/L.
5.1.3 Gene Expression Array Validation
The miR495 target genes selected were validated by RT-qPCR (Figure 5.4).
Of the 13 selected targets, AHNAK was not found to be significantly down-
regulated in BT-474/L compared to BT-474. FADS1 and EMP1 expression is
decreased by less than 50 % in BT-474/L. Of the other genes, seven were selec-
ted for further functional validation, these are highlighted in Figure 5.4 and will
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Figure 5.3: miRNA Seed Site Presence in Significantly Downregulated Genes in BT-
474/L Cells Compared to BT-474. There are only two genes that have
miR127 seed sites, one also has as site for miR495, and the other has sites
for all three miRNAs. 12 targets have sites for both miR409 and miR495,
4 only have sites for miR409 and 9 only for miR495. Therefore miR495
has the most putative targets downregulated in BT-474/L cells compared
to BT-474.
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Symbol Gene Name miRWalk miRanda RNA22 TargetScan Sum
AHNAK AHNAK Nucleoprotein 1 0 0 1 2
ATP8B2 ATPase, Aminophospholipid Transporter, Class I, Type 8B, Member 2 1 0 0 0 1
BASP1 Brain Abundant, Membrane Attached Signal Protein 1 0 0 1 0 1
CA12 Carbonic Anhydrase XII 1 1 0 1 3
EMP1 Epithelial Membrane Protein 1 0 0 0 1 1
FADS1 Fatty Acid Desaturase 1 1 0 0 1 2
GATA3 GATA Binding Protein 3 1 1 0 1 3
INHBB Inhibin Beta B 1 0 0 0 1
KLF9 Krüppel Like Factor 9 1 1 0 1 3
MSI2 Mushashi RNA-Binding Protein 2 1 1 1 1 4
MX2 MX Dynamin-Like GTPase 2 1 0 0 0 1
NEDD4L Neural Precursor Cell Expressed, Developmentally Down-Regulated 4-Like 1 1 0 1 3
NRCAM Neuronal Cell Adhesion Molecule 1 0 0 0 1
PAAF1 Proteosomal ATPase-Associated Factor 1 1 1 0 1 3
PGR Progesterone Receptor 1 1 0 1 3
PKIA Protein Kinase (cAMP-Dependant, Catalytic) Inhibitor Alpha 1 0 0 1 2
PQLC3 PQ Loop Repeat Containing 3 0 0 0 1 1
PREX1 Phosphatidylinositol-3,4,5-Triphosphate-Dependant Rac Exchange Factor 1 1 1 1 1 4
SH3BGRL SH3 Domain Binding Glutamate-Rich Protein Like 1 1 0 1 3
SOCS2 Suppressor of Cytokine Signalling 2 0 0 0 1 1
STC2 Stanniocalcin 1 0 0 0 1
TACSTD2 Tumor-Associated Calcium Signal Transducer 2 1 1 0 1 3
UQCC Ubiquinol-Cytochrome C Reductase Complex Chaperone 1 0 0 0 1
Table 5.1: miR495 Target Genes Downregulated in BT-474/L Lapatinib Resistant
Cells Compared to Sensitive BT-474. Genes highlighted in grey were se-
lected for further validation based on functional and mechanistic consid-
erations. miRNA interaction prediction databases are listed on the right:
miRWalk, miRanda, RNA22, and TargetScan, along with whether they pre-
dicted at least one hit for the target gene, marked as 1, or none, marked
as 0. The number of databases that predicted the presence of a miRNA
seed site in the 3′UTR of the gene is totalled in the column on the far right
labelled Sum.
be discussed further. A list of putative mRNA targets for the miRNAs upregu-
lated in the resistant cells was generated using the databases listed previously
and the thirteen downregulated gene targets were compared to it. The presence
of miRNA seed sites in their 3′UTR is shown in Figure 5.4.
All these targets have seed sites for at least two of the miRNAs selected (Figure
5.4). These genes are downregulated in the resistant cells, therefore to model
resistance and investigate the role of the gene targets in acquired resistance to
lapatinib, we used knock-down assays in the sensitive lines followed by IC50
experiments. The potential targets will now be discussed in detail.
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Figure 5.4: Downregulation of Targets in BT-474/L and miRNA Binding Sites. Tar-
gets selected for further validation are highlighted in a darker shade.
mRNA expression values were obtained by RT-qPCR and results were
analysed using the DDCt relative quantification method and averaged for
biological triplicates. mRNA expression was normalised to RPLP0 expres-
sion, relative to BT-474. Statistical significance is determined by one-way
ANOVA with Dunnett’s Multiple Comparison post-test. Where results
are statistically significant p-values are shown on the graph, with ? for
p ≤ 0.05, ?? for p ≤ 0.01, ??? for p ≤ 0.001, and ns for not significant. The
presence of miRNA seed sites in each target is represented as a filled box
in the column under the target name.
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5.2 miRNA Target Genes Downregulated in BT-474/L
are Involved in Resistance to HER2-Targeted
Therapy
5.2.1 Suppressor of Cytokine Signalling 2
Suppressor of Cytokine Signalling 2 (SOCS2) has been suggested as a pro-
gnostic marker in ER+ breast cancers as high expression levels have been cor-
related with good prognosis (351). Loss of SOCS2 has been linked to increased
cell proliferation and tumour growth (352); cancers that have lost SOCS2 have
been found to be less differentiated. As such, it would be interesting to see if
loss of SOCS2 affects response to HER2-targeting therapies.
SOCS2 was found to contain one putative miR495 seed site (Figure 5.5a), as
well as sites for miR411, miR433, and miR539 (Figure 5.4).
Levels of SOCS2 were found to be lower in HCC1954 and SKBR-3 cells com-
pared to BT-474 (Figure 5.5b). In the resistant cells however it was only de-
creased in the BT-474 isogenic lines, BT-474/L and BT-474/T, a trastuzumab
acquired resistance line (Figure 5.5c). BT-474/T was included in this analysis
to compare the response of both of the BT-474 lines with acquired resistance
to HER2-targeting therapy. There was an increase in SOCS2 expression in
HCC1954/L and SKBR-3/L compared to their parental cell line (Figure 5.5d, e).
To replicate the miRNA targeted downregulation of SOCS2 and determine if
loss of expression affects sensitivity to HER2-targeted therapy, IC50 values were
determined following treatment with SOCS2 targeting siRNA. The experiments
resulted in the downregulation of SOCS2 in all three of the sensitive cell lines
(Figures 5.6a, b, and c) which translated into a trend towards an increase in
IC50 for both BT-474 and HCC1954 cells after siRNA knock-down (Figure 5.6d
and e). These results, however, are not statistically significant. In SKBR-3
only siRNA 2 lead to a decrease in lapatinib sensitivity (Figure 5.6f). These
results suggest that SOCS2 loss may contribute to lapatinib acquired resistance
in BT-474/L cells.
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Figure 5.5: miRNA Seed Site and Baseline Expression Levels of SOCS2. (a) SOCS2
contains a putative miRNA binding site for miR495. (b) Levels of SOCS2
mRNA in all three sensitive cell lines compared to BT-474. mRNA levels in
paired resistant and sensitive cell lines, normalised to the sensitive cell line
for (c) BT-474, BT-474/L, and BT-474/T, (d) HCC1954 and HCC1954/L,
and (e) SKBR-3 and SKBR-3/L. Statistical significance is obtained from
a one-way ANOVA with Dunnett’s Multiple Comparison post-test for (b)
and (c), and Student’s T-test for (d) and (e). Where results are statistically
significant p-values are shown on the graph, with ??? for p ≤ 0.001.
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Figure 5.6: Effect of SOCS2 Knock-down on Lapatinib Resistance. SOCS2 mRNA
expression after treatment with two different siRNAs normalised to the
non-targeting control siRNA (-ve) in (a) BT-474, (b) HCC1954, and
(c) SKBR-3. Lapatinib IC50 value after siRNA treatment in (d) BT-474,
(e) HCC1954, and (f) SKBR-3. The IC50 values are obtained from non-
linear regression analysis of cytotoxicity experiments and are averaged for
at least three replicates. Statistical significance is obtained from a one-way
ANOVA with Dunnett’s Multiple Comparison post-test. Where results
are statistically significant p-values are shown on the graph, with ?? for
p ≤ 0.01, and ??? for p ≤ 0.001.
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5.2.2 Protein Kinase (cAMP-Dependant, Catalytic) Inhibitor Alpha
Protein Kinase (cAMP-Dependant, Catalytic) Inhibitor Alpha (PKIA) inhib-
its the Ca and Cb subunits of cAMP-dependent Protein Kinase (PKA) (353,
354). PKA signalling has been found to be activated in trastuzumab resist-
ant cell lines (82) and has also been identified as a driver of tumourigenesis in
breast cancers through Proto-oncogene tyrosine-protein kinase Src (Src) (355).
The latter has previously been shown to be important in the development and
progression of breast cancer (356) as well as in trastuzumab resistance (357,
358). Hence, downregulation of PKIA could be linked to resistance to HER2-
targeting therapies.
PKIA was found to have three miRNA seed sites for miR495 (Figure 5.7a, b,
and c) as well as sites for miR433 and miR539 (Figure 5.4).
Both HCC1954 and SKBR-3 express less PKIA mRNA than BT-474 (Figure
5.7d). In both BT-474 resistant cells, mRNA levels for PKIA are lower than
in BT-474 sensitive cells (Figure 5.7e). This is also the case for the other two
paired lapatinib sensitive and resistant cell lines, where the acquired resistant
cells express less PKIA than their parental line (Figure 5.7f and g).
siRNA knock-down in the sensitive cell lines resulted in a significant decrease
in PKIA expression for both siRNAs (Figure 5.8a, b, and c). Loss of PKIA
expression led to shift in IC50 in both BT-474 (Figure 5.8d) and in HCC1954
(Figure 5.8e) which suggest a trend towards an increase in IC50. These results,
however, are not statistically significant. In SKBR-3 cells, only one siRNA,
siRNA 2, appeared to lead to an increase in IC50 value.
This decrease in sensitivity to lapatinib observed after reduction of PKIA
expression suggests that this target may be involved in acquired resistance to
lapatinib in both BT-474/L and HCC1954/L cells.
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Figure 5.7: miRNA Seed Sites and Baseline Expression of PKIA. (a, b, c) PKIA con-
tains three putative miRNA binding sites for miR495. (d) Levels of PKIA
mRNA in all three sensitive cell lines compared to BT-474. mRNA levels in
paired resistant and sensitive cell lines, normalised to the sensitive cell line
for (e) BT-474, BT-474/L, and BT-474/T, (f) HCC1954 and HCC1954/L,
and (g) SKBR-3 and SKBR-3/L. Statistical significance is obtained from
a one-way ANOVA with Dunnett’s Multiple Comparison post-test for (d)
and (e), and Student’s T-test for (f) and (g). Where results are statistically
significant p-values are shown on the graph, with ??? for p ≤ 0.001.
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Figure 5.8: Effect of PKIA Knock-down on Lapatinib Resistance. mRNA expression
after treatment with two different siRNAs normalised to the non-targeting
control siRNA (-ve) in (a) BT-474, (b) HCC1954, and (c) SKBR-3. Lapat-
inib IC50 value after siRNA treatment in (d) BT-474, (e) HCC1954, and
(f) SKBR-3. The IC50 values are obtained from non-linear regression ana-
lysis of cytotoxicity experiments and are averaged for at least three rep-
licates. Statistical significance is obtained from a one-way ANOVA with
Dunnett’s Multiple Comparison post-test, where results are significant p-
values are shown on the graph, with ?? for p ≤ 0.01, and ??? for p ≤ 0.001.
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5.2.3 Brain Abundant Specific Protein 1
Brain Abundant Specific Protein 1 (BASP1) has been identified as a negat-
ive regulator of c-MYC as it inhibits MYC transcription (359). Low levels of
BASP1 have been correlated to an upregulation in MYC, which leads to in-
creased cell growth and proliferation (360). Additionally, MYC expression has
been reported to be induced by Forkhead Box Protein O (FOXO) transcription
factors in cells with reduced sensitivity to the lapatinib (361). This suggests
that downregulation of BASP1 by upregulated miRNAs could be involved in
upregulation of MYC in lapatinib resistance.
BASP1 was identified as a putative miR127 (Figure 5.9a), miR409 (Figure
5.9b) and miR495 (Figure 5.9c) target. BASP1 is also a miR433 and miR539
target (Figure 5.4).
BASP1 mRNA expression is lower in both HCC1954 and SKBR-3 cells com-
pared to BT-474 (Figure 5.9d). In both of the BT-474 resistant lines, BT-474/L
and BT-474/T, BASP1 mRNA was decreased compared to BT-474 (Figure
5.10a). In the other resistant lines, HCC1954/L and SKBR-3/L, expression
of BASP1 was increased (Figure 5.10b and c).
siRNA knock-down was efficient in all three of the cell lines (Figure 5.10a, b,
and c). This trended towards an increase in lapatinib IC50 for BT-474 (Figure
5.10d). There was only a trend towards an increase in IC50 value for one of
the siRNAs in the other two cell lines, with siRNA 1 in HCC1954 cells (Figure
5.10e) and siRNA 2 in SKBR-3 cells (Figure 5.10f). These results, however, are
not statistically significant.
After siRNA knock-down of BASP1 (Figure 5.10g) BT-474 cells had an in-
crease in IC50 for one of the siRNAs only (Figure 5.10h). This suggests that
loss of BASP1 may be important for lapatinib resistance in BT-474/L cells.
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Figure 5.9: miRNA Seed Sites and Baseline Expression Levels of BASP1. BASP1
contains putative miRNA binding sites for(a) miR127, (b) miR409, and
(c) miR495. (d) Levels of BASP1mRNA in all three sensitive cell lines com-
pared to BT-474. mRNA levels in paired resistant and sensitive cell lines,
normalised to the sensitive cell line for (e) BT-474, BT-474/L, and BT-
474/T, (f) HCC1954 and HCC1954/L, and (g) SKBR-3 and SKBR-3/L.
Statistical significance is obtained from a one-way ANOVA with Dunnett’s
Multiple Comparison post-test for (d) and (e), and Student’s T-test for (f)
and (g). Where results are statistically significant p-values are shown on
the graph, with ??? for p ≤ 0.001.
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Figure 5.10: Effect of BASP1 Knock-down on Lapatinib and Trastuzumab Resistance.
mRNA expression after treatment with two different siRNAs normalised
to the non-targeting control siRNA (-ve) in (a) BT-474, (b) HCC1954, and
(c) SKBR-3. Lapatinib IC50 value after siRNA treatment in (d) BT-474,
(e) HCC1954, and (f) SKBR-3. Trastuzumab treatment was also used
to confirm whether the effect observed in the cells was specific to lapat-
inib or could be applied to other HER2-targeting therapies. (g) mRNA
changes in BT-474 cells after siRNA transfection for trastuzumab treat-
ment. (h) BT-474 trastuzumab IC50s after siRNA treatment. Statistical
significance is obtained from a one-way ANOVA with Dunnett’s Multiple
Comparison post-test, where results are significant, p-values are shown
on the graph with ??? for p ≤ 0.001.
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5.2.4 Neural Precursor Cell Expressed, Developmentally
Down-Regulated 4-Like
Neural Precursor Cell Expressed, Developmentally Down-Regulated 4-Like
(NEDD4L) is a ubiquitin ligase involved in negative regulation of the Dishevelled
receptor (362). It has been reported to inhibit canonical Wnt signalling and
downregulation of NEDD4L has been found to correlate with poor prognosis
in colorectal cancers (363). Indeed, low levels of NEDD4L lead to increased
canonical Wnt signalling, which means the cells are receiving more survival and
proliferation signals. Additionally NEDD4L is also responsible for regulating
Transforming Growth Factor Beta (TGF-b) (364) as well as its induced Smad
complexes, thus moderating the extent of TGF-b downstream response (365–
367 ). Furthermore, loss of NEDD4L and its inhibitory effect on TGF-b sig-
nalling has been linked to a poor prognosis in gastric cancers (368). Elevated
TGF-b expression itself has been linked to poor prognosis in breast cancers
(369).
NEDD4L was found to be a miR409 (Figure 5.11a) and a miR495 (Figure
5.11b, and c) putative target by three algorithms, miRWalk, miRanda, and
TargetScan (Figure 5.1). It is also a target of miR433 and miR539 (Figure 5.4).
RT-qPCR showed NEDD4L mRNA is expressed at different levels between the
three sensitive cell lines with BT-474 being the highest expresser. On the protein
level HCC1954 appears to have the lowest levels of NEDD4L (Figure 5.11f). In
the acquired resistant lines, the target mRNA was found to be downregulated
in all three cell lines compared to their parental line (Figure 5.11g and h, and
i). This result was validated by western blot for BT-474 and SKBR-3 lines,
however, this did not appear to be true for HCC1954 and HCC1954/L.
BT-474/T, a trastuzumab acquired resistance line was also tested to identify
whether the effect observed was specific to lapatinib or translated to HER2-
targeted therapy in general. BT-474/T was found to have lost NEDD4L expres-
sion (Figure 5.11g).
To model the change observed in the acquired resistance lines, we used siRNA
knock-down experiments to silence NEDD4L expression. In BT-474 cells, both
siRNAs lead to efficient knock-down of the target on both the mRNA (Figure
5.12a) and protein levels (Figure 5.12d). This resulted in approximately a two
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fold increase in IC50 to lapatinib for both siRNAs (Figure 5.12g).
HCC1954 cells displayed siRNA silencing of NEDD4L (Figure 5.12b), how-
ever, on the protein level siRNA 1 treated cells displayed better silencing of
NEDD4L than siRNA 2 (Figure 5.12e). These results were reflected in the IC50
values as siRNA 1 resulted in a increase in IC50 and siRNA 2 did not (Figure
5.12h).
In SKBR-3 cells siRNA 1 lead to a 3-fold decrease in NEDD4L, siRNA 2 did
not significantly affect expression (Figure 5.12c). Both siRNAs, however, even
without much decrease in mRNA levels, resulted in loss of NEDD4L protein ex-
pression (Figure 5.12e) which lead to a trend suggesting an increase in lapatinib
IC50 in the siRNA treated samples (Figure 5.12i). These results, however, are
not statistically significant.
When BT-474 cells with reduced levels of NEDD4L (Figure 5.12j) were treated
with trastuzumab there was a trend towards an increase in IC50 for one of the
siRNAs (Figure 5.12k). These results, however, are not statistically significant.
These results suggest that an increase in miRNA levels which leads to the
downregulation of NEDD4L may play a role in acquired resistance to lapatinib
in both BT-474/L and SKBR-3/L.
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Figure 5.11: miRNA Seed Sites and Baseline Expression of NEDD4L. NEDD4L con-
tains putative miRNA binding sites for (a) miR409, and (b,c,d) miR495.
(e) Levels of NEDD4L mRNA in all three sensitive cell lines compared
to BT-474. (f) Protein levels in paired resistant and sensitive cell lines.
mRNA levels in paired resistant and sensitive cell lines, normalised to the
sensitive cell line for (g) BT-474, BT-474/L, and BT-474/T, (h) HCC1954
and HCC1954/L, and (i) SKBR-3 and SKBR-3/L. Statistical significance
is obtained from a one-way ANOVA with Dunnett’s Multiple Compar-
ison post-test for (e) and (g), and Student’s T-test for (h) and (i). Where
results are statistically significant p-values are shown on the graph, with
? for p ≤ 0.05, ?? for p ≤ 0.01, and ??? for p ≤ 0.001.
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Figure 5.12: Effect of NEDD4L Knock-down on Lapatinib and Trastuzumab Res-
istance. mRNA expression after treatment with two different siRNAs
normalised to the non-targeting control siRNA (-ve) in (a) BT-474,
(b) HCC1954, and (c) SKBR-3. Protein knock-down in (d) BT-474,
(e) HCC1954, and (f) SKBR-3. Lapatinib IC50 value after siRNA treat-
ment in (g) BT-474, (h) HCC1954, and (i) SKBR-3. (j) mRNA changes
in BT-474 cells after siRNA transfection. (k) BT-474 trastuzumab IC50s
after siRNA treatment. The IC50 values are obtained from non-linear
regression analysis of cytotoxicity experiments and are averaged for at
least three replicates. Where results are statistically significant, as de-
termined by one-way ANOVA with Dunnett’s Multiple Comparison post-
test, p-values are shown on the graph, with ?? for p ≤ 0.01, and ??? for
p ≤ 0.001.
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5.2.5 SH3 Domain Containing Protein Ligand
The SH3 Domain Containing Protein Ligand (SH3BGRL) has been previously
identified as a tumour suppressor in humans (370). Loss of SH3BGRL has
been found to lead to v-Rel-mediated transformation of cells via activation of
TGF-b/Sma- and Mad-Related Protein (SMAD) signalling (371). Additionally,
elevated TGF-b signalling, along with EMT, have been observed in trastuzumab
resistant cells (372).
SH3BGRL was found to have a miRNA binding site for miR409 (Figure 5.13a)
and one for miR495 (Figure 5.13b). It also has miR411 and miR433 seed sites
in its 3′UTR (Figure 5.4).
SH3BGRL is expressed at lower levels in the other two sensitive cell lines
compared to BT-474 (Figure 5.13c), on the protein levels, these cell lines appear
to have similar levels of SH3BGRL (Figure 5.13d); and was decreased in all three
of the acquired resistant lines, both on the RNA and protein level (Figure 5.13d,
e, f, and g). Additionally, SH3BGRL mRNA expression was decreased in BT-
474/T cells (Figure 5.13e).
siRNA knock-down experiments resulted in good mRNA knock-down in all
three cell lines (Figure 5.14a, b, and c). Yet in BT-474 and HCC1954, only
one of the siRNAs led to a trend towards an increase in IC50 (Figure 5.14d and
e) and none in SKBR-3 cells (Figure 5.14f). These results, however, are not
statistically significant.
In the BT-474 cells with reduced SH3BGRL (Figure 5.14g) an increase in
trastuzumab IC50 was observed (Figure 5.14h). This data suggests that, al-
though loss of SH3BGRL does not appear to be involved in lapatinib acquired
resistance, it seems to be important in trastuzumab resistance.
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Figure 5.13: miRNA Seed Sites and SH3BGRL Baseline Expression. SH3BGRL con-
tains putative miRNA binding sites for (a) miR409, and (b) miR495.
(c) Levels of SH3BGRL mRNA in all three sensitive cell lines compared
to BT-474. (d) Protein levels of paired resistant and sensitive cell lines.
mRNA levels in paired resistant and sensitive cell lines, normalised to the
sensitive cell line for (e) BT-474, BT-474/L, and BT-474/T, (f) HCC1954
and HCC1954/L, and (g) SKBR-3 and SKBR-3/L.Statistical significance
is obtained from a one-way ANOVA with Dunnett’s Multiple Compar-
ison post-test for (c) and (e), and Student’s T-test for (f) and (g). Where
results are statistically significant p-values are shown on the graph, with
??? for p ≤ 0.001.
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Figure 5.14: Effect of SH3BGRL Knock-down on Lapatinib and Trastuzumab Res-
istance. mRNA expression after treatment with two different siRNAs
normalised to the non-targeting control siRNA (-ve) in (a) BT-474,
(b) HCC1954, and (c) SKBR-3. Lapatinib IC50 value after siRNA treat-
ment in (d) BT-474, (e) HCC1954, and (f) SKBR-3. Trastuzumab treat-
ment was also used to confirm whether the effect observed in the cells
was specific to lapatinib. (g) Target mRNA changes in BT-474 cells after
siRNA transfection for trastuzumab treatment. (h) BT-474 trastuzumab
IC50s after siRNA treatment. The IC50 values are obtained from non-
linear regression analysis of cytotoxicity experiments and are averaged
for at least three replicates. Statistical significance is obtained from a
one-way ANOVA with Dunnett’s Multiple Comparison post-test. Where
results are statistically significant p-values are shown on the graph, with
? for p ≤ 0.05, ?? for p ≤ 0.01, and ??? for p ≤ 0.001.
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5.3 SOCS2, BASP1, NEDD4L, and SH3BGRL Appear to
be Clinically Relevant to HER2-Targeting Treatment
Outcome
To confirm these results and investigate how expression levels of these genes
affect patient outcome we used data obtained from the NeoALTTO trial (Clin-
icalTrials.gov Identifier: NCT00553358). This trial looked at dual blockade of
HER2 in the neoadjuvant setting for HER2+ early breast cancer, the study
design is depicted in Figure 5.15. Patients were randomly assigned to treatment
with either lapatinib alone, trastuzumab alone, or a combination of both HER2-
targeting agents. Paclitaxel was also added to the treatments after six weeks.
The patients then underwent surgery and received adjuvant chemotherapy in
combination with their previous HER2-targeting regime (373). The primary
endpoint is the rate of pathological complete response (pCR), defined in this
study as ypT0/is ypN0, meaning the absence of disease in both breast and
lymph node tissue regardless of the presence of DCIS (374).
Baseline frozen core needle tumour biopsies were collected and 135 were avail-
able for gene expression analysis (375). Due to this low number of patient data
available, the treatment groups were combined for analysis. RNA expression
data was used to calculate the pCR odds ratio for each of the target genes.
NEDD4L, FADS1, STC2, and NRCAM all had significant p-values when the
whole cohort was analysed. Of these, NEDD4L was the most downregulated in
the gene expression array validation, results from this cohort do not show the
other targets significantly affecting the outcome (Table 5.2).
We hypothesise that high expression of the target genes would lead to better
survival for the patients. The top quartile of gene expression values was used
to represent the high expressers for each target as the gene expression data
had a positive skew in distribution. There was data for 135 patients, thus each
quartile contained either 33 or 34 patients. After calculating the odds ratio for
this subgroup, more than 70 % decrease in odds ratio was observed for BASP1
and SOCS2 between the whole cohort analysis and the top quartile result (Table
5.2). This suggests that patients with high expression of these genes are more
likely to reach pCR.
115
5 Putative Targets of 14q32 miRNAs
B
A
S
E
L
I
N
E
Tras
Lap
Lap
+
Tras
Lap
+
Pac
Tras
+
Pac
Lap
Tras
Pac
S
U
R
G
E
R
Y
F
E
C
×
3
Tras
Lap
Lap
+
Tras
Radiotherapy
(if indicated)
6 weeks 12 weeks 9 weeks 34 weeks
Figure 5.15: NeoALTTO Study Design (373). Baseline core needle tumour biopsy were
collected and used for the gene expression analysis presented in Table 5.2.
Lap: Lapatinib, Tras: Trastuzumab, Pac: Paclitaxel, FEC: Fluorouracil,
epirubicin, and cyclophosphamide.
Gene
Whole Cohort Top Quartile Decrease
in OROR 5 % CI 95 % CI p-value OR 5 % CI 95 % CI p-value (%)
AHNAK 0.849 0.511 1.416 0.595 0.151 0.001 6.537 0.404 82
BASP1 0.865 0.742 1.008 0.117 0.196 0.008 2.019 0.225 77
SOCS2 0.778 0.557 1.061 0.196 0.207 0.024 1.000 0.089 73
CA12 0.939 0.776 1.136 0.585 0.269 0.006 2.982 0.389 71
NEDD4L 0.608 0.401 0.906 0.044 0.540 0.015 7.406 0.679 11
SH3BGRL 1.129 0.892 1.458 0.412 0.584 0.080 3.102 0.551 48
FADS1 1.463 1.057 2.045 0.056 0.720 0.216 2.191 0.567 51
STC2 0.733 0.569 0.929 0.036 0.871 0.289 2.018 0.766 -19
EMP1 1.112 0.883 1.402 0.450 0.875 0.163 3.673 0.861 21
PREX1 0.794 0.539 1.154 0.318 1.244 0.211 5.611 0.778 -57
NRCAM 0.695 0.511 0.918 0.040 1.374 0.625 3.221 0.432 -98
PKIA 0.962 0.771 1.194 0.771 1.776 0.717 4.752 0.219 -85
KLF9 1.225 0.695 2.173 0.556 6.479 0.643 90.507 0.128 -425
Table 5.2: Data Analysis of Gene Expression and pCR from the NeoALTTO Clinical
Trail. Due to the small number of patients, the odds ratio for pCR was
calculated for either the whole cohort or the top quartile of expressers for
each gene. The targets that appear to be involve in either lapatinib or
trastuzumab resistance are highlighted in the table. CI: confidence interval,
OR: odds ratio.
116
5 Putative Targets of 14q32 miRNAs
The odds ratio for NEDD4L and SH3BGRL also decreased in the analysis
of the high expressers, however the value only decreased by 10 and 48 % re-
spectively. For PKIA on the other hand, there was almost a doubling in odds
ratio (Table 5.2). This appears to suggest that high expression of PKIA is not
beneficial to pCR. These results, however, are not statistically significant due
to the low number of patients in the group analysed.
This trial is not the ideal setting to study the role of these genes in acquired
resistance to HER2-targeting therapies as the RNA analysis was performed on
baseline biopsies. This doesn’t permit to take into account any changes in gene
expression that might occur during the treatment course of the patients. In the
case of acquired resistance this is the period of time when we would expect to
see the most changes in miRNA expression and therefore in target gene expres-
sion. In this setting the data obtained might be more appropriate to study de
novo resistance. Another consideration to be noted is that all patients are also
receiving chemotherapy, which might influence the mechanism of resistance as
this is putting additional pressure on the cells. Obtaining biopsies at different
time points would allow the study of mRNA expression at baseline and after
treatment generating results more relevant to acquired resistance. Looking at
miRNA expression levels at these times would also permit a better understand-
ing of the clinical relevance of the proposed miRNA role in acquired resistance.
Another interesting experiment to do, would be to look at what targets these
miRNAs are bound to within the cancer tissue after treatment. This can be
done through biochemical isolation of the miRNA RISC with methods such as
high-throughput sequencing of RNA isolated by crosslinking immunoprecipita-
tion (HITS-CLIP). In this technique, the RNA bound proteins are cross linked
through UV irradiation before undergoing immunoprecipitation. The RNAs are
then be sequenced allowing the identification of mRNA targets for the miRNAs
(376).
5.4 Summary
We previously identified miRNAs that were upregulated in acquired resistance
to lapatinib. These will in turn affect gene expression in the acquired resistance
lines. To identify miRNA gene targets affected by the changes we focused on
a list of downregulated genes in BT-474/L compared to BT-474 obtained from
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a gene expression array. This was compared to a list of mRNAs with putat-
ive miRNA binding sites predicted by various databases. This highlighted 23
miR495 target genes, these all have at least one other predicted miRNA seed
site. 13 genes were then chosen for validation, of which one was found not to be
downregulated in BT-474/L cells by RT-qPCR. From the downregulated genes,
seven were selected for functional validation.
These results showed that, although none of the changes in IC50 are statistic-
ally significant, a trend is observed suggesting that NEDD4L, BASP1, SOCS2,
and PKIA loss is involved in acquired resistance to lapatinib. When expression
of these genes is lost the cells lose sensitivity to lapatinib.
SH3BGRL, appears to be exclusive to BT-474 cells. The last two targets
tested, KLF9 and PREX1, did not appear to be involved in acquired resistance
to lapatinib as their loss did not affect sensitivity to lapatinib in the cells tested.
The experimental data confirmed that the reduction in expression levels of
BASP1, SOCS2, NEDD4L, or SH3BGRL was sufficient to increase the IC50
value of the cell lines to either lapatinib or trastuzumab. The NeoALTTO data,
suggests that these targets could be involved resistance to HER2-targeting ther-
apies, as high expressers of the genes appeared to have better pCR. However,
as mentioned previously, this is linked to intrinsic resistance rather than ac-
quired resistance as the mRNA samples were extracted from baseline biopsies.
Altogether this suggests that these genes could be involved in resistance to
HER2-targeting therapies. Thus these proteins, or other downstream proteins,
could be targeted to overcome resistance to HER2 therapies.
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6.1 Overview
HER2+ breast cancer remains a significant clinical challenge, despite im-
proved outcome of patients following targeted therapy. Few patients respond to
the treatment (77 ) and a significant portion display primary resistance (50). To
improve the outcome, it is important to study the process of acquired resistance
and identify new therapeutic targets to overcome refractory disease progression.
Here, through demethylation assays and methylation resequencing, we have
shown that demethylation of key sections in the 14q32 domain causes to in-
creased expression of miRNAs coded in this region which are involved in ac-
quired resistance to lapatinib. Subsequently, this leads to downregulation of
certain target genes of the upregulated miRNAs, identified by gene expression
array and in silico analysis. Therefore, we propose a novel mechanism of ac-
quired resistance to HER2-targeted therapy initiated by epigenetic changes in
the 14q32 region leading to an increase in expression levels of miRNAs in this
region. In turn these miRNAs will repress the expression of gene targets. We
have identified four downregulated targets, with the potential to be involved in
resistance, SOCS2, BASP1, NEDD4L, and SH3BGRL (Figure 6.1).
6.2 Cells with Intrinsic Resistance to Lapatinib Adapt
Through Different Resistance Mechanisms
JIMT-1 and MDA-MB-361 are both intrinsically resistant to lapatinib and
do not respond to the drug. Both cell lines are also resistant to trastuzumab
(66, 77 ) but are sensitive to neratinib. This is likely to be due to the difference
in mechanisms of drug action, as neratinib exposure leads to G1/S phase ar-
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Epigenetic Remodelling
↗ 14q32 miRNA
↘ SOCS2, BASP1, NEDD4L, SH3BGRL
↗ Resistance to HER2 Therapy
Figure 6.1: Proposed Mechanism for Acquired Resistance to Lapatinib. Epigenetic
remodelling in the 14q32 region of HER2+ breast cancer cells sensitive
to targeted therapy leads to an increase expression of miRNAs from these
clusters. This in turn causes downregulation of target genes such as SOCS2,
BASP1, NEDD4L, or SH3BGRL leading to an increase in resistance to
HER2-targeting therapy.
rest (377 ) whilst lapatinib has been found to induce G0/G1 phase arrest (378,
379). Additionally, these cells display differing cross-resistance patterns for da-
comitinib. JIMT-1 is resistant to the drug, which, like lapatinib, leads to G0/G1
phase arrest (68), however, as dacomitinib is a pan-HER inhibitor this could
account for the sensitivity of MDA-MB-361 cells to this treatment. Therefore,
the intrinsically resistant lines might still be dependent on signalling through
other HER receptors. The different response of the cells to dacomitinib could
also originate from differences between the two cell lines: they are derived from
metastatic site in different patients. JIMT-1 originates from a pleural effusion
and MDA-MB-361 the brain. Additionally MDA-MB-361 expresses ER which
JIMT-1 does not.
miRNA levels in these cell lines are quite different, with MDA-MB-361 dis-
playing high levels of miRNAs, similar to those in BT-474/L, and JIMT-1 having
low levels of 14q32 miRNAs similar to those in the sensitive BT-474. There is,
therefore, a heterogeneity in response to different types of therapies across ge-
netically diverse, yet classed as the same subtype, cancers. It might, however be
interesting to study the selected gene targets in the MDA-MB-361 cells in order
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Cell Line Trastuzumab Neratinib Dacomitinib
BT-474/L
HCC1954/L
SKBR-3/L
Sensitive Resistant
Table 6.1: Summary of Lapatinib Acquired Resistant Cell Line Cross-Resistance. Sens-
itivity to the drug is shown in green and resistance in red. These results are
detailed in Figure 3.2. BT-474/L is resistant to all the other drugs tested,
whilst SKBR-3/L is sensitive to all. HCC1954/L shows a more nuanced
cross resistance pattern.
to identify whether these targets are involved in both acquired and intrinsic
lapatinib resistance when there is increased 14q32 miRNA signalling.
These results confirm that miRNA changes leading to the development of
acquired resistance do not mimic intrinsic resistance.
6.3 Lapatinib Acquired Resistant Lines Display Different
Phenotypes Suggesting Adaptation Through
Different Mechanisms
6.3.1 Lapatinib Acquired Resistant Cells Display Different
Cross-Resistance Patterns to Other HER2-Targeting Agents
It appears that all three cell lines have adapted differently to develop ac-
quired resistance to lapatinib. This is evidenced in the different cross-resistance
patterns observed, as previously described in the results (Figure 6.1). Trastu-
zumab is the least effective drug as can be expected since it is a reversible
HER2 inhibitor; the cells treated here have already become resistant to lapat-
inib which also targets HER2. They could therefore have accumulated HER2
receptor mutations (78) as well as switched to signalling through different RTKs
(1) to overcome HER2 inhibition. Although SKBR-3/L can still be treated with
trastuzumab, its sensitivity has halved.
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It is important to note that neither lapatinib, neratinib, nor dacomitinib are
routinely used in treatment of advanced breast cancer although they are in-
volved in optimisation studies. The two pan-HER inhibitors, neratinib and
dacomitinib, do not have the same effect on the cell lines. These are two ir-
reversible small molecule inhibitors therefore they covalently bind the receptor
active site and permanently block its activity. Dacomitinib has not been used in
clinical trials for HER2+ breast cancers whilst neratinib is licenced and has been
used in a phase III trial (380). The drug has been shown to slightly improve pa-
tient survival even after trastuzumab or lapatinib treatment (380, 381), however
in a previous phase II trial it was also shown to bring no benefit or disadvantage
when compared to lapatinib treatment (382).
In the cell lines tested here, BT-474/L is resistant to both neratinib and
dacomitinib, whereas HCC1954/L is only resistant to neratinib, and HCC1954/L
and SKBR-3/L are sensitive to dacomitinib. The various resistance patterns
observed between the cells suggest they have adapted to lapatinib exposure
differently. They could also be due to the differences between the cell lines.
BT-474 and HCC1954 are both derived from primary ductal carcinomas, but
BT-474 is ER+ and PR+ whilst HCC1954 is negative for both. SKBR-3, which
is also ER- and PR- is derived from a metastatic pleural effusion site. These
difference between the cells could contribute to the differing cross-resistance
observed.
The varying degree of response to the pan-HER therapies could also be due to
the disparate binding affinities the two compounds have to the individual HER-
family receptors and the difference in their mode of action; while neratinib treat-
ment leads to G1-S phase arrest (377 ), dacomitinib exerts its anti-proliferative
effect through G0/G1 arrest and induction of apoptosis (68). These mechan-
isms could be a reason HCC1954/L responds to dacomitinib but is resistant to
neratinib.
Both these agents have previously been shown to be effective against lapatinib
or trastuzumab resistance in vitro (68, 383, 384), however, here we have shown
that they cannot reliably be used to treat lapatinib resistant lines. Therefore,
in clinical trials where patients have been previously treated with other HER2-
targeting agents, it might be necessary to further stratify patients in order to
derive optimal benefit from neratinib once they have progressed through their
treatment.
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6.3.2 Lapatinib Acquired Resistant Cells Display a Different
Behaviour and Appearance Compared to their Parental Line
Another difference observed between the three cell lines comes from their
growth speed. BT-474/L was found to proliferate at a much faster rate than
both the other resistant lines as well as its isogenic pair; the other two resistant
lines divide at slower rates. These results further confirm the cells have adapted
differently. The faster growing cell line could have become more invasive, as
suggested by the increase in stress fibres in the cytoplasm of the cells as well
as their irregular appearance with many lamellipodia and filopodia. The other
two lines could be developing more stem cell-like features, such as quiescence,
explaining their slower population doubling rate. A gel invasion assay would,
however, be necessary to confirm the invasiveness of the cells.
Moreover, both BT-474/L and HCC1954/L were shown to, on average, have
a larger cytoplasmic area than their paired sensitive line, with the difference not
only caused by an increase in nucleus size. This could be due to TGF-b induced
EMT which has been found to lead to an increase in cell size (385). This is
also accompanied by an increase of invasive behaviour such as the development
of lamellipodia, filopodia, and stress fibres, necessary for migration (386, 387 )
and consistent with EMT (388, 389).
Overall this suggests that certain of the lapatinib resistant cells have under-
gone EMT, which could have contributed to their resistant phenotype. Indeed,
EMT has previously been associated with reduced drug sensitivity in cancer
(390–393). Additionally, TGF-b induced EMT can be promoted by miRNAs
located in the 14q32 region: miR487a (394), miR134, miR487b, and miR655
(395); and artificial overexpression of 14q32 miRNAs has been shown to lead to
more migratory and invasive cells (341).
HCC1954/L, however, shows a large spread in individual cell size suggesting
not all cells have an enlarged cytoplasm. SKBR-3/L cells do not appear to
be significantly bigger than the sensitive line, which would be consistent with
these cells becoming more stem cell-like rather than becoming more invasive.
Cells with stem cell features have been found to be resistant to chemotherapy
(396, 397 ). Cancer stem cells can also arise as a result of EMT (398–400), and
can have high TGF-b expression (401, 402). Furthermore, increased levels of
miRNAs from the 14q32 have been linked to cells developing more stem cell-
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like features in hepatocellular carcinoma (403) and miR495 was shown to be
involved in breast cancer stem cell formation (307 ).
In order to confirm this hypothesis, further validation would be required;
5-bromo-2′-deoxyuridine (BrdU) incorporation assays could be carried out to
asses the stemness of the cell population (404) as well as flow cytometry ana-
lysis using expression of know cancer stem cell markers, such as CD44+ and
CD24-/low (307 ), to quantify the stem cell population. Invasion assays could
also be carried out to measure the invasiveness of the cell populations, addition-
ally, levels of known markers of EMT, such as loss of CDH1 or upregulation of
Snail Family Transcriptional Repressors 1 (SNAI1) and 2 (SNAI2) (405–407 )
could be investigated. In the Illumina arrays, 34.5 % average decrease of CDH1
was observed in BT-474/L compared to sensitive BT-474. These results were
not statistically significant, therefore, RT-qPCR or western blot assays would
be necessary to confirm the loss of CDH1 in BT-474/L resistant cells. A 4.5 %
and 2 % decrease was observed for SNAI1 and SNAI2 respectively. As these
changes are so small and results were also not statistically significant, further
experimental validation would be necessary to conclude on the expression status
of these genes in the resistant lines.
6.4 Epigenetic Changes Lead to Increased Expression of
miRNAs from the 14q32 in Acquired Resistance to
Lapatinib
6.4.1 14q32 miRNA Expression is Upregulated in Acquired
Resistance to Lapatinib
All of the lapatinib acquired resistant cell lines studied here display an increase
in expression of miRNAs from the 14q32 region compared to their isogenic par-
ental line. Interestingly, the paternally expressed coding genes found in this
region were not found to be differentially expressed between the cell lines by the
gene expression array. The maternal allele contains only non-coding genes.
miRNAs from the 14q32 region have previously been found to be important in
many different cancers and have been attributed disparate roles as both tumour
suppressing or oncogenic depending on the setting. Indeed, decreased levels of
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the miRNAs were shown to be important in glioma progression (408), melan-
oma (409), neuroblastoma (410), osteocarcinoma (411), and ovarian carcinoma
(412). In these examples the miRNAs are functioning as tumour suppressors.
In other cases they are oncogenic: increased expression of the miRNAs has been
correlated to a decreased time until relapse in ependymoma (413); in hepato-
cellular carcinoma to stem cell-like phenotypes and increased invasion (403),
and in lung adenocarcinoma to a decrease in disease free survival time (341).
For these latter examples, the apparent correlation between increased levels of
14q32 miRNAs and metastatic progression and relapse suggests a role for these
miRNAs in resistance to therapy.
In prostate cancer these miRNAs can either be downregulated, suggesting a
tumour suppressive role (414) or upregulated promoting cell proliferation and
invasion, indicating an oncogenic role (287 ). These two studies, however, did
not investigate the same individual 14q32 miRNAs. In the former, ten miRNAs
were found to be decreased in tumour compared to normal samples whereas in
the latter only miR409 was investigated. As the experiments were not carried
out in the same cell lines and did not investigate the same miRNAs, the results
are hard to interpret. This highlights the importance of context specificity of
miRNAs. 14q32 miRNAs have been attributed different roles depending on the
cancer type and cell lines used in the studies.
To directly confirm the correlation between miRNA levels and resistance, here,
miRNAmimics and inhibitors were transfected into the cells prior to cytotoxicity
assays with lapatinib or neratinib. These experiments measured the IC50 values
for each condition (Supplementary Figures 7.3 and 7.6) and were also used for
viability studies (Supplementary Figures 7.5 and 7.7). However, none of the
conditions used displayed the anticipated increase or decrease in resistance.
The experiments were designed with miRNA mimics or inhibitors being trans-
fected into the cells on day 0, the drug was then added at day 1 and left until day
7 where the MTT assay was performed. While miRNA mimics have been shown
to be effective in the cells on average 3 days (415), in our experiments, high levels
of miRNA were still measured at day 7, the end day of the experiment. This
could, however, be the stem-loop RT-qPCR assay picking up the unprocessed
miRNA mimic in the cell. Although the stem-loop primer should be specific to
the mature form of the miRNA, it has previously been shown that some assays
can detect unprocessed mimic (416). Preliminary stem-loop RT-qPCR results,
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with mimic addition before and after cells were collected for miRNA extraction,
showed this was probably the case for our experiment as well. Therefore it is
possible that the miRNA levels obtained by RT-qPCR after mimic transfection
really include the original levels of mimic transfected and thus do not reflect
levels of mature and active miRNA in these experiments.
This is not the case for inhibitors as their sequence is complementary to
the mature miRNA and cannot bind to the stem-loop primer, allowing for the
detection of the actual amount of mature miRNA present in the cells after trans-
fection. There was a time discordance with the IC50 measurements, optimised
at day 7, and the maximum effect of the inhibitors, observed at 48 hours. There-
fore, a different end point assay may have been better suited to determine the
sensitivity of the cells to lapatinib following mimic or inhibitor transfection. For
instance, measuring an event that occurred faster in lapatinib response such as
upregulation of Forkhead Box O1 (FOXO3A), CDKN1B, Cyclin D1 (CCND1),
RB1 Inducible Coiled-Coil 1 (RB1CC1), and Nuclear Receptor Subfamily 3
Group C Member 1 (NR3C1) which can be measured by RT-qPCR from as
early as 12 hours after drug exposure (417 ).
Although there was no direct confirmation of the link between miRNA upreg-
ulation and resistance through our experiments, a clear increase in expression
of the miRNAs from both 14q32 clusters was observed in acquired resistance
to lapatinib compared to the low native levels of these miRNAs in the sensitive
cell lines (Figure 3.7a).
6.4.2 miRNAs from the 14q32 Region are Epigenetically Regulated
and Demethylated in Acquired Resistance to Lapatinib
The 14q32 region has been shown to be tightly regulated by both DNAmethyl-
ation and histone modification (418). Very little research has been done to
confirm that the changes in miRNA expression observed in cancers are due to
epigenetic changes in the 14q32 region. This is the first report of its’ kind. In
lung adenocarcinoma the increase in miRNA was found not to be due to loss
of imprinting in the region, but due to a gradual hypomethylation from healthy
cells to lymph node metastasis which correlated to miRNA expression levels
(341). In uterine carcinosarcoma no decrease in methylation was observed in
the IG-DMR (419), however, the other DMRs in the region were not studied. In
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hepatocellular carcinoma loss of imprinting has been suggested to be the cause
of increased 14q32 miRNA expression (403), although no experimental valida-
tion has been carried out. In this study, epigenetic changes were shown to occur
in acquired lapatinib resistant breast cancer lines.
Here, we investigated the influence of epigenetic markers on miRNA expres-
sion using DNA demethylation and inhibition of histone deacetylation. Due to
the random nature of this experiment, with Aza and TSA affecting each in-
dividual cell differently, there was some variation between the results. Thus
a representative biological repeat was displayed in Figure 4.3. There are two
miRNA clusters in the 14q32, which will be discussed separately by examining
the different miRNA expression patterns.
In the 14q32.31 region, these experiments showed that miR495 was the most
consistently altered miRNA between all the cell lines. It displayed an increase
in expression in the sensitive cell lines with both Aza and TSA treatments and
little to no change in the acquired resistant lines. miR409 also presented this
pattern apart from in SKBR-3 cells. This suggests that the regions controlling
the expression of the miRNAs are already demethylated in the resistant cells,
whereas they are not in the sensitive lines. Additionally in the sensitive lines,
the methylated DNA seems to be in a closed state as TSA in addition to Aza
treatment further increased miRNA upregulation. Thus, in the sensitive cells,
the DNA is not in an open configuration as the genes are not normally expressed
in adult tissues. In the resistant cells, the chromatin, which could have been
decondensed through acetylation of key histones, is now in an open state al-
lowing for the newly demethylated genes to be expressed. This suggests that
the chromatin, in a facultative heterochromatic state in the sensitive cell lines,
transitions to a euchromatic configuration.
In SKBR-3, these results show that HDAC inhibition, on top of demethyl-
ation, does not lead to much variation in miR409 expression compared to de-
methylation alone suggesting that here DNA demethylation might be more im-
portant for miRNA expression than histone acetylation. The chromatin could
already be in an open configuration with the DNA methylated in the sensitive
lines.
miR127, located in the 14q32.2, varied the most between all the cell lines, with
BT-474 displaying the previous pattern of upregulation in the Aza and Aza with
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TSA treated samples. Interestingly, miR127 levels also increased in BT-474/L,
however in this case there was little increase in the Aza only condition and a big-
ger upregulation for the TSA conditions. This implies that, here, the promoter
DNA is already demethylated and the inhibition is occurring from the acetyla-
tion levels and thus the histone configuration. In HCC1954 and HCC1954/L
cells, there is almost no change in any condition suggesting the promoter region
is demethylated and in an open configuration. As the epigenetic control tak-
ing place on this gene is neither dependant on DNA methylation, nor histone
acetylation, other regulators could be more important. For instance, activating
histone methylation marks, such as trimethylation of lysine 4 on H3 (H3K4me3)
in the MEG3-DMR (420), could be more frequent in the resistant cells lead-
ing to the 10-fold increase in miRNA expression observed between HCC1954
and HCC1954/L (Figure 3.7). To measure changes in histone methylation fur-
ther experiments, such as chromatin immunoprecipitation (ChIP) followed by a
DNA microarray (421), also called ChIP on chip, could be carried out. In the
SKBR-3 line, a big increase in miRNA expression is observed for the Aza treated
conditions highlighting the role of methylation, more than histone acetylation,
in controlling miR127 expression in this cell line. In the resistant SKBR-3/L
there is also an increase in miRNA expression in the Aza treatment alone. This
suggests that, here, not all methylation is lost in resistance. This could explain
why SKBR-3/L cells have the lowest 14q32 miRNA expression out of the three
resistant lines (Figure 3.7a).
These results show that the subtle differences in variation of expression ob-
served between miR127 and the other two miRNAs is controlled by different
promoter regions which do not respond the same to DNA methylation and
histone acetylation patterns, and are probably dependant on other epigenetic
regulators as has previously been hypothesised (334).
Methylation resequencing experiments were carried out to confirm the location
of DNA demethylation leading to the changes in miRNA expression observed
previously. In BT-474/L cells the IG-DMR was found to be relatively demethyl-
ated compared to BT-474 where the region was highly methylated. In HCC1954
cells the IG-DMR was already demethylated and in HCC1954/L some sites in-
creased in methylation levels but they remained under 50 % methylation. In
the SKBR-3 lines there were no significant changes in methylation levels in this
region. Similar result have previously been observed in uterine carcinosarcoma
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where no change in IG-DMR methylation was observed although there was in-
creased miRNA expression in the cancer compared to healthy tissue (419). In
both SKBR-3 and SKBR-3/L, overall methylation levels of the region were of
approximately 5 %. Altogether, these results suggest that imprinting of the
IG-DMR is lost in most of the cell lines and other mechanisms are also involved
in controlling the expression of the miRNAs. This was observed in the previous
experiments where in most cases the combination of Aza and TSA lead to the
biggest changes in miRNA expression, suggesting histone acetylation could be
a key regulator in controlling expression of the miRNAs.
The MEG3-DMR appears to be a key regulator of the miRNA expression as
it is the only region significantly changed in all three cell lines. Demethylation
is occurring in the distal region of the DMR confirming that methylation levels
in this region are essential in controlling expression of the miRNAs (327 ).
CpG islands 1 and 2 have undergone the most demethylation in BT-474/L
compared to its sensitive parental cell line. The amount of demethylation ob-
served could hypothetically explain the extent of the changes in miRNA ex-
pression levels between BT-474 and BT-474/L. Indeed, this resistant cell line
displays the biggest increase in miRNA expression levels which could result from
the demethylation observed across all four CpG regions tested. HCC1954/L has
undergone more modest changes, but it still displays low levels of methyla-
tion overall which, when combined with changes in histone modifications, could
lead to the increase in miRNA expression levels observed between the sensitive
and resistant cells. In SKBR-3 and SKBR-3/L cells these regions are generally
mostly demethylated with on average less than 3 % methylation. This implies
that methylation in these regions are not key in controlling 14q32 miRNA up-
regulation for this cell line, with histone modfication maybe driving the change
in miRNA expression between the sensitive and resistant lines.
Overall SKBR-3 and SKBR-3/L have the lowest levels of miRNA expression
in their respective categories as lapatinib sensitive or acquired resistant cells.
These cell lines also displayed the least changes in cross-resistance patterns for
SKBR-3/L. All these factors could be explained by the methylation changes
observed here, where the only significantly altered region is the MEG3-DMR.
Therefore, out of the isogenic pairs, SKBR-3 and SKBR-3/L have undergone
the least epigenetic changes.
129
6 Discussion
6.5 Key miRNA Target Genes are Downregulated in the
Resistant Cells and Appear to be Involved in
Resistance
6.5.1 Differences in miRNA Expression Occur with Changes in Gene
Expression in Acquired Resistance
miRNA therapy has not yet been widely investigated and there are no suc-
cessful clinical trials. The first phase I trial, MRX34, used a miR34a mimic
to reduce metastasis in hepatocellular carcinoma, however, the trial had to be
ended prematurely due to serious adverse effects in patents (422). Moreover, it
has been suggested that unexpected effects of miRNA therapies could be caused
by the context dependant role of miRNAs (423), as illustrated by miR34a which
was found to be both inhibiting metastasis (424–426) and promoting it (427 ).
Although a number of miRNA based therapeutics have been trialled with more
successful results than the MRX34 trial, none of the ongoing cancer trials have
published successful results (168), however, certain patients might benefit from
miRNA therapy. Cancers, compared to other diseases, are constantly mutating
and changing. This makes cancer cells very adaptable, as demonstrated by the
therapeutic resistance phenomenon. This characteristic of the cells combined
with the ambiguous role many miRNAs play which is very context dependant,
suggest that tumours are likely to hijack a miRNA therapy to its advantage.
Additionally, in many cancers, it is not just a single miRNA that is alter but a
whole cluster or family which is deregulated, as is the case here with the 14q32
cluster. Removing a single drop of contaminated water from a glass of muddy
water will not clean the contents of the entire glass. Similarly, targeting one
or two miRNAs out of the whole cluster will probably not induce a significant
change in downstream targets as these are most likely also regulated by many
other miRNAs deregulated in the cancer (Figure 6.2a). Identifying a different
level of where an action could have a vaster impact is essential. Here, acting
on downstream effectors of the miRNAs, with clear defined roles appears to
be the better treatment option (Figure 6.2b). This is the same reasoning for
the widely accepted conclusion that transcription factors are difficult cancer
therapeutic targets.
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(a)
miRNA 1 miRNA 2
Target 2Target 1 Target 3
Effect 2Effect 1 Effect 3
(b)
miRNA 1 miRNA 2
Target 2Target 1 Target 3
Effect 2Effect 1 Effect 3
Figure 6.2: Differences Between Targeting miRNAs or Downstream Targets. In cancers
where whole miRNA clusters are deregulated, miRNAs will likely affect
similar targets. Here only two miRNAs and three downstream effectors
are considered, however in the case of the 14q32 miRNAs and resistance
investigated in this work, 52 miRNAs from a single genomic cluster are
deregulated. These miRNAs affect hundreds of mRNA targets. In this
schematic the therapeutic target is shown by a red cross on the digram and
impaired downstream effects are greyed out. Targets and effects that play
a key role in cancer are highlighted in red. (a) miRNA 1 is targeted in this
scenario. This prevents the miRNA from affecting its downstream targets,
however, these are also regulated by miRNA 2 which can compensate for
the loss of miRNA 1. Therefore, in this situation, targeting miRNA 1 is
not significantly affecting downstream effects and not resulting in clinical
benefit. (b) In this situation, Target 2 is selected as the therapeutic target.
In this case, selecting a downstream effector of the miRNAs overcomes the
redundant nature of miRNA targeting. This leads to impaired signalling
downstream of Target 2 leading to therapeutic benefit.
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As previously mentioned, many different and contradictory roles have been
identified for 14q32 miRNAs with evidence hinting that they can act as both
oncogenic or tumour suppressor miRNAs depending on the context. This, and
the results from the MRX34 trial, advise against targeting miRNAs as it could
lead to unwanted effects. Thus determining how the miRNAs are affecting
downstream genes will help to identify therapeutic targets. Therefore promising
therapeutic pathways should be downregulated in the resistant cells and targeted
by multiple miRNAs from the 14q32 cluster as miRNAs from a same genomic
cluster tend to have similar effects in cancer (414).
In the experiment here, genes were selected from a gene expression array
comparing BT-474/L expression to BT-474. This identified 27 genes that were
differentially expressed and miR127, miR409 or miR495 targets. From these,
13 genes were selected which had sites for at least two of the six validated
miRNAs. Seven of these targets were validated in siRNA experiments. Each
target was studied individually to assess their role in resistance. Therefore in
these experiments the IC50 values for the cell lines was not expected to go from
sensitive to resistant, yet if a gene is important in acquired resistance, the value
is anticipated to increase making the cell more resistant to the drug than the
untreated sensitive sample. Following knock-down of a single target, we do not
expect to see a complete shift in IC50 from sensitive to resistant, but, if a gene
is important in acquired resistance, we anticipate some loss in sensitivity when
compared to the control.
Having identified targets with the potential to be involved in resistance to
HER2-targeted therapy further experiments could be carried out to confirm
their importance through the reciprocal experiment: re-expressing the targets
in resistant cell lines through plasmid transfection with the aim of reducing the
IC50 value for these cells.
Furthermore, to confirm the miRNAs directly target the mRNAs of the chosen
genes, luciferase assays could be carried out (428). The target mRNA 3′UTR
sequence would be cloned into the luciferase vector and then transfected into the
paired cell line, this should lead to lower levels of the luciferase protein in the res-
istant lines where the higher levels of miRNA are binding to the seed site in the
3′UTR and inhibiting luciferase translation. This was attempted, however due
to problems in the cloning process these assays were not successful. After nu-
merous attempts varying PCR conditions, it was found that the seed sequences
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used as templates were too palindromic and GC rich for successful cloning. If
this had worked, the luciferase could have been transfected into sensitive cells
at the same time as miRNA mimics to validate the inhibition of each selected
miRNA on each target gene. Another method to identify miRNA-mRNA in-
teraction would be to use photoactivatable-ribonucleoside-enhanced crosslinking
and immunoprecipitation (PAR-CLIP) to identify miRNA-containing ribonuc-
leoprotein complexes (429).
6.5.2 Three Putative miRNA Targets, SOCS2, BASP1, and
NEDD4L, Appear to be Involved in Acquired Resistance to
Lapatinib
SOCS2 is a putative target of four out of the six investigated 14q32 miRNAs.
Loss of SOCS2 has been found to lead to an increase in cell proliferation and
less differentiated, thus more stem-like, tumours. In the resistant cell lines there
was little upregulation in SOCS2 levels in HCC1954/L and SKBR-3/L com-
pared to their isogenic pair, however in both the BT-474/L and BT-474/T cell
lines there was a decrease in SOCS2 expression. This difference is a reminder of
the individual adaptation each cell line has undergone in the process of acquired
resistance. Only one acquired lapatinib resistant line was tested for each sens-
itive line. To obtain more robust results would require clonal selection and the
repetition of these experiments on multiple clones. Cancer is a clonal disease
and individual clones might adapt differently to the drug, multiple adaptations
can originate from a sensitive cell population where one mutation can dominate
until it is targeted and eliminated, allowing for another to take its place (430,
431).
Here, siRNA knock-down leads to a decrease in SOCS2 mRNA expression
in all the sensitive lines and the upregulation in IC50 was observed in both
BT-474 and HCC1954 after treatment with lapatinib. No consistent effect was
observed in SKBR-3 cells, however, as identified in previous experiments, this
cell line has adapted the most differently to lapatinib compared to the other
two lines. Consistently, this results for this cell line do not match the other two
cell line pairs studied. This could explain why SOCS2 knock-down only lead to
the increase in resistance in HCC1954 and BT-474. SOCS2 appears to have a
potential role in resistance to lapatinib, and possibly HER2-targeting therapies
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more generally, although more IC50 experiments with other HER2-targeting
agents would be necessary to confirm this.
BASP1 was found to be a putative target for five out of the six miRNAs in-
vestigated. Its expression was lower in HCC1954 and SKBR-3 than in BT-474.
In both HCC1954/L and SKBR-3/L there was an increase in BASP1 compared
to their paired sensitive line. As expected, due to these results, an increase
in IC50 was only observed for the lapatinib treated BT-474 cells after siRNA
transfection. BASP1 is involved in inhibition of MYC signalling, therefore loss
of BASP1 could lead to increased cell proliferation; this characteristic was only
observed in the BT-474/L cells compared to BT-474 and not in the other pairs.
This could be explained by the levels of BASP1 measured in the resistant cells.
It could also be a reason why HCC1954 and SKBR-3 cells did not respond to
the siRNA experiment in the same way as BT-474 cells did. Surprisingly, no
consistent effect was observed in the cells treated with trastuzumab. An explan-
ation could be that lapatinib and trastuzumab are quite different as lapatinib
is a small molecule inhibitor targeting the ATP-binding domain on the intra-
cellular part of the receptor (378), whilst trastuzumab is a monoclonal antibody
that binds the HER2 ectodomain, on the extracellular side of the receptor (36).
These distinctions lead to different cellular responses (432), which could clarify
why BASP1 knock-down leads to an increase in resistance to lapatinib but not
trastuzumab in BT-474 cells.
NEDD4L is a putative target of four 14q32 miRNAs tested, and its mRNA
expression was lower in both HCC1954 and SKBR-3 cells compared to BT-474.
The resistant cells also had lower NEDD4L expression than their sensitive pair.
On the protein level both HCC1954 appeared to have NEDD4L levels consider-
ably lower than the other sensitive cell lines, with the protein being expressed
at a similar degree than HCC1954/L. Discrepancies between observed levels of
mRNA and protein can be caused by differences in either transcription, trans-
lation, or degradation rates as well as by inhibition of the mRNA transcription
by RNA interference (433). In the siRNA treated samples where protein knock-
down was measured, an increase in IC50 was observed The effect is consistent
for both BT-474 and SKBR-3 cell lines. In HCC1954 cells, the baseline levels of
NEDD4L were already low thus the siRNA knock-down might not have affected
the sensitivity of the cell line for lapatinib.
These targets, therefore, appear to be involved in acquired resistance to lapat-
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inib for at least one of the cell lines tested. Although none of the changes in
IC50 are statistically significant, a trend is observed. The lack of statistical sig-
nificance could be a reflection of miRNA processes, upregultation of the 14q32
miRNAs leads to the downregulation of many target genes which in turn affect
multiple signalling pathways. Here, in the experiments, we targeted individual
genes. This causes a more modest downstream effect which leads to a smaller
increase in resistance. Additionally, three of these genes, SOCS2, BASP1, and
NEDD4L, seem to have some clinical relevance as high expression of these in-
crease the probability of pCR, however, due to the low number of patients, these
results are not statistically significant.
PKIA, a putative target for three of the tested 14q32 miRNAs, was down-
regulated in all the acquired resistant lines compared to their isogenic sensitive
line. This target was already expressed at lower levels in HCC1954 and SKBR-3
compared to BT-474. Similarly to the results observed for SOCS2, there was
only an increase in lapatinib resistance for BT-474 and HCC1954 cells after
siRNA transfection. As previously stated, SKBR-3 cells adapted to lapatinib
resistance in the most different way. SKBR-3/L cells have the lowest miRNA
expression and have the least change in methylation levels out of the acquired
resistant cells. The clinical data for this target is inconclusive as the odds ratio
for the top quartile of PKIA expressers is greater than 1. This suggest that high
levels of this target might not be beneficial for pCR, although the data set used
for this analysis is very small and a larger cohort would improve the statistical
relevance of this result.
6.5.3 SH3BGRL, a Putative miRNA Target Appears to be Involved
in Acquired Resistance to Trastuzumab
SH3BGRL is expressed at lower levels in both HCC1954 and SKBR-3 com-
pared to BT-474 cells. In all the acquired resistant cells, expression is also
lessened compared to their isogenic sensitive cell line. In the lapatinib treated
siRNA knock-down experiments no consistent changes in IC50 values was ob-
served across the panel of cell lines. In the BT-474 cells treated with trastu-
zumab an increase in IC50 was measured. As mentioned previously, these two
drugs do not inhibit HER2 signalling in the same fashion, which could lead to
the differences observed here, where loss of SH3BGRL seems to be involved in
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trastuzumab but not lapatinib acquired resistance.
6.5.4 Reduced Expression of SOCS2, BASP1, NEDD4L, and
SH3BGRL Could Lead to Upregulated MYC and
TGF-b Signalling
The combination of the IC50 results and the clinical data discussed above,
seems to suggest that these targets are important in resistance to HER2 ther-
apies and patient outcome as, in patients, high expression of the genes is associ-
ated with better pCR. Both NEDD4L and SH3BGRL are involved in negative
regulation of TGF-b signalling, BASP1 is a MYC inhibitor, and SOCS2 inhibits
JAK/STAT signalling (Figure 6.3). These pathways are involved in defining
characteristics of resistant cells: cell growth and EMT. BT-474 was the cell line
where loss of all these genes appeared to be implicated in resistance, therefore
preliminary validation experiments were performed in BT-474 and BT-474/L to
investigate how levels of MYC and TGFBI were affected in the resistant cells
(Figure 6.4). This would suggest the resistant cells have upregulated signalling
through these pathways, enabling the cells to compensate for the block of HER2
signalling promoting cell proliferation.
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14q32 miRNAs
SH3BGRLNEDD4L BASP1 SOCS2
WNT TGFb/SMAD MYC JAK/STAT
Figure 6.3: 14q32 miRNA Inhibition of Target Genes and Effect on Downstream Path-
ways. 14q32 miRNAs inhibit target genes such as NEDD4L, SH3BGRL,
BASP1, or SOCS2. These genes are involved in inhibition of WNT,
TGFb/SMAD, MYC, and JAK/STAT signalling. Additiannally, the
WNT, TGFb/SMAD, and JAK/STAT pathways are involved in promot-
ing MYC signalling. Therefore an increase in miRNA levels leads to higher
inhibition of NEDD4L, SH3BGRL, BASP1, or SOCS2. This will remove
inhibition on the downstream pathways promoting WNT, TGFb/SMAD,
and JAK/STAT signalling. Ultimately leading to increased proliferation
and cell survival.
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Figure 6.4: Preliminary Validation of MYC and TGF-b Activation in the Lapatinib
Resistant BT-474/L. RT-qPCR measuring levels of MYC and TGF-bI
mRNA in BT-474/L cells normalised to levels in BT-474. Statistical signi-
ficance is obtained from a one-way ANOVA with Dunnett’s Multiple Com-
parison post-test, significance is shown on the graph, with ? for p ≤ 0.05.
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6.6 Concluding Remarks
At the end of this research, the main conclusions are that upregulation of
14q32 miRNAs, caused by epigenetic alterations, such as methylation loss and
altered histone acetylation, was identified as a driver of lapatinib acquired res-
istance in HER2+ breast cancer cell lines. This lead to downregulation of key
genes that are putative targets of the upregulated miRNAs and also appear to
be involved in resistance to HER2-targeting therapy. These genes have previ-
ously been shown to be involved in regulation of signalling pathways which can
lead to EMT and stemness and in turn, these can affect resistance. Addition-
ally SOCS2, BASP1, NEDD4L, and SH3BGRL appear to be relevant in patients
since high levels of these gene targets seem to correlate with a better probability
of pCR.
Expression levels of 14q32 miRNAs could thus be a relevant prognostic bio-
marker, after first round of HER2-targeted therapy, to identify patients that
are likely to relapse and develop refractory disease. Gene expression of the tar-
gets could also be used as a predictive biomarker to identify patients who will
respond favourably to HER2-targeted therapy.
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7.1 Other miRNA Putative Gene Targets
7.1.1 Krüppel-Like Factor 9
Krüppel-Like Factor 9 (KLF9) is a member of the Krüppel-Like super family.
Its expression has been found to suppress invasive growth in breast cancer by
transcriptionally repressing matrix metalloproteinases, thus preventing remod-
elling of the extracellular matrix (434, 435).
There is one putative miR409 seed site in KLF9 (Figure 7.1a) and three
miR495 sites (Figure 7.1b, c, and d). KLF9 is also predicted to have sites for
miR411, miR433 and miR539 (Figure 5.4).
KLF9 mRNA levels were down in HCC1954 cells and up in SKBR-3 cells
when compared to BT-474 (Figure 7.1e). In all the lapatinib resistant lines as
well as in BT-474/T, the trastuzumab resistance line, mRNA levels of KLF9
were lower than in the paired sensitive line (Figure 7.1f, g, and h).
siRNA transfection in the sensitive cell lines resulted in a decrease of over
50 % in mRNA expression for all three cell lines (Figure 7.1i, j, and k). The
knock-down, however only resulted in an increase in IC50 for siRNA 2 in the
BT-474 and HCC1954 cells (Figure 7.1l and m). In SKBR-3 only the siRNA
1 treated sample had an increase in IC50 (Figure 7.1n). The effect observed in
these cells suggest the IC50 changes are caused by off target effects of the siRNA,
indicating that KLF9 loss is not essential in acquired resistance to lapatinib.
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Figure 7.1: miRNA Seed Sites and Baseline Expression of KLF9. KLF9 contains pu-
tative miRNA binding sites for (a) miR409, and (b, c, d) miR495. (e) Levels
ofKLF9 mRNA in all three sensitive cell lines compared to BT-474. mRNA
levels in paired resistant and sensitive cell lines, normalised to the sensit-
ive cell line for (f) BT-474, BT-474/L, and BT-474/T, (g) HCC1954 and
HCC1954/L, and (h) SKBR-3 and SKBR-3/L. Statistical significance is
obtained from a one-way ANOVA with Dunnett’s Multiple Comparison
post-test for (e) and (f), and Student’s T-test for (g) and (h). Where res-
ults are statistically significant p-values are shown on the graph, with ? for
p ≤ 0.05, and ??? for p ≤ 0.001.
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Figure 7.1: Effect of KLF9 Knock-down on Lapatinib Resistance. mRNA expression
after treatment with two different siRNAs in (i) BT-474, (j) HCC1954,
and (k) SKBR-3. Lapatinib IC50 value after siRNA treatment in (l) BT-
474, (m) HCC1954, and (n) SKBR-3. The IC50 values are obtained from
non-linear regression analysis of cytotoxicity experiments and are averaged
for at least three replicates. Where results are statistically significant,
as determined by one-way ANOVA with Dunnett’s Multiple Comparison
post-test, p-values are shown on the graph, with ? for p ≤ 0.05, ?? for
p ≤ 0.01, and ??? for p ≤ 0.001.
141
7 Supplementary Data
7.1.2 Phosphatidylinositol-3,4,5-Trisphosphate-Dependent Rac
Exchange Factor 1
Phosphatidylinositol-3,4,5-Trisphosphate-Dependent Rac Exchange Factor 1
(PREX1) is a Rac1 GEF that exchanges Rac bound GDP for GTP activating
Rac and allowing for downstream signalling through the MAP kinase pathway
(436–438).
PREX1 was found to have two miR495 seed sites (Figure 7.2a and b) as well
as being a miR411 target (Figure 5.4).
mRNA levels of PREX1 were found to lower in BT-474/L cells compared to
be BT-474 (Figure 7.2c) this was confirmed on the protein level, with BT-474/L
appearing to have lost PREX1 expression (Figure 7.2d).
To investigate the functional role of PREX1 in lapatinib resistance, a knock-
down experiment using siRNAs was performed in BT-474 cells. With two indi-
vidual siRNAs, knock-down of PREX1 protein expression was observed (Figure
7.2e). This did not, however, affect the sensitivity of the cells to lapatinib as
all conditions have similar IC50 values (Figure 7.2f). These results suggest that
PREX1 is not causal in lapatinib acquired resistance.
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Figure 7.2: PREX1 Baseline Expression and Effect of Knock-down on Lapatinib Res-
istance. (a, b) PREX1 contains two putative miRNA binding sites for
miR495. (c) Levels of PREX1 mRNA in BT-474/L cells compared to
BT-474. (d) PREX1 protein levels in BT-474 and BT-474/L. (e) Protein
knock-down after siRNA treatment in BT-474 cells. (f) Lapatinib IC50
value after siRNA treatment in BT-474. The IC50 values are obtained
from non-linear regression analysis of cytotoxicity experiments and are av-
eraged for at least three replicates. Statistical significance is determined
by a Student’s T-test, where results are significant p-values are shown on
the graph, with ??? for p ≤ 0.001.
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7.2 Modulating miRNA Levels in Vitro to Affect
Lapatinib Sensitivity
To directly link miRNAs and acquired resistance to HER2-targeting therapy,
we decided to modulate miRNA expression using miRNA mimics or inhibitors.
This was combined with drug treatment to investigate how the induced changes
in miRNA expression affect resistance.
7.2.1 miRNA Mimic Transfection in Sensitive Cell Lines with
Lapatinib Treatment for IC50 Studies
As we found elevated levels of miR127, miR409 and miR495 in BT-474/L
cells relative to BT-474, miRNA mimics were used to increase the levels of these
mature miRNAs in the lapatinib sensitive cell lines in an attempt to make them
more resistant to the drug. miRNA mimics are synthetic oligonucleotides that
form small double-stranded RNA molecules imitating endogenous pri-miRNAs.
When they are transfected into cells they are be processed by the miRNA ma-
chinery and loaded onto the RISC complex thus increasing the proportion of
RISCs containing the selected miRNA.
For all three cell lines different seeding densities and mimic concentrations
were used for IC50 assays (Figure 7.3). In BT-474, for all three conditions, no
effect was observed on the IC50 values in mimic transfected samples (Figure
7.3a) even though over a thousand fold increase in miRNA expression was was
achieved after mimic treatment (Figure 7.4). The only effect observed was an
overall decrease in IC50 value when cell numbers were decreased.
In HCC1954 cells, a significant decrease in IC50 was obtained when the
highest concentration of miR409 mimic was used with a seeding density of
6.0·104 cells·mL-1 (Figure 7.3b). In the other conditions tested, no signific-
ant change was observed between the treatments though miRNA levels were
increased as measured by RT-qPCR (Figure 7.4).
SKBR-3 cells were only tested at a seeding density of 6.0·104 cells·mL-1 and
2.5 nM mimic (Figure 7.3c). No change was observed during the experiment
albeit the 100-fold increase in miRNA levels achieved after transfection (Figure
7.4).
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Figure 7.3: Cell Line Sensitivity to Lapatinib after Modulation of miRNA Levels by
Mimic Transfection (a) in BT-474 cells, (b) in HCC1954 cells, (c) in SKBR-
3 cells. For all three cell lines irrespective of the different experimental
conditions used there was no significant increase in resistance to lapat-
inib. The IC50 values are obtained from non-linear regression analysis of
cytotoxicity experiments, average for three replicates. Where results are
statistically significant, as determined by one-way ANOVA with Dunnett’s
Multiple Comparison post-test, p-values are shown on the graph, with
?? for p ≤ 0.01.
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Figure 7.4: miRNA Expression Levels Measured by Stem-Loop RT-qPCR after Mimic
Transfection. Results are analysed using the DDCt method and aver-
aged for three different biological replicates. (a) 2.5 nM, (b) 1.0 nM, and
(c) 0.04 nM of mimic. In all cases a high upregulation of the mature
miRNAs was observed after transfection with the mimics.
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7.2.2 miRNA Mimic Transfection in Sensitive Cell Lines with
Lapatinib Single Dose Treatment
The sensitive cell lines were transfected with different concentration of mimic,
ranging from 50 nM to 40 pM. Cells were plated at a density of 4.0·104 cells·mL-1.
The cells were treated with a single dose of lapatinib for three days, rather than
for seven days as used for previous IC50 experiments. The lapatinib dose chosen
was close to the cell lines IC50 value for the drug. Within the treatment groups,
no difference in miRNA mimic compared to scb negative control was observed
(Figure 7.5).
When the cells were treated with 50 nM mimic, approximately 50 % death
was observed for all conditions in BT-474 and SKBR-3 cell lines (Figure 7.5a
and c). In HCC1954 cells for this condition, 30 to 40 % cell death was observed
(Figure 7.5b). The other mimic transfection conditions, 1 nM and 40 pM, had
between 70 and 80 % cell death. Again, no increase in resistance was obtained
in the mimic transfected samples compared to Scb (Figure 7.5).
7.2.3 miRNA Mimic Transfection in Sensitive Cell Lines with
Neratinib Treatment for IC50 Studies
As BT-474/L and HCC1954/L showed the biggest change in sensitivity to
Neratinib, when compared to their paired sensitive line, we decided to study
how transfection with the mimics affected resistance to this drug in the sensitive
cell lines.
All three paired sensitive cell lines were transfected with the individual mimics
and treated with a range of Neratinib doses to obtain IC50 values. For all three
cell lines this yielded similar results to the lapatinib treatment where the only
significant change observed was for the miR409 mimic treatment in HCC1954
cells (Figure 7.6).
Although the experiments technically worked and miRNA upregulation was
present, we were not able to detect an increase in IC50 value after transfection
with miRNA mimic in the lapatinib sensitive cells.
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Figure 7.5: Lapatinib IC50 Dose Treatment after Mimic Transfection (a) in BT-474
with 50 nM of lapatinib, (b) in HCC1954 with 200 nM of lapatinib, and
(c) in SKBR-3 with 100 nM of lapatinib. Optical density of the samples is
normalised to the untreated control for each condition and is averaged for
three replicates.
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Figure 7.6: Cell Line Sensitivity to Neratinib after Modulation of miRNA Levels by
Mimic Transfection. For all three cell lines there was no increase in resist-
ance to neratinib after mimic treatment of the cells. The IC50 values are
obtained from non-linear regression analysis of cytotoxicity experiments,
average for three replicates.
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7.2.4 miRNA Inhibitor Transfection in Resistant Cell Lines with
Lapatinib Dose Treatment
To model the change in miRNA expression that occurs in the acquired resist-
ant cells, BT-474/L cells were transfected with 25 nM miRNA inhibitor. miRNA
inhibitors are short synthetic oligonucleotides with complimentary sequences to
the mRNAs they inhibit, therefore they will bind to them with high specificity
and prevent the miRNA from binding to the 3′UTR region of mRNA targets.
The decrease in miRNA levels in the resistant cells should make the resistant
cells more similar to the paired sensitive cell line. To see if the decrease in
miRNA had an effect on resistance, the cells were treated with 500 nM or 1 µM
of lapatinib for either 5 or 7 days.
In all the BT-474/L conditions cell survival was close to 100 % after 5 and 7
days with both 500 nM (Figure 7.7a) or 1 µM of lapatinib (Figure 7.7b) whereas
survival in the control BT-474 cells was between 10 and 1 % after treatment
with the drug (Figure 7.7).
Although a 60 to 80 % decrease in miRNA levels was observed (Figure 7.7c),
the cells did not appear to become more sensitive when they were treated with
the miRNA inhibitors.
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Figure 7.7: Cell Line Sensitivity to Lapatinib after Modulation of miRNA Levels by
Inhibitor Transfection. BT-474/L, lapatinib resistant cells were transfec-
ted with 5 nM of mimic and treated (a) with 500 nM and (b) with 1 µM of
lapatinib. For each experiment, BT-474 sensitive cells were used as a pos-
itive control. Optical density of the samples is normalised to the untreated
control for each condition and is averaged for replicates. (c) miRNA ex-
pression levels measured by stem-loop RT-qPCR 48 hours after inhibitor
transfection normalised to RNU44 relative to the scb treated sample. Over
60 % downregulation of all three miRNAs was observed in the BT-474/L
cells after transfection. Results were averaged for two replicates.
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7.3 Supplementary Figures
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Figure 7.8: Comparison of Nucleus Area in Paired Lapatinib Sensitive and Resistant
HER2+ Breast Cancer Cell Lines. Nucleus area measured for two to four
frames per cell line. Both HCC1954 and SKBR-3 sensitive and resistant
pairs on average appear to have similar nucleus size. The mean nucleus size
for BT-474/L cells is greater than that of BT-474 cells. Overall, HCC1954
and HCC1954/L have the biggest nucleus. Statistical significance is ob-
tained from a one-way ANOVA with Bonferroni’s Multiple Comparison
post-test. Where results are statistically significant p-values are shown on
the graph, with ?? for p ≤ 0.01.
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Figure 7.9: miRNA Expression after 5-Aza-2′-deoxycytidine (Aza) and Trichostatin A
(TSA) Treatment. Replicate two of the experiment. The experiments are
shown separately due to the high variability of the experiment. Stem-loop
RT-qPCR is expressed as fold change relative to RNU44 and normalised
to the untreated condition for each cell line. This does not permit direct
comparison of miRNA levels between the sensitive and resistant cells but
shows the effect of each treatment on miRNA expression levels. (a) In
BT-474 cells, (b) in HCC1954 cells, and (c) in SKBR-3 cells.
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Figure 7.10: miRNA Expression after 5-Aza-2′-deoxycytidine (Aza) and Trichostatin
A (TSA) Treatment. Replicate three of the experiment, miR433, miR411,
and miR539 were only performed on this replicate. The experiments are
shown separately due to the high variability of the experiment. Stem-loop
RT-qPCR is expressed as fold change relative to RNU44 and normalised
to the untreated condition for each cell line. This does not permit direct
comparison of miRNA levels between the sensitive and resistant cells but
shows the effect of each treatment on miRNA expression levels. (a) In
BT-474 cells, (b) in HCC1954 cells, and (c) in SKBR-3 cells.
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